var title_f29_41_30352="Fibroma";
var content_f29_41_30352=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F67437&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F67437&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Oral fibroma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 234px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A fibroma resulting from a chronic dental abscess in a 5-year-old child.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Caulfield PW, Griffen AL. Dental caries. An infectious and transmissible disease. Pediatr Clin North Am 2000: 47;1001. Copyright &copy; 2000 W.B. Saunders.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_41_30352=[""].join("\n");
var outline_f29_41_30352=null;
var title_f29_41_30353="Mucinous cystic neoplasm";
var content_f29_41_30353=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F65253&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F65253&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Pancreatic mucinous cystic neoplasm",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 400px; height: 306px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAEyAZADASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwCxbpmUOoJi7mpru9jXCwrlO9NjlNtasrEHdxVBWWIkMc5oAiebcXKjPpT4inkAN1J5qCYbnHl9RUwKgETfKT3oAfxH1fOBkYpoVpVMucAdBUY2A7d2D6mrCSBEAIGKAGCXruPA60yZEkUfMQamE8YYgqCr96gvZjaxjbHuXsaAFuJ/IhKqwLY4FceZ57LWI7iQZWU4x6VHcahNc6sAuVQHmp/Ecu+0UxHDpzuoA7RT50SsSDkcUioCF3jDdqyfC90NQ01XD/Onysa1VQrNgvuAHWgCRWE7HHVOMUsiO0m08N0GKSGJstKfli9fWkV3EpdDkds0AW57CaK2yE+U/wAVVod+AGGAP1q/NrD/AGTyW2sTxj0rOVmd8S/KnXNAAUZXZ9uKWNUyQ7ZJ5zTCrSuMPlQcYFJcZYYXAIoAfBIZ7vBUlF4qK5ikFyefkHTFWLK6FpEw2B3fofSopmeVdoPzk9KAGqSRtHOT8xqcTbGVIwUBHPvUCEqoUgiTvinTo7uG7AYoAmZEPCgjv9aWRmVRsxu7k9qamY1+9nFYGuaybeRvLIYgYI9aAJda1uPT7WSWX5pD8qgda89vbs6hukmyoJwq0ur35v5mJB44AHc1neeYZ4luRyT09KAPY/Ao+w2NouAGUZbPfNeH/GKzktviBqk8mDHeSG5jI/ut2PuOlewaVqG+CztlUo5XdvPpTPEum6P4l0e907UWjt76Mb7a6I5Vh/MHoRQB820lSTRNDM8Ugw6MVI9xUdABRRRQAUUUUAFFFFABRRRQBLawSXVzFBCu6WVwiD1JOBX0Z4L8PjwT4cWx1G9tUvbyXzXDOAAcABVz1xj8zXzjFI8UiSRsVdCGVh1BHQ1s2x1bxZr1vHLcy3F3IQokc52Ad/YCgDv/AIiWAt9XjmYmQvznsKxbV5I8PGwBznB7V6H4j0v7fp1tbKx3QKAzkctxXnlzaS2t55Jxge9AHd+BvECzySwXAPmrjYP71ehmUapbrFKViI7A814FBfTW1+s1qBvT7zHoBXpvh7X7XU44/wB8EuVGCpOM0Adza6cLdVR3G09K02tPKaOONS5mOMjrWboWvaNBcRQ6+0phY43xDdt+uK9V07UfBtjFHd2uoWkgC5T97vYfh1FAHkvjXwvLp7JHKhQzrkluwrxLxHpj2s0sRBdM5U9hXuPj7xG2ueIGljk22ca7YwPT1rgvFlg13poa2XLLkknigDyNo280B2LbfTtVy3nCTKyNjb3aiZY1crkO6n5sGku3hLRrHHk96APc3O8lWHXp7VUcKEZXHzjpSwzOxDk96neTe6nZketAFOKPEZZ2+Y9BVoxiRUAGWHNETAzNuTKmpXcjJjwB0oARYRO/72PbjgGrltZQSP8Ae4HGKoOz4Xa2VHWngPgG3JL9c0AXrjTEDB4zwOorPni3I0LsMdqd9rmaNg2c98VXj3CbeRuXuaAIE0G2aIuMCT1rIvtHmNo6bdy5+9XRiKSWQrCCD1x7VdDD7OYscjqDQB57oEU+j3TxjP2ebqD2NdnG4CKg4Uj71Q6rpiPEJAcE9BTLGaSNUglj346GgDVkuQsKQqMqBnnvVfznZSPLC4qaWPcg9T+lRSrvjBUkMvr3oAIoVK5YYkPSo5vOkPBAReM0rScB2BDnilG0r5YO4Dk47UAW9OnhsEczxb3YcVSkeSadmRQAe2KjEomuCx4RBj61NA+GZhxnpQAiynfiVVX0NTLNtVtqDK96oyuXLcZbPFOyxXP8I6rQBNFLv/eSkD0FIkzIrtIwIz0FQXLqIwyoen5Vz+q3xto9zSY4zQBc1TWFgV5M47AVyT6gt27MVO6khmOuXBiIKKvIbtUt3YrZvGiShn7+9AGXCY7S+R3QugOTUWuzR6trEA09fLEYG8kVd1tPItl8tl81vSq2kJBHbzG4z5jDhloA7OS5S4eyW1IDRoA2O9a7eGU1RxPNctGcdFrz7wwl2usxrG48onkv2r0zUpLm0ij2EYYdR0oA8z1jw9atr7KkKv5Z5Zh96pW0jTHmK3FlAVA4UIBmuhu4pHmEm9N56470xo4kkBK8nvQBRXQtKluoJP7LthAF27do5962LHw74Zt0cLo0EjPzukXOPpVNyd6ueEB+UCrizSOhMhx6CgB8eh+HIrYk6PaM5bgmMVVm8L6NKrB9Nto4W6lUAP4VLJcM7BccDoKmkLtCN7YA60AU7fwn4XiGyPT43GeWkO4/rU82geHVIa10m2LYxkoCBTTKDwgCr6nvQkpfgMVjXqaAM278N6fIr/6FbrGRztQAmqtz4R0R7BIYrYLL3k7itx5wAdp3DuTUQfCFtufU0Acy3gTSZdsMPng95A3P+FdR4U8IWeh3v2i3SUNs2lnbO6nW100V1HKY/kHRfWuoOpQXQjjOVkfjA7UAUdUJS2YbwHavLNRV/wC2JS+5iK9R8VpDBbLtLMQMlq8umLSyzSHMajjcf4qAM6UhpG6qvcCm23mRz+bAWT0OelSRMgkIMm4980kkxZ/JtlXHcmgDf03xPd2bpHdwrPATgydwK7/TVtb+2+02ADFv4uleaNFjSyu0HPVqn8Oa1daNcLl/9FI5Q84oA9Bhklj1D/SFG0eta0jw3sLIeYscheM1n6Zd2eq27XMW6RhwQ3TNPgfyGkXBwx4A6CgDy7xDZDTdUlVYwIpSSuDyKx2jkDNt5Pb2r1Hxlo/2y0E6RjzYxkY715q0csg2ngqeVoA9lQPHJyMKe1So65MYbr0pyO0isHG7NVGRo5VAU7T+lAF35o12EjPrSMfJZc8lu1JM27ZxlegpFVWf95kMOgoACCsodePVafLMwbdFlR3ApkgZVx1yeppsU7xsYp1z6EUAPW6RDuZTz1FXYZY3XewAU9BVItFuyenTFTSxx+XG27j0FAFqXUEQKltGRKeM1XkY7cuMSk9qN4ZvlUBQMbqjaF2kXk565oAngxnM2WcdqJoUhka4c4GOBTEWZ5io6j1qvqE7OVglXAB5x3oAVL0S5KthicAGrGA64lYZzziqEtvArKwyDjgUCZQdjgiQ9+1AF93UACXG3sahnCRP+6PD9aBJHJGIpRgjndUEriPkkOR93FADrhIAFCMQw6470EblUZwvrUAl52yAAN39KfICsY+YGMnp3oAmmlWNkAG7A6jvUck0SNuDfMaIo5MAKvydiad/Zsz3AEuBERnjrQBUkLzKxEgA/nXKaxp019dukch2jtXpUOmxSRBET5FPWpI9FtTKWiUiRf1oA8mj0TUrS3fyAxLd/Ss2WG8F4lvMjtL1LHtXvaWiJGBJGpJ7VUuNGsrhi4tx5/TdigDyiPQmuAPPl24HBNZz6e2kX0TSAzwFuRjrXs76HGsYxb5KjrVC+0pPspSSIEtz06UActq1pZW7abqFtHJHHIB5gHbpXQ3kZvdIQWgaQnoT2rnNfgle1itkZyqnI9q0/B2sq8wsAVMkY5NAGdcWD2ADTKTLjgVUCvgySbQfT0rpvF07eeoIwVGM+tcyUUq553HrmgCN2Eig9/aiVpSoRiBjuaAF48pMY6k9KjkjdgXbBH1oAljAU4aQt6kVO8sWdiEhu5PQVWWVIY8EnJ9BSfaI2JUDPqaAJdyhiirvP96ljfLKgGVHJqNZGWIhF5NSOrIqrHhWbkmgBBGGZmfGD2pC7H5QR5YpDEWwZJQqdPrRFGiqxBbbngDvQBOiNKxEYLEDoBxWtpdpumUOuHAyAKseHEdoHK7VJ45FXY0dbiQqqnjqKAOX8e3My2ixxMI1zhie9cIyvJDhAskg6Z6V0PxIlc3kEanjGcVy9m+18YYnFAED2j53uVB7+maURrCoCISx6kVYvS4Ckxj2FVlNzIxX5FB7jrQBft1mmVeQlv0NNvo7dpFS3Y4X7x9TUU2IrdImdg3XmkUKQvlruxQB0ngW5aC/NvJKIo5OAvqa7S7nitn8jceeQxHevMdKD2+qW8jybcsPlj5Jr3zwH4PHi3VWNxMIrKCMM+377E9APT60Ac1Zy/aI2Mn+rAxk964HxdpUsU7S2eFiY8t6V7j8RfAF74ajTUNAhl1LT14mg48yI/3vdf1HvXn90P7Q08xtCIznJB7UAaKQtEhc8U77TkKxXPtTbiYkHHKdBUHmMF5wSfSgCxG0TZ8zPsB2oYQs5RiwYd6Zv3AFU+YUSb2QzFMsOMUAPywUL95D0aiQ71wqA+jVGS/lgn5Awxg0sZMcIjfoxzmgBTtVQqKCe5NMO4YSQbR61MsMMWQ02W61DLLHAubhg2elAEg2qpidyB1B9alN2kQRFOW96y5NSgmnX5hhewqVpodxkChgO3cUAXw1zcEkL5Wf4qilkt7L/WuZZT0zWTe+J/MUxooQRjj1Nc3plzqOra8GlwtrnBNAHVXmsWzSeUVw54BHampciN0QEPnkn0q8fDFtKzTW0zSPjJXFcTei7ttUkiLFIwcc0AduxhdT6kdRWfLcQwMV5Z+tVbIytCdrZCjqTWXfNOrNJH83qfSgDQN7FNlUJ39xV6zOMecSV7VzFq+Xy52v/Oug0WGRm3PICOuDQB09vFJGiu4yh5ArRtYXaUO44fgD0FU7DzbmQJIQIU5yK2I3RUO3O8fdJoAguWFs22IFV75qS3uIupfD9qpXZlnmCsxKjuKijtSSSCRj1oA21zLKHkA+X3qVGUPuUViCKaIjEpZm9atxpfIu5UDMe1AGs0zLGPL555zSBYnBWRAxbvWU011CGe5XavYAUJfMqhvLY7ulAD9R0yOZHSKJRx3rltK8LQWuoz3O/Zcn7i9q7K2eSZxkhRis/wAQW8kiGS3kAlUYGKAMrUIYL+FoJ2BuY+mK5K+t5bZCG+8DwMVPavJZ6iZJ5T5rHkN3rqo4Y7+zkdgpIHFAHAzykQAMuN3cdqikkiQoBuOakuSY9ReGRuF9uKgTBkdnZdg6HFAD1R5DuUqAex7U6BSCcqpPao0lh5Znb/ZUCnFiSqquPegCX5hnYpL5/KgLIzFSTkjk1H+8yQH2gd+5pzGYErHIpJHOaAHJEuB5meDxUrsV+4hUL3qKEiIhZTuk7AVaMExUna53dBQBa0HUJYG2FCwY9TXTvJbG0dg22TqQDXMWFpeCdHaPKngDPSumNrstGCxgYHzE0AeR+MGmn1V3U4VRgE1h/vQWKEM4H0FdV4lt1M8rtn2Arl4toJU5B65oAv2IneI/agjP2HpTfIJLSP0XsKisyPtBkMoCtwFrQvFSIfKTgjn0oAp3cDSokq4X9aoJuQsFjLMf4ielXre7jU7CDtPGaL23WRMxuQDQBRguPLv4MB/vDnFfU3wEmkj1q4jdjie1DBT7Hr+tfLaI0Uqur/cPVjXtHgDxI9jeabqST7/JYLMqcFk6MPyoA+i9O1CW38S3ejagRIJl8+3Yjgqc5U/rx7GvGPix4Xj8N+IVntfO/s7UMuqhflhcdVz79R+NeteNtJute0zTdV8PTYv7RluIOQBMhGSpP5H8Md6zPinbyan4Atri+tvJu45I5GhD/cYjBGe/WgDxZzExwRt9qWLaiKAMjPelCI/7zBI9PSm+Wsr/ACkgLQAJuFwwTAxT5GZeNwy3p2pWC4BcbWbjIqndrLGCIDuc9zQBf8lRCPOk3AUy4uLWOMuQQiCslbbU3jJZ48A5Az1qtq11IbYQyR8ng4oAS68Qw3MwjtbdmA4L1BdytcoTLkIOmKhtFtrSHGPmbrRiYgSKw8vPANADbSwQN5m9lYjjNQ3JutPzJLIGVzgVpLtY7pyFwOMVXn0+81RxDBGSOu49KAKmn6LLqF2rQfO8vBB6CvVrfwDZeH9Hjubu7EkjjcUXt9K5vw3omoadGCxTePQ1r3f2+9lQXMh2pxtoA0dA1TSoJSkfDnj5u1W9d8MabrCCbaFOM5XqTXFaroNyxE9sWX2FWrDxVPpdsIrxDIVOM+goAx7/AES40uYr5mbdjj3qF7KJT8jFsjOyujvdcstVG1MBsc57VzjYinaVSWUHAoAxNT02eQ77dCrD9Kl0y6MTCK4chx3rVe+j8w7ZBkjLCsvUbmzVWuDbtleAF70AddoF7K8kkKYYN3NdDLJLGnl7QSR19K8js/EE8Vws9vAyoOMGus8OeLb3Vrz7Etg00mMrsBJoA7OD/U7CADURikds7sY6CuZGtX0PiWPTb2zlt5W5UMCOK6a6Bhj8yRtpY4FAE8UcpUNIuAvetW1t/OhLNNh/aqkVxFBp7bvnYjPNXfA8L67cTpG6Yj5IBoAqaojJCIBIHPXNVoxsRSQSveuk8WaPcWMkb7AU6ZFYTkwpggAHpmgBkUAIMm/YPeoT5KsfL3PnuatK6lCjuBuqJrdgf3RzQBh6rpsF07O1vh0H3hVKwkEcTQhiozzXW3Eim1MWFBPU+tc7e2otSGEed3pQBzeq2UL3DyKp2qOSe9YqIuxxsypPFdVfuTbNA8e5pPu47ViGylijcNgKBwpoApCN+AkaqB3qKSCRiHZhGg7nvVvTJUFz5coJJq1rloVCSNgIf4BQBkq4GPLUyZPWpZISFLnCE9KjjL4CwxFBnqakmZcL5hLNnAAoAI49oEmQGHcnrXXaVdQXdukSr+9HUmuLa2LSgn7o7E1qaK8sWood6xqeAPWgDrPIeGXdMdsY6AVBf6mhxBGrnA5A6VLdJc7CQ+7PcVjJIscxVyxc9TigDD8UMZQotbXB7sa4mZWEjeYqq3QkV3uv3RK4jPQdBXnt0xa4czDCk8epoAsW9vFEyty5ByBV/VARbxnywd3H0pmlR2s6kgsCvatd7RZrYjn5egNAGNNoki2EdzCxYnr6CslyY3w0+T/KuzsILl7CWORzHEeF4rltT02CxLAzGZyc8dKAM6W2WVWeW4x6YFXdA1KbSrhAkryQseVJxVVgWHBwR2pCeQCAQo5z60Ae/eCfiNrWh2gFi8eoaexBMNyTmH/cI6fQ/pWp4o8d3fixIopUS0tYzkRo2dzeprxTwDPdtezWzSMLeRc4A4ru7SOO33oAWPrigCyJ3EjKQAh6mpInhiAZiTiltoLi7fykjBDH71P1aSHT08mWLdIo7UAUJLpCJCc7M5HtWHdX15c3IjtuIh/FUk/iGyuS1ukRRl4at/wbZJeF5DGPKj5JNAFPTNLu5x5l1M6RDofWtK9GnWsQRVMrnqTVPxN4jRrr7LAnlwx8ZHesa01KKa4MatvlPHsKAJpTZs5d1x6Cq4jmvbhILJf3bHB9q27XSVuw6upBXndjitrQ4oEkFraWxaXu+KAINP8AD8FtGBfuHkI4UVt2NiY3HlIAh7iugg0OGLbNcyb3/u1oxR20KNIU6fdWgDDbS5mdCuQD2q7DY2hlCzMfMXrUs0lypMoG0H7oqrZSFpGaQfOe/rQBbvoY442EKZQjpXkvje0njZpIYcKT92vVXkYKwLhVHOTXC+I7ktKxZlZTwCaAOW8NWClSzBiT1z2rbktI1Ro1YbRzzUVjIYgPu5PXFWJ5oMlHb5SOTQBy+qaPx9oimx64qpGqi1Jds46A1ev9RtpJ3t7OTCr1z61gXF0Hu0idSDngjpQBbe4WKEYjUZ6g967v4Y65Y+EribUrhFmaVcBAOV+lef36GeeGOPgqMmrMdq/nLFncp6nPSgDs/Ffjq013xNHfpZGFkXaWPXFVdZ8Xi5tljtId8in+KsldPijRmlcD04zVC6t4xEXhLLL2OMUAaum+KDIJor+Rd4HyoOK9N+Dd/Fai8lkQxmUgqxPavnHVEeOeNzlZM/Mw716Z4W1Uy2Mf2eQkgYwKAPd/GOpRXdnFCjZbOdwrhJ95cApvPY+lU9F/taW6DSBmhPUt2Fb18pPCJsUDr60AU4443O1sZXk4ptzJ5zqltJgDg571XiV43ZlGS3ViacTtJkC7uwxQBAzjeY2Hzf3qiliLZBPI71ajLOD+646k1AzROrgK+48CgDGuEihuVfb5jDv6VR1kxXMZJVkGOWFdGtnEqcqS3rWRqdiwkBJIiA5FAHKafDHFdR5Q4c9TXUajp7PYMYSryAZAJ6VQkgVx+4OcevWptJN0WaOQ7R2Ld6AORxd+cUkBjAODV77KxTc7AKo4rU1+0lmbfHtTbxkHrWZENsOydzz1PpQBSSQRyk5DH3PSnLMZZSVX5x0PYVbfTJGXzIkzCe5pLGNYbkKeU70Abnh6+lLeRI2446ntV+8iiZXMgViP7vWq8awIpaDG4iq014Ibdg3BPegDk9fkAMmFZAOFXua5g2DTo0qDMg9av+ItRDzbchsnjB5rOjvJYGUxgqpPOeaANDSythF+8jcyHqMVpxkvJ5gfZu7VRnvd6xyRrub+InpU+nvFcSNJKWXb+FADtRu7zKRlh5P0xWReJhcr8q9SWroLm3jMTPHKHz09qwr+2uBBiRdymgDIZ/NztIP8qXEuBtC+mBUUaiNiCOM9BTgzxy5Xdz7dKAOj8BiWXXGVj8yrwDwDXpUpmgmDOI1Qdh1rzHwhdSWurofkYycAmvdvh74Wh8TeI3TVNzWlvD5jorFS5PAGR2oAqqphgMlmu361jG2nN8092A6vxg9qu3t0Psi4chQe1UNNgu9WvQqynyV5NAFG68ERPfLc28gWOQ5f2roNXij0Xw8IrB8M/BbvW69qIYNgPI4xXJ+JYJpcJFuYDqPSgDh7m2a6nTc4DGuo8M6bYWW6S4iy/c1Qt9O8ubzJMtjpjtV+KOaTODkdhQBvi8Fx+4slABPJrrtFgisrVT5I83ruxXMeHLWGKRGlRt1dnHc+WgCxjHvQBYgxLvluCQewFSlA21iOnSqNxexWmGlKrntmnLq1vtLh9yY6UAGqSPlFVCSf4RRFEHiPmKI8d6y11eV7l5Y1UDoN3aszVzfagnlPcm3U9SnegCl4y8SWliptYplkk7hTnFefvqp1FnZgdinHWtS/8GzyTSy203njuzHmuf1LRdS09S4j+QDqOhoA0LO9hjUiWQhuwrRaa0+yMRLukI6elcTp9ybiQi4wHXtV+4dFA3EBz0APagCrYaVJeanM/meXHn86u6xpzW88awkMFHLmmWF5HLdx29tkvnn3rVuLN7i92uWAA6UAYtlEZ5XCO28dWrT03SbproTzXAjg6be5rds7C2t0UKMP34rc8O6E+savFGiN5CHLg9xQBd0fQraWOMPE8u7+LFHijw3beWRHG0YUZyK9r0fSra3tUigiQADByKj1jw9DcWsgkReRwB3oA+PfEum44iJdl7Vp/BISXXii5spnUqF3BO9b/jbRmsdVuYY1K55C1yXgG6Tw742SaZzHLMfL5HABNAH1BFZxxQBSFVB0x1qG/snuLQ7U2qtTW13bXdsskcjM+OvarEcjsPLU5OOaAPP5QhZ1GTsOMVG1zIlv5aRLt7+taOt26x3zuGA7ECs3KJKFdyc96ALUNzi2K+Xj3rNt53luGQjaqn7xq/PcoIPLjBLDk8VQ08Blmkmz5eeAOtAFqdy7KIGDL3NVb24jSEptyemWq5CUAxEhBPTNFzaR3EXO1dvWgDBWDybdmCKS/PA6VVhhkafLq20DiujS0dEJBUqKp3KyRgksm0joOtAGLqMYmjHlIfl6isGe3kuBsaJlYHp611yzvb4zENp7EdainkLkv5O3PfFAFO2dhZx28qiNRwc1XuYtNjPyPsxyT61nXX2q4utihx6VYtvDbTzebdO7ntGtAEct5awwErLketcd4h13zNyxq4Uce5r1OHw7YJGrTQs59DQ/hLRZiJbi1PHagDwGMvJLujXDMeS/JFXFQRAmeQse3pXp2v8AwzgmvRd6NM0Nuw+ZH5wfauJ8QeFr7QoDNLE9zEx/1gHC0AZe+Z1UuQ8WeAowa0baV2dY9hVD2IrHimj8oy+YwPZfSr2kzTTPkOcH1oA3ba0KSYRwT6VU1112Kkk+COMCrmGiXDOwY9/WsW9WJWYrueRuhNAGRBFM85EADc8ZGK2IfDOrXi74lwp65rq/BXh15mWe4hZ1HIJ6V6Va2sdvFiKNVA7AUAfP99p9/olxBPd2Uyxq42sOM19Mfs4aiNTu9VmCFCIIhycnqaw7/TU1G0kguI8CQY3MOlZ/wimg8B+Mrs6jqQjsJ4yjkr8vHK/zoAZlZV8oqFFX/CyJaXc4ikG5h3rIysZKgkse9S2+IpRtLBupNAHbWq5d3uiG96yfEBgUAW5G89aoS6rIgVScgDOazDcLdSl3cqM0AaFmkP2dzKmPas9biOO8Uxr8lXGnUQMq/MB3qj8rhXddozQBpPeTI2SVUHpisjWPEN9awMYm3heM1LdZljIhJJHT2rO0fT317xFb6XE+UT95MfRR1oAveBtD13xVcG81G4kWyRuA3p7V6FrOlpBbw29nHhF+82ea6NJrTSbJLa2UKqjaQBWFqlw8kWYHAoAr2OkxKFcsWJ7elN1m18gpkLk9vaqVpfNCW3t8/wBeKqX9+bm4zKW3LwBQBcVoo4mVcbcc4rnddeOaEwrnYe9akF4kcbgrnPQVi6lkyiQKwU9V9KAPM/FOjyWoe5siR3Y+lcxpktzfXo80t5YGCa9d8RxRLo0iqhaRxgDFeXpFcWkvlYG5jkbTQB33gOztIUuXkQeb/Cx5rXKM1yW4AHc96yPDVpPa6aTcZWRzkZ9KtT3ubq0tSrbpXC5X3OKAPQ/BHhka3d73QeWn3jXruleHrHRbcLbriQ9WNR+E9KttF0S2jhUl3UMxPUnFak0jSDbkUAIgRQSx+Y9hTgTICWbIHQVXCgkMOWHUVI8seUCg7j6dqAPGvi3pSwakl2OBIMZ9K8K8TAW+rQyKykjkMK+o/i9YC78NvIpw0R3ZI/SvlnxHAHuLY7GLbsGgD2X4eeJ5rrT0ieFSIwAznvXc2uow5aTzAS392vGdJinsbGMQAgOBkL3rqdIu7mEbXA8sjPPUUAb+oLFJekRg7n5PpWfMqQylXXcw6YrT067S8z5SK23qfSnTRRRkypyx4JNAGVP5jxlowFBHU9aq2pZVMcjrk9MVZvY2ckO+PTFVlWGTiNsSL/EaANGFSrcnIxwRUbIN2055/WqhkuII928MnoKes8kqhmIUCgC8YI8AFwF9M0ghtl3xsoyBkH1rIMs0k2IkZl7mpgSSQ7YagBrypLJ5flMGXoSOMU8srDYI/lHUkVLHI0a7flkb2pySOrlvKGMdDQBD5VvkJ5fzdd+KzrjVINPkZVlUyelZfiPWwLry4pSp6EKOlcyZTJOX2vt6biOtAHT3HiffKqBtg7kVYttfJDFJEYf7VcYynecKoHqTRGoVwsWCG6kmgD0G31XzQVaQE+i9KtywR3+nyQXOHRxjBFed208tv83mBRn866vR9WRlBkkU9sZoA8i8aaFPoGrMtwiC0k5i2nORVTTZ4kZW5AFewfETSItb8ONKg3PB8w9a8WsBFDJ83JU457UAdBc6napGrhHZjwF70eHrZtY1QKsAjRTk7qx7yUm4Uxx5zxzwK9R+HVgkdiZpDtdjzgZoA660tTDbxxx/uwo7VctUO8kvn0qW2hRh95iav29oq5bHTpQBSuIblznenoAK5rxHpkZUPOeehOK71YeAXXcx6DpWR4gET27I8Qdl6Y7UAclDGXXOAKfI7g/wgDvUSOCpVsqTTmSQKRlWBHWgBjSxvkMajRYgwXr7VIo8qEqyKx9qb5cTNvTKtjpQBYjKk4RTin3KpkFRx6VFHMEGG+UnpRGDkvMcRjvQBWu3FtayzB8A9BXR/CbT4xaXmrRo3nyt5eT3A9K5LXZYmsmRTn0r0/4bM7+EIEihVACenegBuuNKsgZzgGsucGKzZw27PQA103iWx+3WQKMEdOT71xUBMiSxibGzgg0Ac/fXtwmSmSwPSrmktc3e4yDdkcVNIYY43Mi7j2xRp2qRJMsYj2gnrQBqRQR2iAyjLelRLGLiVpdpCDtVud4Z3UhvnIrE8QaoNMg2lwsh+4B3oA5z4gaiLSFYLcZd+n1rnvB2hrPJJeasZFYH5R2FalrY3GpX5vdSO8H/AFa+lXPE959h0XCYEjHaFHXFABcXlursrTAInQ57Vi6HrtrN4ztFIzBG4O89qpaf9ik06QzyOZGHOTzXLW4/s3UmuoA7ru79qAPvjTJ47vTLaaFw0ZQYappnVCCBya8q+C/j201PSotLuA6zoPlL9MV6p5f2gg+YCO2KAA7TGHUjJ4p0Rj8zYq59WphhRXJZsY6D1qC6vYLNWaR1QEetAHO/F+8S18IzpGA0jnAB/nXyx4mmks9KhuiytL5nC4r1v4n+J21XU4LGKZBbjqo5JNea+PLQR6bBJbpld2MN3NAFjwrr19f+UrwooUdq7aW58yE7gAxHOK5PwJar9g8x4ik5/KumnMcUZ8wgOPQ9aAINAvHs75gJmWJzgjFdmPMu4giAbRyGPevPpLtYZ18wKu7oa6vQNSldVClWX60AWLjT5VbNw7DPTFSf2WCFOQIz19a6OPZcKjSEHHale2jaVQi7nPp0oAxIhYRFY5N2PcdaguhBJLhF2qOldM+gx3D5mcIvUAVm3miMGKxSZQdyKAMmCOVnCR7AlQXBRJGVVyw61cVEhLJK5JHQioDcoAdsO7JxmgBrAJGvlxkE9TWF4hv5YICinGeODWxfXJt4GZycY7VwGo3rXkrBXwoPWgDOkkdpt/l7mPrUgWefIEiiJeSB2pkRAzlix/nSyRv5RMK4DHkA80ARyRxquA5cn0oFv5owjkFexFPjjZWDLGwYdjUazZkYSswkJ7DigB32cso80g7egqzCrI28IFAHWoRbCQbyZA2euaRIR5hAlds9qAOw0SaO5tJreUs6SKQfavHvElkmma5c20Kbl3FgfSvRNJlZLlI9zxoevNcd49gEPiAsGdsqD7UAczD5st5AhYr8wznkV9HeHLEw6TaqkClto3Y4rwLTlma8iCw4DEYb0r6K8PRSQ6RbRZLttGXJ5oAv28BX5tpJ/uir8URAJkOw01BKm1CMKepHWpw8YYkLJgf3j1oAjaNPNBeQ9OxqjqMaMrqqHPqavSBuTHsUn1FUpROwIZ1c+lAHn0UUruN2Me9LsmLNt5AoP+ry77XqRZmRQQOT39aALVnps104KD5e4qvqFssFz5aNucdQKfBfTROWgfGRg1FJHMsvmMcFud1AELxOzDggY70wOV++C0Y7VMrMSS0gJNNkilVBh1PrQBieJ54IrPfgqMcV1XwU8XWz6Vd6eJS9yH3BD2FcD41crblQM1meANE1Oz1AapbSBARjHqKAPoj7WyyuJ32h+1c9rFvDbSF4mGH6kUzTJm1AD7VIDMPSpb2BJkeEjDAdSaAOTvnKuDAxcHrVN4TGwaR2GeeK0XhW1dldlK55NY2qavFpysSvmhume1AGhDqAtA3my7hjIPeora2Gtym+uCRFF8sat1Nc3o5udU1B5WTEA5rqb68t7O08xn8sIMBfU0AR6je21jEXnkMaJ6VwHiPWJdRmElopkjXgD1qzdLqPiCbLAR2wOBnvXR+Dvh1qniHUTYaQBHCgBmupVOxPb3PtQBwFsl5qEix29sVI+8x6CtweHr2OEMWVmz07Gvp3wt8HtD0S2C31xLezN94vhVz7Cugl0jwvpWy3k02PYf4tpYUAfI1rc6tpuoRzWqFEj4cDoa9U8M/GK7tBHDfWJVAOGDV7LcaZ4SIWGXT7Yo/I+Q4rG134VeHNYiY6eTZyjlfKIK59we1AHIat8ZrSOAsLWRmI421wXiP4ovrVuY4g8P8AOul8QfDrU/DDPcNbpfWIXmSEZ2/UHmvM9U0lA81xDFtkY5C46UAVvDt9JP4hVp42lY8727Vv+O0a504N8wVGGFFcv4Znn/t9IpSIiP4q7TxFH50Hls5GMZIHWgCx4bWO20OGV5j93LZ7Vx2u6wk+sFILs7M44NbuqXappENlB8gcbSwq14J+HtvcTNdSgzM3QN0FAGXq1xB/Z1oAzPMOpFXNK1ZYVjjjd1PcYr1WDwlpsaIn2aNio6nmkuPCOnOxJSNJPUdxQBzuleJ4N6xs7fU11+m30U7K0cn4Vzdx4OiVy0AAPYU2G2vLE7VA4PWgD0WKRQ5LfNn9KsKQCQRvTvXDWHi600+Qw6mkjf7aDOK6zTdUg1C2M+nOHgPB9c0AY3jKBrWKG7tYN29trqB90etY8YzEPNIVm5AFdw8UkyEMRgjoawtZ0qS2RZI0Lr3x2oA4LxfK8cISN1aM9cdRXE5jSQKXzuHQV0vjZPmUzAoncA9a5UtGDugjO0dM0ASHz9+1Yl2evc1H5V2p3R4UE8g9RUvn3DRgJGqkd81GZZXwZpPmX06UAOdZNwJnJbvTzcKqAFAzE9arGdGypdjn0HSnrOVkWLYrqOcnrQAk8szHBcqlCSmBB+/QA9cjmnNPv+WO3wc8k9KdJGMqdkZHde9AFixcm6RoiZcdQKyvHN6kt9DbLbKrsOXJ5rodIg8y6Vki8tR1NcX8QXgPiKNo2UhAAxVu9AFBpnsdYsRjeqsPlboa+jfDkiGyt5JDs3KCw9K4Lwr4CHiDR7XVWIAVsrt5zivQWgjtrVUwcoMc9zQBsvd2yuMyBl9BSPcxS/cQkCueXzXdWCKoHfNXftUka7Dkk/xAUAaAbdJuVGC+9U7woucjnviltkQqz3E59gKq6g8KwtiRic9BQBw8iAKCwJwfzpS7AhmQ7O1N/eOgwc+1Szn5F38H0oAi81ZCBt2kH86s7nlQqzjjpUSqix9QZD69qgEcqksDkGgBWEaNhmy3tUUtwIlYykgdialfy40DlCD71zHifWYQhTndQBznivVHmuvLHzKOmK2/CviB7bRblJkJZR+7VRyaw/Deh3niXUjDZxlucs56KK9x8JfDyx0iDdfN50h5BI4BoA4jwbrGrXqyGHS7gMTgFlIz+ldVc6Rr11aOzxPG2Otej2cdraRqqBMngCrTXSxxbSAxbtQB88ajp2qWNwXuhJIvoBXN6nqEWo3sdtsdCh5B719O30SvtU28fI6kV5D8TdFtND1G11MQjdO2whR0NAFLQoo7K1GzOSOlZZdNV1429wV8legB70/X9WaPS1jsVRZHHBbqK6P9nfwu3iTX7q+1KHdY2BVi/aWU8hfwHNAHceEfhNJePFc6pI9pYqA0cSf6yT6+g/WvS7++0vwfp1vaWsQiRztXaOh9WNVvE+sara65aW1gkX9nlN00mMkHPSuS13zdaubq2eT5Qu6NvU0AdLrV9NPHAFuQGPzDb3FZ+sakz2aIse8qfnY9qwvDF5u0V43VpLy2cx5POB2qx5F0Y5cuuJOoPpQBsrNZXYhHmjft4FZl5qNxZzObZpDIh529MUyKxtoAjrId2P1q5DExsp3BUS4wAe9AGl4f8cRzBodZTYvAWQLkf8CFYHxL8DQTRtr2hIGUjdcQochl/vr7+orNtoYluBDKxy5yx7Cu68O6pBZFNLvJF8qX5Yc+/UH60AfJviWCWy1KO9sQBCOGxzXUx3bXPhtrlVzIFzg10fxO8PDw74kmso7cHT7xTPbNnOP7yn6H9DXC2eoLPBeWVqG3oCGXpQBx914gkn1S1WVSg3hQuODzX1T4etLWy0G1wG3vGCSO2RXx1eNMuqhZFwUk6ntzX1/4TkN/4T0+beGURDkd8CgCO/v0tUZUD7uuT3FZkGqR3bFWdlOeBmpfEYklt2G3aR0x1riZS8UqMC6HPpQB6CL+GEiPcc46tVlZbWeMl0LEelcfKy39pHLbyOZ4vvj1q/o7Xck6nGY/SgDQ1Szsrq2bdaFFH8QHJrjIJbvR9SY2FwywnqlergL5AR485HTFZc+kWTyY8hRIf4jQBP4X1WPVoisk2J4x8ykY/GtiaMSgxPPwRXHLpEmn6ot3FLtA4YDoRXSSXNtNaeakih16jNAHmvxAshbyMGbeo5FefYUDcj/Kf4e9emeN9TtrmJVZ49wOC2a8/ubZRJ5kMqMPQGgCq06EERklzwAeMUqQMxUSr7nBpv8AF9wE+wqNdyyglnHrQBZ3QFtiRlQOpxQUJG5EVsdCTzUW2U7ihDZ6EnpQYZty/MA3qKAJhI3m4aFgB1pV3G4JjCEgd+1QO0xXLuwA64FamgaTJqE42I5Tu3SgCxZW949hM8QMkjcBRWRF8PWuSZtSklhaQ5xtyRXpltpcWmRqVDlj2BzW7bIJ4d86ZC9jQBlfD+GXwppA0x7hZLXJZWI55rQvpo5AzxK8u45PHSoL2JQwd4Sf7tEb3CRFdgRGoAZEEZlaSQg+lWJFH3YZM57mqyiKM72zk9iakivgD5flpt/WgCUYiTEgDE/3ao6g8a2xdsoM1blnYj9xGFPqTVGdJbwC2G1pHPfgUAc9dXEf2rai7IsVXIIJZm3A/dpWCPwGDN60XMgMSLjaydxQBEUR3+cNuPekd1hziT5Rzg1FcX3lnAbgjr6Vz99dXN9P9lskMkh4yKALGs6/CkeA/TsK5fStFvfF3iBLe0z5XVmI4UV3+g/Dq4uVV9RVUJ5IPNel+HNBsvD1v5VvEFJOS4HWgBvhLwxa+E9MSC1TfIwzI5HJNXNU1NbXDFgRj7tM1S7nVXaLJUDivPNUubi7mZ2bG09KAOmtPEAuNUDuuyNBxzV0aw11dt5RwlcJGW2jgjPetnTVRpFiRz5poA7mGOa4VWklwo6VxvxlgEOk6blg7PNtGfpXa6JCUttk+GbtXC/HaVIotEicucysVC9M470AeR+KLP7RdwQtK6yBeAnNfV/wc0GDwx8NLKONjunU3MjvwSzetfMH25rfxBatawh7lmUYfpX094w1WTTvB2jxGHe1wqBynRAFBzQBleJL64hkVrRhtOQ6nuKbpkG62WfeEkBzhu9Z7Wcl9FFcRz74VHPqDVq2lWBAtwrbBQBXt4TpPjH7UHVdMvExLnoH9f8APqa1NZRfOM8DjyzwOetUVUanZTwu3lRbsoW61ahl0BbL7Bf3sn2lVyjKCf6UAVrhXjjj+Vy78gCpLySa38pohu3DDA9qj0y7/dtCzmSUZ8tyO1V2e6eORmbG1up70AW7hrRbLaZFa8kOfLHUVn6uryTWRiRhJGQWcn7uKq3m+O2e4trfN3jhmPFZB1TU7nTpJZIwXQ7WQdTQB2nxk00654N0vWbSUSNYSCSVk/iQja2focGvDrm2Ww1hbu3G6KdfmVepNe/Qg33wY1KJYBDKbaRWTOfm6185eJby7002LbRgHmgDlPGyldSZhatEWGct3r6C+BF7JfeAUh2g+Q5QtXjPiC1l1uEXISQ/JzgdK7r9m678uHVtMRnJVhJtP5UAeuX9sjJ90b/WuZu9OiSctckMjcDHauvmgxEQud565ritcna3ldJZE46AHmgC7odtaWc8rRMCCOQ3etW1vbOG72qY/MPO2vNJLqZpdyMwHb3rR8ONI+tRvOyjsNx4oA9F1TUjDbmVyqLjggdK4+TxGjysVDSEdSK6fXrSe+0x0jdAAM4HevMJiLdmSJ8Op+YGgD0DTdR/tK3ZFzjoc0y/0OJraWSGZklx0Nc/4Z1mG2OyaNt7H73au9jUXESlcbSMkigD568UaRe2movNcyF4TxkdqxbW6+xyFT+8Vuc+le8eM9Dt5rBy7Bc+vevBfElkbSXEBCgHv3oA3UnWS3EsG0npgdakhEm3fKgKt6dRXG6Qbua9VIpMbuD7V6fpfhu6aEGWTdkZzQBz1yRCFVQDzyO9NtJd7EQwuT64rsB4aaMCRtoOeh71tWOlKSvnBSVHGBQBx+n6Fd3ZBbKDOea9I0i3trG0SOQosgHamRiCEbZF+lLO1srLlGJPY0AWD5kkyvDtdat7VlBAyJR2FV7adZI8RbEx2q/pK77os+MDigDKumZJAJtxPYGnQxFyAPmHXjtU2teUL0iNgT3qrbsSTtkwT1FACXcKCU7mVsjoO1U1NtDjywTIT3p9xF+8IDNvPQioDaEgiVuR1IoAkEhLkAKfoaoNL/p8H3wyk9Kv2tvCgZ+q45x1rnbi+gt9UeRJXRV4zigCpJ1V0TiqkkszSOVQFR3NWmdJAcOUQdqqJHPezLbWYJBPJoArW9jf6nceRbRBix59q9N8JeD4dLhEs8YNweSfSrvhDQ49JtFkkG6Zh1Par2r3z2yBywCjrigBs84hkJEZ44FSpdnyS0qgp1964XWPE0zzhbcZXuT2rf065ku/Dty6PvmCHp24oAswXyXfn+Wm5F4xXn9/hdRmyQvP3fSsrwl4ln0vxTNFqIkNvKSPTB9a2PFWyfUhcWQGxxljmgCkJp2k7FPQVp2KyrOhhTLn061kWUMpmXawz6V2Oh2VxHcCWReT0oA7TQYZRYq0iEP15rzP44ai9vr2hW5AZWDMRjvkCvVNOy7rlzwORXh3xRvE1b4lrbjKx2cQUZPVu/8ASgDmL22e48TQXTOY0iZWOB2Br6n1429/8P7C7ibdCkaOD1yMYP61803ccUBeWSYbjgba+jPDcYh+ElmIZlukaIMTjjBP3fwoA42ymnjjY2zDyyc7KuNNcvERsBduhPQVkLLiZ2ERRQcEA9KtS3WYBGrAIf4s8igC9bWd5cFYmlQ84+XtW1pXguOK5+03rpKOwHpWZoEMVrF5kk7Zzn61vXutIiKlu3zMOtAF6LTbMXDNCuzHGMVgavBmZoUGEBzmpNI1/dPLBKMsOd1Bure+uGgm3xSk8MRwaAMC8eKORXnuAEXgIO9Y7ukepmQOIoJBwG4Ga6rVdBhjcMcSqOeK43xOqxzxfaU3W4PG09KAPR/CSRjw1rls8ygyoZASc/wkcfkK+d/HjrBpdtI6lgJCpkPavcvhqkuoayrKoaxWIq6k/lXj/wC0C8Vv41k8P26BYECzKB0yw6UAYfhy98+ze3imBwM4PUitT4UX0ej/ABFex+aP7ahBY8AEcj+tY+laWbGGK42HeOMLT9dL2V3Z6zaROXiYF17igD6XuIGIyJsgda868VadDHdh4GLljyCea7TwtqcfiLw5a3tucb1w47g9xWf4psWggaWOEO/qO1AHml7IQwjGQRzx2q14cjuLjUkDt8gPWobou7ldqgk/e9Ku6JGbfUIyoZh3oA7bxBfx6dp4EQfeVxnsa86bfNL5hI3scmux8cXCvp8GxcE8bTXDI7ROcIWPoKAL8TOLhfkwO9ek6GrS2qFJCy4xxXnGmlmvEeQERDqprv8ASb4PEUtsIBxk0AX9Vg32jo6hkA714b8RLSNHDoF3Dtmvdpw32RzPIGXHOK8Q+Inlea/kqznPHNAHPeC445b1SBmTP3cV7ZY2zfZky2MDpXkvgeFmuFYRbHB7V6a0pWMCScq3pQBpXE0K4VojIw7ZqujM5YxqFHoTUdmrSt5i7zjuRUs6oU/eFlb2FADi8Dw4kBMo6Gqrkyzbdygr0BqxGYI2XzFYr7UxkZ5Wkjgwg7nrQBcgjEW0tGN3XGakkuFV9w3RnuBWXJ52d43Z/lUlvJOJA23enfPagBfN+2zt5QZCvr3qSO1uQ2flye+asQuquTLHtB7ir9nIj5DIW9DQBz8uFkKlm3+lW7GASoQxZWP407U7gLcYjgVmHGOlW7Z5HhB+zmN/UGgBtzHHBpkjFTuHfFeU+KbxYkaR1VcnA5613fim/mWEQKSCevNeL+ML8T3iW+/cy9QBxQB6FLGpxCn32rtPBnh5YT9oncZ7Liue8L2cl7qHmNGWQHrXqFtGsKhUXBxzQAtxggKrYUelcT41u3jjEMPJY967aaRVQ7sAivOfGV4JLkLEnzDgmgDm1hmjDNIybT1r0n4cQQ22jXEksgYOc4rzPY0sioW925rpNN1hLLTpbZSMHvQBheLLS2udbmlt02ru6elQQBjGVYEqvSiZo/NZlkZnY5JpsJmGcMNnqaALljMsLeYsfOeK9B8K6hDe27F1IkXjJ6VwcU2IQohziul8FJOZHeQBEJ+7QB3kRWGFmUZcDqK+e541ufGuq38u6QiQjHp2/pXv9zcC00u7lkYLGiFt3pxXgWnXKs97cplxJITux15oAwNavcagxS3cx9+OlfSnweu11j4UvDYInnRNJCEfpu7fnXguowtd2T+SoEretdl+zhq0/h3xLc6LqhkEOqYNv3CyrnOfqKAJ769ms3eCOLfJIxDD0qlZyyyXTBwY0Uc5r0v4h6ZZ6Dq9vqotZJba4Yq6IOEf/wCvWWNI03xNJFJatJZDPzAqMmgB2gSKlr5jIZs8AVZltnukma2t23Ad+MV32k+GrDT7RQGLoq8s3T615L8RfiRYRTSad4Wff5TFJ7hR8pPop7/WgB9hpNzDKZNQu4rcs3ALc12+lWDXESxrJDK4+6wNfPF3qd7eSLJJIzzHuxq3a61rOmhW066Mbqc5B6UAfQ19oephlXEbwgZZweR+Fc+NM0SE3D3bNfFuBFj7prG8F/GV/tEVj4ptwsZGPtsXIB9XHp7ivS49EsLtxqWlyRyRXA3hkIZGz3BFAHD/AA2nk/4TO6hjt5IbYREBSOnIxmvJfjfHaz/Gm8SU/vVghIA+hr6d0HTRbTzXLxBJn+Q+4FfMPxmt0tPj1ePc8Ld2kTxk98Ag/wAqAHWFwkLCK4jxHjjFSSGHEokAkikGNvpVKV4VjaTf90cA1T0nxBDcPJbCEGYH73bFAHS/DjXJfC2sSWNwGawuzlGPRG/wr17UszW+OCHXPFeIXh86ARPIpPVSOq103gbxXBY/8SrWbhx/zxmfkf7pNAFDWdOuoL5/IQbScgmr/hTRtRkvlnuGURD+EGuvvIFuj5kMfmDsR3rR0i1MSDEeD3z2oA4HxpG8l0IFk2hRyTXLLBLbONrb4z3zXcePIR5ocDnPUVxkrx5AYOp7jtQBNZ7xvZpQFHauh8J3UM9y1uxct1z2rBWOMw+YFwh4Oa1PCrRjUUWGNmyewoA9E2xw2r5ORjvXgPxN1OA65HHHk/3lUV9DXKA2LEx8hc184eLri01DxXMQ6xOny4x3oA6nwM2+NcWrDI4bFdldW+wq8ibmPauX8GubcKok38d66iW4ZpxvZQvvQBcsxtOU3ID1Q0+4KMfmQkDrS2skaoS8mVI4IqtuWSY4lYj0xQAxpSoZYo8j1I5FV3lkUhTKeexq86TNLtjG1feobq1kIw43L/eFADY0lkI+YAn3q2tt5a4dyhPXB4qhCZoWXCq0Y9etW7hmm2jkeooAtFYwoHnKw9KV5Et4/kf8BVGJI43ByCPepf3RfcMZHYUAQRXkM11l4JCR3IrRu9Qis7ZnLFVxwp61TkmMamRiiJ2GK5jV7+e7nwzIYV6UAY3iHVxtnmfcSfu15lpG/UNdl85GMfJyBXR+NtUEUJiWJWJ4GDVTwnMI7F2VWW4bqO1AHv8A4VVIbUtGnWt1biQjBjIbtUOgpHbWwjVdxNXeS5bYSw7UAUr64jFsxnUg9q818Qyq85YHgeld/r1/DBEyzj5iOBXm17IJ7xiv3aAM62G4l1U/U1q+GtKk1W9lXAAUZwe9UPLk3EjhemBXWeCbOb7QZE+hoATUPB8v2b7REyKU6pXOm0HmFBxjrmvQvFMk1haEMSFavN2Ekl0zFiA3TFAF+0jWWdEXIAPIrvtFtYrePIJUkVi+H9ORIkkwST/ERXYW6wxxBpiML37UAct8UtYOk+DLnYv7yfEQ/GvJtEjkGmQRKNrOd2TV74n+ID4o8WwaZp7M1jZ8uw+6W71FMZ7GyaSKMuFGAKALci+VIgwWfHVauWzywvHdxOqTxMGVj2rJ0y6nlsfNlTYxPerZuYjGTKGCY5oA+lnlXxR4Mhu7aMOZ4hNGh7sO3865vwhF9ov/ACRH5Txn94jDB461a+CExm8A23JMaSyJHnsueldstnbpdtcrGonYbSw7igDyr49+MTo2lwaFp7sl7eDdIV42RD0PueK+f7dzI53R7Y/p1ruPjvdm++IkyOGxBAkSEDgdSa46xhcxyZIbbQBMblVADxttxgYprcDzFVgvoe9XrL95kFB9TTZfMOR5e8DoRQBStJFEcvmoST0Ar0z9nnxjLb+IJvCd3IXtp0a4slPWNhy6/Q5Bx65ry6aaeM42Lt7Gr3ge+uofiBok1lBm587b8vJKnr+lAH2VXhn7R/gCbXLnRvE9lkvpmYrmNV+ZomPDZ/2TnPsa9zpk0aTRPFKoaNwVZT3BoA+P/ENhEmmAwMQGGMDrWJ4f0oWKmSZgUbknvXt3jf4XXNpdyX2h7rqxY5a0x88f+76iuN1jSl0rS1nv7aWIMdoDoQQaAMaCNSS8Zyh7mo9Vt0aJRjc2cg45qidag064jWUZhc/KfStyRjfIsttLCFAyQT0oAf4f8X6nooSG7VpbQHhcfMor1nw94i0rXYN1jcgygfPE3ysPwrxeC5guLwwPcIzDg4GRS3tvPptyt7o9yIrhOeO9AHrviDTortPLaNuec1xr6NOt6kawq0eeSe4qHwt8T7eWVbPxEpgmPHm4+U/4V6NFHaXcSXFtdRSRsMgqQaAOC8T6fEzwxwRshVfmC9K1fA+lxQyNK8rbxwBiuhm05Xcllyp71asrGG1iPKp3yaAM/wAb6gNI8PXNzHIwIU18lR6qLrXJruRi29yScc16/wDHjxZbyLHpNlK5fP7wp0Psa8atVjgkDIF3Z5FAHsXhC4EqxtFuZSOpFdvPJG0f7yJj/tCvPvBN0HtVLJwPSu6WcMAnO0j7poAmtZNoIiIZfQ9qnjmO7ciYx14qvBakyfugMntmtaKB44cbMmgCGK5lOCwBB4zjpVlUmfIiK5P948VWmhmV1z8oP92rcNqGyxlbd1AoAg8idMifYeeMdqgktpPN5dcHvmtEW0bszPL8w/hz1qti1MhV9ynoMUAVzHASAzg4ptzLaWMBklOPemaleWOnQkzlvbA5q94K8JXXi29TU9ZR4fD8Z/c2zrte6PqfRP1P05IBzsC6vq4kfT9Pnm05M5uAvyr/AJ9q5PVNSFrHOAPnGQSe1e7/ABg11fCngR4NLMVvc3OLaBAMYX+Igey18laprlxcSCwhRpifvMBQBDvfV9W2FkePPzEnkV2Vvp9vYWeLU/M3XNc/4ZsY4PN/csLg/wB4V0M081taf6SqqB3oA9y0WfzItwwcVpNOQp2HGOtcb4G1OGe5MGcsK7e5UJztGDQBxPiuTf8AdGSfauOlEbsEGd/qK9I1W0EmWwpz2rlLzRJY43liX5iaAMJImDbNwy1dz4UtGj2OshHrmsPRvDk3niaU5J6A13emWhiQq2BQBX8RWUuoxlHI4HHvXO6X4eCTEXAHHIrs5ovMwC4+WsXxH4i0jw/al7y5jM5+7Gpyx/CgC/EI4LYg7UiUck8V5j8QvH8UobRdKYOTxJInb2FYWueL9V8VO9vp8DQWI4Y55aq2keH4rX9/Iu6Q9SaAKWnwLpVszuQJJjkuat6jerJaxxQTqz9xmpNWtYr1PL39OgFcxeaBfW6GaLJVOTz2oA7fQtOS6tTK0jfLxj3pPE2l3E9gkdgwWZmAweM1y3hvx9BYy/Y7iKRhnHyjPNdmmvw3l5CLZMnr8w6UAfQvwy0h9C8CaNp85DTxQDzGH8THkn9a6euK+Gup3d5ZSQ3jh9mCnsPSu1oA+afi3aSp4+vHmKmFkV1AriFZgxEaHGelfU/jfwzp2u6RObqNY54kZ0nVfmUgfqK+Zru2u0BaADA6cUAMtUJmRUVih+8PStK4iZQBbgdORWNbJfKheSZUI7U8XkzbQSQc4JFAFTWLciAkK5kJwAvJJ9K9W+A/wy1HT9Qj8U+JF+zzhGW0szyyq38b+h9BUXwy03TYNZj1LWCJIo13RbhlVf1Ir2Xw54m03xA91HYTEy277XjcbWx2YDuD60AbZpkTOykyJtOelPqjqlzcWiJLBB50QP7wA4IHrQBakdlbhRj1JrL1+3029svJ1OKKeNuMEZxWnDJHdW6unKOM1xHj/XvDfg+BbvXNQWFn+5bg5d/oOtAGdc/C3w7rKgPbhIBypTqDVb/hSeiJGUgvbuMHjs1efXvx900XQTS7W8WLsxwM/hWppHxp0yW+hXUri5t4XPLEZx+VADtd+D1x4dkW/wBFlfUYc/vYmUCRB6jHUVy2uWMpuEEULRsB8wYYr6N0DxRoesWgk0zU7e4jC5J34I+ua8U+LHi/SbvxUtvpUqSPEm2Z1+6zZ7UAef6hocGoRn5tk6+grCtbm/8AD96Cl3KuD8q5O38q6lrhvN807eewqjqCQ32Q64Y9M0AX7T4uXVpGYry3adsfLsOMVnaz8UNT1SExRBbVccNnJridU068hvNiRB4x/EnWsvUEUMoyyt3BoAkvZri6vGnlcSsepPeqkp8zJHyH1Aqa0W4eNkRFKepqvdTXH+q2hCOMAdaAOr8Bah9luvKklchj0Ne06dJ9ohD7MkDrXzlpst/Z3Ucqorlf1r3jwXqovbCN8iNwMMue9AHT+SxZX2EYrQswWyctt96itXZzh2B9KtM4jGGHB7igCIo6OcgsOxBpySS7vmUDHrSqGdyyHC+h61FdSJbwNLcOFHbJoApajcTo37po+aybjVJIGG8xlxzwetVr7UPtLmFE6/dYDrWRPcWVlIi6mCNzDPrigDvPhz4Vu/FWrf27rny6Tbttt4M8zODyT/sg/mfYV7NqmoWWjabNe6hPHbWdum53Y4Cgf56VxsXj3wvo3he2ksrhZoo0CLbwD5wcc5HavAPiN421nxtctA5WOxibdFAn3R6M3qaAMv4w+Px418RmSyWVLWFTFbRtwcd2I7ZrC0DRTa2v2u5kb7Qx4X2qXR/D6W0ou72RRI3TmrOu6pbWEOyJ/OnPQKelAFt5lto/OadY1x36muQ1zUpNRudsE5ZFHPPWqF1qN1fErOuFXopNVIHERJdcHtigD0KXWL/w9qcV1A5Man5hnrXtHgz4geH9ds0+036Q3QGPJkOCT7V414v0+P7GylmL9a4Cyg8qcujFGToaAPtBltXUSQkMp6HNQmFWUqNp9a+XNL8XanYDH22Z88bdxwKvT+PvEIUpBMQrD7xoA+lIEtYcmaVQF9TjFcx4p8b6RolvIy3HnSgcLHzXg7+JtWuIMXV3I7dOtR29ne6oQBGzL3JoA2NU+JGu6tLIlgWhjJwuOuKTSvD1xeuL/WbhnkPIVjkmtjR9IgsEUvGCw68d611YSMSwGxegoAhiHkxqlrAEQcZx1okSZjgtgdwKumVHTHRR6VE56GPGO5NAFXy0QqMAd8mqWsXcgjMFsu5mGKnuZoWYhJQZR2qs0EiOHcbiemKAOctfDI0/feXWwyucqPStfwhaTXOuRqyk7yFGK0J7W9urOQPGPlHy881m+B9Rn0zxRatNC7gTBcY96APr7w7p6adpVvCEUSBBvIHU1p01WGxScDIp1ADJk8yJ0/vAivB9a8MahZ6zcW0dtJNHGPM8xF4K173SYHXAzQB8g+LmLQSy6XA8kkORJHjkEdeK8vk8Qa5LfRRwWpQM2CGFfWPxhtdP0fUbLUhCkT3zGKYgY3sBwfrivPLnQtMidruIBi4yV9KAOh+GFrd63pItIFTzo1BkZvurn1r0zwj4JXRtVk1K6kjkudmxPLyAoPXOetcN+z1qNjFqGv6YkwN07pMqE87QCDXttABWbr5uBpzfZDh88/StKkYAjB70AYfhEMunujzeYwcnH932r4z+Kyap4j+JOvNcbneC6aCMHOEQYwBX2Akd3pOuApEZba6bGF/h9zXjXxp086d8R0uokQQ3durlVHJYEgk/XigDxqy8HXMawyB42A+8p6iq/iLS2tHQbkJbpivSZJFAG2EqT1NYOp2Cak4VFIKc5oAZ4HtL/T4nYSqsUq8oWrD8Y6HqCXBvNPiaQZy208g11GivHGDHcs3mR8Y9qt6jJtspZIN8g9KAON8PanfJCBqEBK9Nx6iuyto1vrKQWq75VXcBjmuK0jUmXV3hvHCxt0Ujoa9D+GtxBZfELT5NSlWPTmyNxHy7iPlz7ZoAzvDfhDxdf2s96nhu6kjLbYy5VS3uAT0qtrnwt142cl3qWmyWTN0Thyf++c19jqQVG3BXtigqG6gH60AfA+l+GrtWmghkYyJ/CwIP61lHR9WW7laeIhUPUivufxR4d0GezubzUI7ezYLlrvAUqPevm651a3u72eCzRZIFYhZMfeHrQB5HP5okCEHd3AFanhzWZdIvQzvLtJxsx1r0SWGxYFpYo1J4JxVWW30xCPOeJu445FAHT6L4x06SFGunlibHQr1rcufFGnPCgTzCT6CuBNpbXO0wqmB0Ip9xbKzD9/5YAx0oA6y48RxYKROQR0HesDVdWluCqhZGz69KqI+nQpiaYFxzurOuNcNzL9nsMELwSwxQBbhuby0n3C5Tefup1xUN4XaX7RqzCZj91R1FVY5mSTbjzZ/UDpUphEKm5vLhc9Qp7UAQzPJcgKFMMC85PeiJbZYmYyLEg6sT1rMTUn1O9lVHAgiHI9a5zX7/AM258kOfIX09aAL2u6oLidY7KVNi8NzXLyo5lfMoEmep6GgoM/u3GT696lWK4VcOEMZ/MUARokocGfafQip2Z9uURQB1HrSCVrcbSqyg+lI8/mNlY+n8NAHc+IL+WUPhTkjGK5HybvdtW2kZnPpXrawW7sWMK7h60iIpc+VCpboDigDzO20i+VMm3OT3NSppkyuEnlCk9q9+8AeDotdvR/asyJCoz5aHDP7CvZtN8K6Hp1uIrbS7TaO7xBmP4mgD470zRJLhgsFpdXbj7qwQlyfyFdlpuh+IyI4ofDmpRR5+80JX+dfU1vaW1t/x7W8MPb92gX+VT0AfMd/a3GnnydQsZ7aVhkeYhGfpXMRasG1FrYRsHX16V9LfEO80+LRZ/tMSXM8Q3BBgsvv7V85apd2d1cteRJ5R6YIxQA+RLmZsRkIprI1eC7t5EijuvnY9Aals9TmnlMMcZODw1a4sEd1nmBaQfpQBjwaLdSyKy8Nj7xrQsIJbeXF2+WU8VupNCItpbGKzdQuUkkUQp93qaAJri5VpFWMsCRjitfwtosGoana2jnE0kgIbHpzXOxOTKWwAMcZrTsdSuNOuIL+1YCe3cMM9CPSgD6K1NHN5ZKCwRTzitcVzel+KtE1jQl1MX0EMCj955jhTE3cHNch43+JemtoksHhfUI7q7k+Tz4jkRe+fWgD026uYLSB5rqWOGJBlndgAPxrkdO+KHg/ULyS1t9bgEyHBEgKA/Qkc142dR1bWNJS11a+ku4wcjzWzzXE65pFrKWDqVkX070Ae4/tG6f8A2/8ADmOfSriNri2uUuImRgdyjIYAj2NeU6bp2ral8JrjVtNY3F9ZOUmi74Hf8iKPBN7Mmk3ekyvJ5Z5jLHge1epfAWSJbXWtHmhBYyeaxA4ZSNpB/KgD5c+G/iXW9L8US6iqlXb5XZjjHNe4z/FjWriE2sLqN68yL1H41x/xt8LW3h7xrJYaeWhiuk+0x8ccnkfgf51W8P6bLDZruQlscse9AHVeGPizrnhfVzFqkc2qabLyyl8yI3qpP8q6nWvidfazPaXmjJNpyQZzFKwPmE+oHGK4RNNiOHnU7x0q2qwAfOjbB3oA9Dg+Ll3Htku9OjZI0+dUfBY+ozXl/jDxnd+MPES3j2n2VUHlxRk5IX3PrTroxuP3IJ55FRR2YmlBMflsvIJ70ASgTMn7wKDj1pAsqnKbQfSnOSW5YBl4pZZGKZbaOMA0AZUw/fmR0xIPTvVtrrESso+VuCpHSnQRsejLgmrLI5IQRK570AYWv6PDqKRyWyIt0OjAYrHiuNS0z91e2zOo4VxXcs4jjAaHbjuKhubY3MLcYA5Ge9AE/hTx34p0KAR2l351tMchLrL+X/u56V0OqfFjxZDEwgksUlxkEwgg/rXEWVg10ztJKQE4C1oR2FvJEyvkuOlAHOa14s8T+LLkpquoPLADloV+WPP+7V3TraSCJdu05+9VuJY4ZmRIFQN3xUzIA+wAnI6rQAGCGZQzAnHYVXfToCWZYgc+tTorRNsUkA9iOaDEwcKWIkNAEkFq0GPLjCj3NLK6lSkqLs/lTJFeNiwkJYfwk1UdJ5kKqyLn1oAztUgs5wscRPynnFS2th+6OUVU/vZ5qO7vbbTIyJWjkkHYHk1yWr+JJrmMxwFoQTyPagDqrjW7XR43WGLfLjqe9cPquvzX8xL4jQ/wisrzZmYrI7uTznNPgheRvucD+9QBdsL37FN5gIIbgimSwNd3LyKdkZ5p0zQW6pkK5/ugZxVee+uS2Y4w0R/u9qALAWOHg7Hb171VE4lmZMlD79KiCGacPsYHuc09rcAHLZJ7UAOikeNmAjRwOhBqGUzOfMQBR3AFPVlVShj+pFRuxQn94UB7EUAe2iAyNnfgr+tW1ZLWPqN2KjintWG7dgjtUd1OHb93Hle5oATSDq8upG4s7l4PLO5WDYrvNG+M+oadqceneItPSaIfKLqFsMfcjp+VcbpjssbbeAayNVtI2vA8rgnrQB67rfxY1NL9E0bS7eS1bnzJnOfyFY/jT4keIm8PTCyWK2u3GFeLqo/GuStpmkgiEa4ROvvReO8/b93igCx4T8SpD4UuE1KZ5tSnLb93JOa4LXxfSgtHCRHnIx3ro7TSDHM9wSNvatJcFAX28dqAOe8I5ltiAhDqfmzW8zSh+uF6VDsW3uTKgCo/pU+c52v16ZoAhZlEp8zn0qpPKC4GNqnqatFlWXZs3Fuc+lIyogO9NymgCu6I+0BiwHPFTyuJIRGFbFLbxpy2Ci9BT1UA8NwOR70AR3WmwXFh5TIMt1zVWw0Q6fhIV3RMckelagzIQ7g4Harygnbg4yKAGLiCLgdO1YN/O0kxOzHua1rxW2NufGOhrJdCXUuwOexNAEsZU2zSK2xgO1d5+zPfNfav4lJDHyvLQsemck1wtxIsds6iLcQO1el/svaZJa6Dr9/LGUN7fZXI52qgH880AWf2l9GN14Ts9ZiiDSabODIR18t/lP4AkGvMNIv4ZLCHBJ45HpX1Nq+nwarptzY3aB4J0KMCM185eIPh5q3h28KWtrJNY7uLlSNoHbPcUAZszq8hCyEY5xVDUbyUSJBbxMSepq7FCLKST7W3z9qsXNujyQ3EbDbjkUAUxLIVVDFhvUUs4ZtoeXgdhU3n7S5cbVFRTBJEBjYEnvQAkghjyxVjgdag2LLEXmDFc/KBTg0igo5BY+lTlwiLs6d6AI1RBHsRdhPPPelglYZ35yOmKsOryLltuOxpoiKL8m3PfNADHlEnyyKR6ZqGOWZrkJkeUOvvU2WZCjLk+tShgLc/J92gCCbylb90CM9aV9kWBDlmxnmnwElGBUBj0zUe5SWJGGHTmgBscrvE5aMZH5io7NTsYqTnP5VKp2ncUAz1GarXl3DEfMDrGo96AFkmbzAG3bvXHSo7icxHdKwNYWreLba3QrayCVz14rk77Wbu+IE0gQdQM9aAO2v9YtYSJQ4Zh/Cp61y+seKprolbWMwntk1zMzOG/dkkHqM1LFaTMQz5VexNAEct09wzPcsWmHqakEYuEVmOG7YqdbMbcXIUnqCKjkmto/lt1YAdaAH4WJcNHlh3FQXFx5ybUYZXuelMmkleMncNpP5UxoAUVuB6j1oAb5j71YRgjuRUkbRuxKSFT6UnliP5o249KkjVHP3VwetADGZVfcCwx1pXmXdk5KkdR2qN1Cy4VxuPrTSqx8ODtbuKAJFA5Kvkeg608Ks7bCvmH07io0hM0ipDgkdK7PRtBgs4G1PWJY7a3jA3SMcDmgDoLniVMcVdsjyaKKANNOIhjis255lGeaKKANa34s+OKhQn1oooAst/x7VWP3x9KKKAHXY/cJUY6rRRQBJCBk8UN/qn+tFFADJ/+PI02x5UZoooAtv9w1Mn+oFFFAFe65Iz6Vg3ZP2oUUUAPQnyJuT0r6F+B/8AyT61/wCusn86KKAO+rI8X/8AIs6j/wBcTRRQB8x+JyfNteTyxq4v/Hqv0oooArz8q2fSqEJOPxoooAtN/wAfMf0pr/x/WiigCxGT5S802cnavNFFADx/q6kH36KKAI7j7zfSsi0JMz5J60UUAWb4kdz0ri9eY715PWiigDlpQPNbgVXuP9ZRRQBbsgN3TtVyUnyByetFFAFKcnb1NVY/9U31oooAlgAzjHGKlHLnNFFACADzG47VSj/17/SiigBk3/LM981KpzA+fWiigDW0ID7avA7Vq/GUkeHNGAOAZWyB3+UUUUAf/9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    An incidental 3 cm unilocular mucinous cystic neoplasm in the tail of the pancreas.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Kevin McGrath, MD, and Asif Khalid, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_41_30353=[""].join("\n");
var outline_f29_41_30353=null;
var title_f29_41_30354="BMD and fracture risk by age";
var content_f29_41_30354=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F72007&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F72007&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 626px\">",
"   <div class=\"ttl\">",
"    BMD and fracture risk by age",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 606px; height: 631px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (A) Bone loss begins in the third decade of life in both sexes. The data are from the Epidemiological Follow-up Study cohort of the First National Health and Nutrition Examination Survey (NHANES), a nationally representative sample of noninstitutionalized civilians who were followed for a maximum of 22 years. A cohort of 2879 Caucasian men (1437 in the bone density subsample) aged 45 to 74 years at baseline (1971-1975) were observed through 1992 [From: Looker AC, et al. Osteoporosis Int 1998; 8:468].",
"    <br>",
"     (B) Age is a more critical determinant of fracture risk than bone mass in humans. Data are from a follow-up of 521 Caucasian women over an average of 6.5 yr with repeated bone mass measurements at the radius. A total of 138 nonspinal fractures in 3388 person-years were detected, and the incident fractures were cross-classified by age and bone mass. The incidence of fracture was then fitted to a log-linear model in age and bone mass [From: Hui SL, et al. J Clin Invest 1988; 81:1804].",
"     <div class=\"footnotes\">",
"     </div>",
"     <div class=\"reference\">",
"      Reproduced with permission from: Manolagas SC. From estrogen-centric to aging and oxidative stress: A revised perspective of the pathogenesis of osteoporosis. Endocr Rev 2010; 31:266. Copyright &copy; 2010 The Endocrine Society.",
"     </div>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_41_30354=[""].join("\n");
var outline_f29_41_30354=null;
var title_f29_41_30355="Laparoscopic mobilization of rectum in avascular space";
var content_f29_41_30355=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F83874&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F83874&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 553px\">",
"   <div class=\"ttl\">",
"    Laparoscopic mobilization of rectum in avascular space",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 533px; height: 484px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This illustration depicts the laparoscopic dissection of the rectum in the avascular space, posterior to the mesorectum.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_41_30355=[""].join("\n");
var outline_f29_41_30355=null;
var title_f29_41_30356="Selenium sulfide: Patient drug information";
var content_f29_41_30356=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Selenium sulfide: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/49/34579?source=see_link\">",
"     see \"Selenium sulfide: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?6/7/6259?source=see_link\">",
"     see \"Selenium sulfide: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F220420\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Dandrex;",
"     </li>",
"     <li>",
"      Head &amp; Shoulders&reg; Clinical Strength [OTC];",
"     </li>",
"     <li>",
"      Selsun blue&reg; 2-in-1 [OTC];",
"     </li>",
"     <li>",
"      Selsun blue&reg; Medicated [OTC];",
"     </li>",
"     <li>",
"      Selsun blue&reg; Moisturizing [OTC];",
"     </li>",
"     <li>",
"      Selsun blue&reg; Normal to Oily [OTC];",
"     </li>",
"     <li>",
"      Tersi",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F220421\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Versel&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10013144\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691803",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat dandruff.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691328",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to control seborrheic dermatitis.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2692075",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat skin infections.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10013143\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702913",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to selenium sulfide or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10013148\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10013149\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698344",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Skin irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698317",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Scalp irritation.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10013151\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699049",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad skin irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10013146\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705324",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         All products:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694772",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take this drug by mouth. Use on your skin only. Keep out of your mouth, nose, and eyes (may burn).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696257",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wash your hands before and after use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Shake well before use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695569",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take off jewelry before use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705394",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Foam:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694495",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Put on affected part and rub gently.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2696424",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Lotion:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694521",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Put on affected part, lather, and rub in gently.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695285",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Leave on for 10 minutes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695595",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Rinse fully.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705526",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Shampoo:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696267",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wet hair and scalp.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694452",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Put on enough shampoo to make a lather.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695277",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Lather well.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695287",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Leave on for 2 to 3 minutes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695591",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Rinse and dry hair.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10013147\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696441",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Put on a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696452",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not put on 2 doses or extra doses.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10013152\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10013153\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11862 Version 30.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-203.80.222.8-3836C529BC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_41_30356=[""].join("\n");
var outline_f29_41_30356=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F220420\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F220421\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013144\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013143\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013148\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013149\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013151\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013146\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013147\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013152\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013153\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?33/49/34579?source=related_link\">",
"      Selenium sulfide: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?6/7/6259?source=related_link\">",
"      Selenium sulfide: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f29_41_30357="Candesartan and hydrochlorothiazide: Patient drug information";
var content_f29_41_30357=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Candesartan and hydrochlorothiazide: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/25/21911?source=see_link\">",
"     see \"Candesartan and hydrochlorothiazide: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F145019\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Atacand HCT&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F145020\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Candesartan HCTZ&reg;;",
"     </li>",
"     <li>",
"      Atacand&reg; Plus;",
"     </li>",
"     <li>",
"      Co-Candesartan/HCT;",
"     </li>",
"     <li>",
"      Mylan-Candesartan HCTZ;",
"     </li>",
"     <li>",
"      PMS-Candesartan HCTZ;",
"     </li>",
"     <li>",
"      Sandoz-Candesartan Plus",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10021859\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700281",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take if you are pregnant. Use during pregnancy may cause birth defects or loss of the unborn baby. If you get pregnant or plan on getting pregnant while taking this drug, call your doctor right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10021861\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691888",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat high blood pressure.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10021860\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701696",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to candesartan, hydrochlorothiazide, or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701385",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a sulfa (sulfonamide) allergy, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703719",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a block in the kidneys' arteries or other kidney disease.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3915366",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high blood sugar (diabetes) and are taking aliskiren.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701080",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are pregnant or may be pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10021865\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697780",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wear disease medical alert ID (identification).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696820",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not run out of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697207",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high blood sugar (diabetes), this drug may sometimes raise blood sugar. Talk with your doctor about how to fine tune this.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698421",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood pressure checked often. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698465",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697100",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are taking a salt substitute that has potassium, potassium-sparing diuretics, or potassium, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697111",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are taking this drug and have high blood pressure, talk with your doctor before using OTC products that may raise blood pressure. These include cough or cold drugs, diet pills, stimulants, ibuprofen or like products, and some natural products or aids.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697562",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Limit your drinking of wine, beer, or mixed drinks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697788",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may get sunburned more easily. Avoid sun, sunlamps, and tanning beds. Use sunscreen and wear clothing and eyewear that protects you from the sun.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696701",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Be careful in hot weather. Drink lots of fluids to stop fluid loss.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697779",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Watch for gout attacks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697740",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use birth control that you can trust to stop pregnancy while taking this drug.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10021866\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling dizzy. Rise slowly over a few minutes when sitting or lying down. Be careful climbing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698027",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dry mouth. Good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help. See a dentist often.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697883",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Back pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697983",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Cough.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698395",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Kidney function that gets worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10021868\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699031",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698650",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you have too much sweat, fluid loss, throwing up, or loose stools. This may lead to low blood pressure.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Cough that does not go away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699086",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sudden change in eyesight, eye pain, or irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698670",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       For women, if you get pregnant while taking this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10021863\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695786",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take as you have been told, even if you feel well.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695872",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may cause you to pass urine more often. To keep from having sleep problems, try to take before 6 pm.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695852",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take this drug at the same time of day.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694865",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Follow the diet and workout plan that your doctor told you about.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10021864\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10021869\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10021870\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11660 Version 39.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-115.25.216.6-E8883028DF-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_41_30357=[""].join("\n");
var outline_f29_41_30357=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F145019\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F145020\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021859\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021861\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021860\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021865\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021866\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021868\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021863\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021864\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021869\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021870\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?21/25/21911?source=related_link\">",
"      Candesartan and hydrochlorothiazide: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f29_41_30358="Sunitinib: Patient drug information";
var content_f29_41_30358=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Sunitinib: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/10/44200?source=see_link\">",
"     see \"Sunitinib: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F2525534\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Sutent&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F5558623\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Sutent&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10025307\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700734",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may cause liver problems. Call your doctor if you see dark urine, feel tired, are not hungry, have an upset stomach, are throwing up, or have yellowing of the skin or eyes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700454",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug comes with an extra patient fact sheet called a Medication Guide. Read it with care. Read it again each time this drug is refilled.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10025309\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691672",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat cancer.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10025308\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702978",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to sunitinib or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701080",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are pregnant or may be pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10025313\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697258",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have heart disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697265",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high blood pressure, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697059",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are on dialysis, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697340",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have seizures, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697343",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have thyroid disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are having surgery, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698421",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood pressure checked often. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698465",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698509",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have a heart function test. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697613",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with your doctor before getting any vaccines. Use with this drug may either raise the chance of an infection or make the vaccine not work as well.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697633",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell dentists, surgeons, and other doctors that you use this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705893",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have a dental exam before starting this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698562",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take good care of your teeth. See a dentist often.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697795",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may bleed more easily. Be careful and avoid injury. Use a soft toothbrush and an electric razor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696900",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take St John's wort with this drug. This drug may not work as well.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s4128402",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you drink grapefruit juice or eat grapefruit often, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697622",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with your doctor before using products that have aspirin, blood thinners, garlic, ginseng, ginkgo, ibuprofen or like products, pain drugs, or vitamin E.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697740",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use birth control that you can trust to stop pregnancy while taking this drug.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10025314\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698074",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698240",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Mouth irritation or mouth sores.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698306",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697876",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Anemia, low white blood cell count, and low platelet count.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697975",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Hard stools (constipation).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698134",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       High blood pressure.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697891",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697946",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in color of skin.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698401",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in color of hair.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698113",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Hair loss.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698029",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dry skin.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698081",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Fever.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698360",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Swelling in the arms or legs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698162",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to sleep.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697983",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Cough.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697902",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Bleeding.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698154",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Holes in the GI (gastrointestinal) tract may rarely happen.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698193",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Harm to the jaw bone may rarely happen.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10025316\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699077",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of infection. These include a fever of 100.5&deg;F (38&deg;C) or higher, chills, very bad sore throat, ear or sinus pain, cough, more sputum or change in color of sputum, pain with passing urine, mouth sores, wound that will not heal, or anal itching or pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698627",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Chest pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699058",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in thinking clearly and with logic.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699087",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sudden change in eyesight.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699019",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699014",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very hard stools (constipation).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699036",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad mouth pain or irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699105",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any bruising or bleeding.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698982",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to handle cold.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699031",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699094",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Swelling in your legs or belly.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698975",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Neck swelling.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698618",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in skin on hands or feet.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699078",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Skin wound that will not heal.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698981",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to eat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698634",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dark urine or yellow skin or eyes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699049",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad skin irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10025311\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2821479",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not open the capsules.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10025312\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10025317\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10025318\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11576 Version 35.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-199.231.185.123-2A680BD67D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_41_30358=[""].join("\n");
var outline_f29_41_30358=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2525534\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5558623\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025307\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025309\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025308\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025313\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025314\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025316\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025311\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025312\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025317\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025318\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?43/10/44200?source=related_link\">",
"      Sunitinib: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f29_41_30359="Complications of breast and chest wall irradiation for early stage breast cancer";
var content_f29_41_30359=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Complications of breast and chest wall irradiation for early stage breast cancer",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/41/30359/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/41/30359/contributors\">",
"     Lori J Pierce, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/41/30359/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/41/30359/contributors\">",
"     Daniel F Hayes, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/41/30359/contributors\">",
"     David E Wazer, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/41/30359/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/41/30359/contributors\">",
"     Don S Dizon, MD, FACP",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?29/41/30359/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 2, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H949705455\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Radiation therapy (RT) has been a component of breast cancer treatment for almost 100 years. Although initially used for the treatment of chest wall recurrences after mastectomy and for advanced inoperable disease, RT has evolved into a critical component of therapy for women with an intact breast following breast conserving surgery, and for women who have undergone mastectomy who are at moderate to high risk for local failure. The type of RT varies with the surgical procedure that has been performed (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/46/39657?source=see_link&amp;anchor=H612454#H612454\">",
"     \"Techniques of breast and chest wall irradiation for early stage breast cancer\", section on 'Type of RT'",
"    </a>",
"    .):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Whole breast irradiation is used for women undergoing breast-conserving therapy (BCT)",
"     </li>",
"     <li>",
"      Chest wall irradiation is used for women who have undergone mastectomy",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Potential complications of RT for early stage breast cancer are similar in women undergoing BCT or mastectomy; they include arm edema, pneumonitis, radiation-associated dermatitis, rib fractures, brachial plexopathy, secondary malignancies, and long-term cardiac toxicity.",
"   </p>",
"   <p>",
"    This topic will cover complications of breast and chest wall irradiation. Techniques for irradiating women with early stage invasive breast cancer, radiation therapy as a component of breast conservation therapy (BCT), indications for postmastectomy chest wall RT, and radiation for locally advanced breast cancer are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/46/39657?source=see_link\">",
"     \"Techniques of breast and chest wall irradiation for early stage breast cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/7/11385?source=see_link\">",
"     \"Role of radiation therapy in breast conservation therapy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/3/41017?source=see_link\">",
"     \"Postmastectomy chest wall irradiation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/55/42873?source=see_link\">",
"     \"Radiation techniques for locally advanced breast cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H949706075\">",
"    <span class=\"h1\">",
"     ARM EDEMA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both the extent of axillary surgery and regional RT after axillary dissection impact upon the risk of ipsilateral (unilateral) arm edema. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/52/1866?source=see_link&amp;anchor=H17#H17\">",
"     \"Clinical manifestations and diagnosis of lymphedema\", section on 'Clinical manifestations'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Because the highest risk follows full axillary radiation after a complete axillary dissection (levels I-III, (",
"    <a class=\"graphic graphic_figure graphicRef57770 \" href=\"UTD.htm?39/39/40563\">",
"     figure 1",
"    </a>",
"    )), full axillary RT should be discouraged in this setting and only offered if there are concerns about residual axillary disease [",
"    <a class=\"abstract\" href=\"UTD.htm?29/41/30359/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. In comparison, limiting axillary RT to the axillary apex following a level",
"    <span class=\"nowrap\">",
"     I/II",
"    </span>",
"    axillary node dissection appears to increase the risk of edema only slightly beyond that observed following surgery only. In one series that restricted regional treatment to limited",
"    <span class=\"nowrap\">",
"     supraclavicular/infraclavicular",
"    </span>",
"    fields, the rate of arm edema was only 3 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?29/41/30359/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H949706082\">",
"    <span class=\"h1\">",
"     PNEUMONITIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risk of transient lung inflammation following chest wall RT is approximately 5 percent or less [",
"    <a class=\"abstract\" href=\"UTD.htm?29/41/30359/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. The risk is greater with increasing lung volume in the tangent fields, treatment to the supraclavicular, axillary apex, and internal mammary regions, the use of concurrent compared to sequential chemotherapy (8.8 versus 1.3 percent in one series) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/41/30359/abstract/4\">",
"     4",
"    </a>",
"    ], and in some but not all series, with either sequential or concurrent use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    as a component of adjuvant chemotherapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/7/11385?source=see_link&amp;anchor=H730200#H730200\">",
"     \"Role of radiation therapy in breast conservation therapy\", section on 'Benefits of regional nodal irradiation'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/28/38344?source=see_link&amp;anchor=H12#H12\">",
"     \"Taxane-induced pulmonary toxicity\", section on 'Radiation recall'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although some reports have raised concern for an increased risk of radiation fibrosis in women receiving simultaneous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"     tamoxifen",
"    </a>",
"    and radiation therapy, such an association has not been uniformly observed. This topic is discussed in detail elsewhere. Furthermore, these changes have not been associated with higher rates of symptomatic pneumonitis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/40/20106?source=see_link\">",
"     \"Adjuvant endocrine therapy for hormone receptor-positive breast cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/33/24090?source=see_link&amp;anchor=H6#H6\">",
"     \"Radiation-induced lung injury\", section on 'Reaction to radiation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H949706089\">",
"    <span class=\"h1\">",
"     RIB FRACTURE AND BRACHIAL PLEXOPATHY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risk of treatment-related rib fractures or a brachial plexopathy is extremely low after BCT or postmastectomy RT (and supraclavicular nodal RT in the case of brachial plexopathy) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/41/30359/abstract/6-8\">",
"     6-8",
"    </a>",
"    ]. In one report, the incidence of a rib fracture was less than 3 percent, and the median time to develop a fracture was about one year [",
"    <a class=\"abstract\" href=\"UTD.htm?29/41/30359/abstract/7\">",
"     7",
"    </a>",
"    ]. The incidence appears to be higher with RT doses that exceed 50 Gy, and with the use of concomitant chemotherapy, even when the RT dose is &lt;50 Gy.",
"   </p>",
"   <p>",
"    Permanent brachial plexopathy occurs in less than 1 percent of women receiving &le;50 Gy in 2 Gy fractions administered to a supraclavicular and axillary apex field. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/34/38437?source=see_link\">",
"     \"Complications of peripheral nerve irradiation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The incidence of plexopathy is significantly higher with an axillary dose greater than 50 Gy, concomitant chemotherapy administration [",
"    <a class=\"abstract\" href=\"UTD.htm?29/41/30359/abstract/7\">",
"     7",
"    </a>",
"    ] and with daily RT fractions in excess of 2 Gy, as might be used with hypofractionated (shorter duration) regimens [",
"    <a class=\"abstract\" href=\"UTD.htm?29/41/30359/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/7/11385?source=see_link&amp;anchor=H600305411#H600305411\">",
"     \"Role of radiation therapy in breast conservation therapy\", section on 'Shorter fractionation schedules'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H540526\">",
"    <span class=\"h1\">",
"     RADIATION DERMATITIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Radiation dermatitis is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/7/36986?source=see_link&amp;anchor=H20#H20\">",
"     \"Cutaneous complications of conventional chemotherapy agents\", section on 'Radiation recall and enhancement'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H541872\">",
"    <span class=\"h1\">",
"     RADIATION-INDUCED FIBROSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Radiation-induced fibrosis of the skin and subcutaneous tissue is seen most commonly in breast cancer patients in areas with overlapping treatment fields following breast-conserving surgery with postoperative RT or after mastectomy and RT. The risk of radiation fibrosis after conventional RT for breast cancer is low, particularly with the use of modern skin-sparing megavoltage equipment. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/46/17129?source=see_link&amp;anchor=H8#H8\">",
"     \"Clinical manifestations and treatment of radiation-induced fibrosis\", section on 'Skin and subcutaneous tissue'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H949706096\">",
"    <span class=\"h1\">",
"     CARDIOVASCULAR MORBIDITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Early studies with RT in breast cancer patients established a link between incidental RT to the heart and a late increase in the frequency of cardiovascular disease. The excess mortality observed in early trials of postmastectomy RT was largely a consequence of treatment-related cardiovascular toxicity, attributable to now obsolete radiation techniques. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/3/41017?source=see_link&amp;anchor=H13#H13\">",
"     \"Postmastectomy chest wall irradiation\", section on 'Meta-analyses'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Improvements in RT technique have significantly decreased the amount of incidental radiation received by the heart, and the available data suggest that these technical advances have reduced the incidence of cardiovascular complications. More recent trials using modern RT techniques show either no increase in cardiovascular toxicity or lower rates of cardiotoxicity in women treated for left-sided cancers than reported in older series that still, however, are higher compared to those reported for women with right-sided controls.",
"   </p>",
"   <p>",
"    Careful attention to technique is critical to minimize the risk of long-term cardiovascular toxicity in women receiving adjuvant breast or chest wall RT. Prolonged follow-up of all women who have undergone RT for breast cancer is needed because of the latency of RT-induced cardiac disease. This topic is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/21/34137?source=see_link&amp;anchor=H3#H3\">",
"     \"Cardiotoxicity of radiation therapy for malignancy\", section on 'Breast cancer'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H949706103\">",
"    <span class=\"h1\">",
"     SECONDARY MALIGNANCIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Potential treatment-induced secondary malignancies following locoregional radiation include contralateral breast cancers and non-breast primary malignancies, including sarcomas, lung cancers, esophageal cancer, and in some but not all studies, leukemias [",
"    <a class=\"abstract\" href=\"UTD.htm?29/41/30359/abstract/11-14\">",
"     11-14",
"    </a>",
"    ]. All of these are rare and, as illustrated by the following observations, the excess risk of a secondary non-breast malignancy is only about 1 percent.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a series of 1884 patients with clinical stage",
"      <span class=\"nowrap\">",
"       I/II",
"      </span>",
"      breast cancer undergoing BCT, 147 (8 percent) developed a second non-breast malignancy by eight years of follow-up [",
"      <a class=\"abstract\" href=\"UTD.htm?29/41/30359/abstract/11\">",
"       11",
"      </a>",
"      ]. However, when compared to the number of cancers expected in the general population over this same time period extracted from the Surveillance Epidemiology and End-Results (SEER) data base of the National Cancer Institute (n = 128), the relative risk was 1.15 (95% CI 0.97 to 1.35). Thus, the absolute excess risk associated with RT was only 19 cases, which represented only 1 percent of patients.",
"     </li>",
"     <li>",
"      A similar magnitude of risk was noted in a large population-based cohort study of over 58,000 Dutch patients diagnosed with invasive breast cancer between 1989 and 2003 [",
"      <a class=\"abstract\" href=\"UTD.htm?29/41/30359/abstract/13\">",
"       13",
"      </a>",
"      ]. There was an overall 22 percent increase in risk of a second non-breast primary cancer relative to the general population (RR 1.22, 95% CI 1.17 to 1.27). This translated into approximately one in every 20 patients developing a second non-breast primary cancer within 10 years of a breast cancer diagnosis, which represented an excess risk of 13 cancers per 1000 women (ie, 1.3 percent) followed for 10 years. Radiation therapy was associated with a significantly increased risk of lung cancer only in women under the age of 50 at the time of diagnosis, of sarcoma only in women older than 50, and was not associated with an elevated risk of AML. The contribution of smoking was not addressed.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H949706110\">",
"    <span class=\"h2\">",
"     Sarcoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although women who undergo RT for breast cancer have an increased risk of in-field sarcomas, the absolute magnitude of the risk for a postirradiation sarcoma is small (",
"    <a class=\"graphic graphic_table graphicRef61730 \" href=\"UTD.htm?43/35/44604\">",
"     table 1",
"    </a>",
"    ). In one series of 274,572 cases of primary breast cancer identified from the SEER database, the 15-year cumulative incidence rates for any sarcoma in women who did and did not receive RT were 3.2 and 2.3 per 1000, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?29/41/30359/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    RT for breast cancer increases the risk of development of all types of soft tissue sarcoma and specifically of angiosarcoma, a relatively rare tumor [",
"    <a class=\"abstract\" href=\"UTD.htm?29/41/30359/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]. These tumors usually present as multiple reddish, bluish and purple nodules or areas of skin discoloration. The topic of radiation-induced sarcomas after therapy of breast cancer is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/3/28729?source=see_link&amp;anchor=H30564621#H30564621\">",
"     \"Breast sarcoma: Epidemiology, risk factors, clinical presentation, diagnosis, and staging\", section on 'Ionizing radiation'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/3/28729?source=see_link&amp;anchor=H529562#H529562\">",
"     \"Breast sarcoma: Epidemiology, risk factors, clinical presentation, diagnosis, and staging\", section on 'Histologic classification'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H949706117\">",
"    <span class=\"h2\">",
"     Lung cancer",
"    </span>",
"    &nbsp;&mdash;&nbsp;Modest increases in the absolute rate of lung cancers have been observed following RT for breast cancer. In three separate reports, the relative risk (RR) among women treated with RT who survived 10 or more years from diagnosis was between 2.0 and 2.8 [",
"    <a class=\"abstract\" href=\"UTD.htm?29/41/30359/abstract/18-20\">",
"     18-20",
"    </a>",
"    ]. The absolute number of women potentially affected with radiation-induced lung cancer is very low; nine cases would be expected in 10,000 women surviving their breast cancers for at least 10 years.",
"   </p>",
"   <p>",
"    Not surprisingly, smoking appears to play a significant role in the development of a second primary lung cancer in irradiated women [",
"    <a class=\"abstract\" href=\"UTD.htm?29/41/30359/abstract/11,21-25\">",
"     11,21-25",
"    </a>",
"    ]. In fact, in at least two studies, the increased risk of lung cancer following radiotherapy for breast cancer was limited to smokers [",
"    <a class=\"abstract\" href=\"UTD.htm?29/41/30359/abstract/22,25\">",
"     22,25",
"    </a>",
"    ]. In the more recent study, the adjusted odds ratio for the joint effects of smoking and postmastectomy RT were 10.5 (95% CI 2.9 to 37.8) for a contralateral lung cancer and 37.6 (95% CI 10.2 to 139) for the ipsilateral lung [",
"    <a class=\"abstract\" href=\"UTD.htm?29/41/30359/abstract/25\">",
"     25",
"    </a>",
"    ]. Smoking cessation interventions should be encouraged. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/0/12298?source=see_link\">",
"     \"Cigarette smoking and other risk factors for lung cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The incidence of lung cancer is also related to the volume of lung in the irradiated field. This was illustrated in a study that compared lung cancer rates in 3515 women with early breast cancer treated on two protocols from the National Surgical Adjuvant Breast and Bowel Project (NSABP) of surgery with and without radiation that differed in the extent of irradiation [",
"    <a class=\"abstract\" href=\"UTD.htm?29/41/30359/abstract/26\">",
"     26",
"    </a>",
"    ]. The B-04 trial randomly assigned women to radical mastectomy, or simple mastectomy with or without radiotherapy to the chest wall, axilla, supraclavicular, and internal mammary areas, while B-06 randomly assigned women to lumpectomy alone, mastectomy alone, or lumpectomy followed by breast irradiation.",
"   </p>",
"   <p>",
"    With 25-year follow-up of the B-04 trial, the percentage of patients who developed lung cancer after receiving postmastectomy radiation was approximately twofold higher than with surgery alone (2.1 versus 0.9 percent). In contrast, there was no significant difference in the long-term incidence of lung cancer in women who received postoperative radiotherapy limited to the breast compared to surgery alone in NSABP B-06 (1.7 versus 1.4 percent). The issue of tobacco use was not addressed. These data underscore the importance of treatment planning to limit the extent of normal lung in the radiated field.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H949706124\">",
"    <span class=\"h2\">",
"     Esophageal cancer",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adjuvant radiation therapy for breast cancer has been related to a modest but significant excess risk of esophageal cancer (ratio of observed to expected cases 1.6 to 2.8) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/41/30359/abstract/13,27-31\">",
"     13,27-31",
"    </a>",
"    ]. However, older radiotherapy regimens are likely to involve greater hazards than modern techniques since with current techniques the esophagus is excluded from the treated volume [",
"    <a class=\"abstract\" href=\"UTD.htm?29/41/30359/abstract/31\">",
"     31",
"    </a>",
"    ]. In the previously described Dutch population-based series, radiotherapy was not associated with a significantly increased risk of esophageal cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?29/41/30359/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H949706131\">",
"    <span class=\"h2\">",
"     Acute leukemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;In women undergoing chest wall RT, the risk of acute nonlymphocytic leukemias (ANLL) appears to be related to the volume of bone marrow in the field, the total RT dose, and the concomitant use of chemotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?29/41/30359/abstract/32,33\">",
"     32,33",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/58/20393?source=see_link\">",
"     \"Clinical manifestations, pathologic features, and diagnosis of acute myeloid leukemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H949706138\">",
"    <span class=\"h2\">",
"     Contralateral breast cancer",
"    </span>",
"    &nbsp;&mdash;&nbsp;Limited data suggest a slight excess of contralateral breast cancers following breast or chest wall RT [",
"    <a class=\"abstract\" href=\"UTD.htm?29/41/30359/abstract/27,34,35\">",
"     27,34,35",
"    </a>",
"    ]. As an example, in data from the most recent Early Breast Cancer Trialists Collaborative Group meta-analysis, the annual odds ratio for contralateral breast cancer for irradiated compared to nonirradiated women was 1.18 (p = 0.002) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/41/30359/abstract/27\">",
"     27",
"    </a>",
"    ]. This result was statistically significant for women 50 years of age and older (1.25, p = 0.002) but not for younger women (1.09, p = 0.3). On the other hand, other data suggest that the risk may be higher with younger age at treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?29/41/30359/abstract/34-36\">",
"     34-36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As noted above, women who have an inherited predisposition to breast cancer (ie, BRCA mutations) have an increased risk of both ipsilateral second primary and contralateral breast cancers compared to the general population. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/42/31402?source=see_link&amp;anchor=H27#H27\">",
"     \"Breast conserving therapy\", section on 'Inherited susceptibility'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/63/44025?source=see_link&amp;anchor=H12#H12\">",
"     \"Characteristics of hereditary breast and ovarian cancer syndromes\", section on 'Second breast cancers'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A Dutch report also suggests that postmastectomy radiotherapy using direct electron fields leads to a significantly lower radiation exposure to the contralateral breast than postlumpectomy RT using photons with tangential fields [",
"    <a class=\"abstract\" href=\"UTD.htm?29/41/30359/abstract/35\">",
"     35",
"    </a>",
"    ]. The joint effects of postlumpectomy RT and strong family history for breast cancer in this series were greater than expected when individual risks were summed (HR 3.52).",
"   </p>",
"   <p>",
"    Although the risk of radiation-associated contralateral breast cancer, if it exists, is extremely low, measures to reduce scatter to the opposite breast, such as omission of a medial wedge from tangent fields should be used to reduce the contralateral breast dose [",
"    <a class=\"abstract\" href=\"UTD.htm?29/41/30359/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H949706145\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Radiation therapy (RT) has evolved into a critical component of treatment for women with breast cancer who have an intact breast following breast conserving surgery, and for women who have undergone mastectomy and who are at moderate to high risk for local failure. (See",
"      <a class=\"local\" href=\"#H949705455\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Potential complications of RT for early stage breast cancer include radiation dermatitis and fatigue (acutely), and radiation associated fibrosis, rib fracture, radiation pneumonopathy, and arm edema (depending upon the surgical approach to the axilla) long term. Rare complications include cardiovascular morbidity; secondary malignancies, including sarcoma, lung cancer, esophageal cancer, acute leukemia; and possibly a slight increase in the risk of contralateral breast cancer.",
"     </li>",
"     <li>",
"      Improvements in RT technique have significantly decreased the amount of incidental radiation received by the heart, and the available data suggest that these technical advances have reduced the incidence of cardiovascular complications. Nevertheless, prolonged follow-up of all women who have undergone RT for breast cancer is needed because of the latency of RT-induced cardiac disease. (See",
"      <a class=\"local\" href=\"#H949706096\">",
"       'Cardiovascular morbidity'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Non-breast secondary malignancies are rare and the excess risk compared to women who do not receive irradiation for breast cancer is only about 1 percent. (See",
"      <a class=\"local\" href=\"#H949706103\">",
"       'Secondary malignancies'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      Smoking appears to play a significant role in the development of a second primary lung cancer in irradiated women; smoking cessation interventions should be encouraged. (See",
"      <a class=\"local\" href=\"#H949706117\">",
"       'Lung cancer'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Although the risk of radiation-associated contralateral breast cancer, if it exists, is extremely low, measures to reduce scatter to the opposite breast, such as omission of a medial wedge from tangent fields, should be used to reduce the contralateral breast dose. (See",
"      <a class=\"local\" href=\"#H949706138\">",
"       'Contralateral breast cancer'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      Women who have an inherited predisposition to breast cancer (ie, BRCA mutations) have an increased risk of both ipsilateral second primary and contralateral breast cancers compared to the general population. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/63/44025?source=see_link&amp;anchor=H12#H12\">",
"       \"Characteristics of hereditary breast and ovarian cancer syndromes\", section on 'Second breast cancers'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/41/30359/abstract/1\">",
"      Katz A, Strom EA, Buchholz TA, et al. Locoregional recurrence patterns after mastectomy and doxorubicin-based chemotherapy: implications for postoperative irradiation. J Clin Oncol 2000; 18:2817.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/41/30359/abstract/2\">",
"      Recht A, Gray R, Davidson NE, et al. Locoregional failure 10 years after mastectomy and adjuvant chemotherapy with or without tamoxifen without irradiation: experience of the Eastern Cooperative Oncology Group. J Clin Oncol 1999; 17:1689.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/41/30359/abstract/3\">",
"      Pierce LJ, Oberman HA, Strawderman MH, Lichter AS. Microscopic extracapsular extension in the axilla: is this an indication for axillary radiotherapy? Int J Radiat Oncol Biol Phys 1995; 33:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/41/30359/abstract/4\">",
"      Lingos TI, Recht A, Vicini F, et al. Radiation pneumonitis in breast cancer patients treated with conservative surgery and radiation therapy. Int J Radiat Oncol Biol Phys 1991; 21:355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/41/30359/abstract/5\">",
"      Lind PA, Marks LB, Hardenbergh PH, et al. Technical factors associated with radiation pneumonitis after local +/- regional radiation therapy for breast cancer. Int J Radiat Oncol Biol Phys 2002; 52:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/41/30359/abstract/6\">",
"      Fraass BA, Roberson PL, Lichter AS. Dose to the contralateral breast due to primary breast irradiation. Int J Radiat Oncol Biol Phys 1985; 11:485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/41/30359/abstract/7\">",
"      Pierce SM, Recht A, Lingos TI, et al. Long-term radiation complications following conservative surgery (CS) and radiation therapy (RT) in patients with early stage breast cancer. Int J Radiat Oncol Biol Phys 1992; 23:915.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/41/30359/abstract/8\">",
"      Meric F, Buchholz TA, Mirza NQ, et al. Long-term complications associated with breast-conservation surgery and radiotherapy. Ann Surg Oncol 2002; 9:543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/41/30359/abstract/9\">",
"      Olsen NK, Pfeiffer P, Johannsen L, et al. Radiation-induced brachial plexopathy: neurological follow-up in 161 recurrence-free breast cancer patients. Int J Radiat Oncol Biol Phys 1993; 26:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/41/30359/abstract/10\">",
"      Powell S, Cooke J, Parsons C. Radiation-induced brachial plexus injury: follow-up of two different fractionation schedules. Radiother Oncol 1990; 18:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/41/30359/abstract/11\">",
"      Galper S, Gelman R, Recht A, et al. Second nonbreast malignancies after conservative surgery and radiation therapy for early-stage breast cancer. Int J Radiat Oncol Biol Phys 2002; 52:406.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/41/30359/abstract/12\">",
"      Brown LM, Chen BE, Pfeiffer RM, et al. Risk of second non-hematological malignancies among 376,825 breast cancer survivors. Breast Cancer Res Treat 2007; 106:439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/41/30359/abstract/13\">",
"      Schaapveld M, Visser O, Louwman MJ, et al. Risk of new primary nonbreast cancers after breast cancer treatment: a Dutch population-based study. J Clin Oncol 2008; 26:1239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/41/30359/abstract/14\">",
"      Berrington de Gonzalez A, Curtis RE, Gilbert E, et al. Second solid cancers after radiotherapy for breast cancer in SEER cancer registries. Br J Cancer 2010; 102:220.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/41/30359/abstract/15\">",
"      Yap J, Chuba PJ, Thomas R, et al. Sarcoma as a second malignancy after treatment for breast cancer. Int J Radiat Oncol Biol Phys 2002; 52:1231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/41/30359/abstract/16\">",
"      Young RJ, Brown NJ, Reed MW, et al. Angiosarcoma. Lancet Oncol 2010; 11:983.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/41/30359/abstract/17\">",
"      Lahat G, Dhuka AR, Hallevi H, et al. Angiosarcoma: clinical and molecular insights. Ann Surg 2010; 251:1098.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/41/30359/abstract/18\">",
"      Inskip PD, Stovall M, Flannery JT. Lung cancer risk and radiation dose among women treated for breast cancer. J Natl Cancer Inst 1994; 86:983.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/41/30359/abstract/19\">",
"      Neugut AI, Robinson E, Lee WC, et al. Lung cancer after radiation therapy for breast cancer. Cancer 1993; 71:3054.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/41/30359/abstract/20\">",
"      Prochazka M, Granath F, Ekbom A, et al. Lung cancer risks in women with previous breast cancer. Eur J Cancer 2002; 38:1520.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/41/30359/abstract/21\">",
"      Ford MB, Sigurdson AJ, Petrulis ES, et al. Effects of smoking and radiotherapy on lung carcinoma in breast carcinoma survivors. Cancer 2003; 98:1457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/41/30359/abstract/22\">",
"      Prochazka M, Hall P, Gagliardi G, et al. Ionizing radiation and tobacco use increases the risk of a subsequent lung carcinoma in women with breast cancer: case-only design. J Clin Oncol 2005; 23:7467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/41/30359/abstract/23\">",
"      Fowble B, Hanlon A, Freedman G, et al. Second cancers after conservative surgery and radiation for stages I-II breast cancer: identifying a subset of women at increased risk. Int J Radiat Oncol Biol Phys 2001; 51:679.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/41/30359/abstract/24\">",
"      Neugut AI, Murray T, Santos J, et al. Increased risk of lung cancer after breast cancer radiation therapy in cigarette smokers. Cancer 1994; 73:1615.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/41/30359/abstract/25\">",
"      Kaufman EL, Jacobson JS, Hershman DL, et al. Effect of breast cancer radiotherapy and cigarette smoking on risk of second primary lung cancer. J Clin Oncol 2008; 26:392.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/41/30359/abstract/26\">",
"      Deutsch M, Land SR, Begovic M, et al. The incidence of lung carcinoma after surgery for breast carcinoma with and without postoperative radiotherapy. Results of National Surgical Adjuvant Breast and Bowel Project (NSABP) clinical trials B-04 and B-06. Cancer 2003; 98:1362.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/41/30359/abstract/27\">",
"      Clarke M, Collins R, Darby S, et al. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005; 366:2087.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/41/30359/abstract/28\">",
"      Levi F, Randimbison L, Te VC, La Vecchia C. Increased risk of esophageal cancer after breast cancer. Ann Oncol 2005; 16:1829.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/41/30359/abstract/29\">",
"      Zablotska LB, Chak A, Das A, Neugut AI. Increased risk of squamous cell esophageal cancer after adjuvant radiation therapy for primary breast cancer. Am J Epidemiol 2005; 161:330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/41/30359/abstract/30\">",
"      Roychoudhuri R, Evans H, Robinson D, M&oslash;ller H. Radiation-induced malignancies following radiotherapy for breast cancer. Br J Cancer 2004; 91:868.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/41/30359/abstract/31\">",
"      Salminen EK, Pukkala E, Kiel KD, Hakulinen TT. Impact of radiotherapy in the risk of esophageal cancer as subsequent primary cancer after breast cancer. Int J Radiat Oncol Biol Phys 2006; 65:699.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/41/30359/abstract/32\">",
"      Welte B, Suhr P, Bottke D, et al. Second malignancies in highdose areas of previous tumor radiotherapy. Strahlenther Onkol 2010; 186:174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/41/30359/abstract/33\">",
"      Cole M, Strair R. Acute myelogenous leukemia and myelodysplasia secondary to breast cancer treatment: case studies and literature review. Am J Med Sci 2010; 339:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/41/30359/abstract/34\">",
"      Boice JD Jr, Harvey EB, Blettner M, et al. Cancer in the contralateral breast after radiotherapy for breast cancer. N Engl J Med 1992; 326:781.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/41/30359/abstract/35\">",
"      Hooning MJ, Aleman BM, Hauptmann M, et al. Roles of radiotherapy and chemotherapy in the development of contralateral breast cancer. J Clin Oncol 2008; 26:5561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/41/30359/abstract/36\">",
"      Stovall M, Smith SA, Langholz BM, et al. Dose to the contralateral breast from radiotherapy and risk of second primary breast cancer in the WECARE study. Int J Radiat Oncol Biol Phys 2008; 72:1021.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16447 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1102-222.190.118.195-652B83C886-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_41_30359=[""].join("\n");
var outline_f29_41_30359=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H949706145\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H949705455\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H949706075\">",
"      ARM EDEMA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H949706082\">",
"      PNEUMONITIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H949706089\">",
"      RIB FRACTURE AND BRACHIAL PLEXOPATHY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H540526\">",
"      RADIATION DERMATITIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H541872\">",
"      RADIATION-INDUCED FIBROSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H949706096\">",
"      CARDIOVASCULAR MORBIDITY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H949706103\">",
"      SECONDARY MALIGNANCIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H949706110\">",
"      Sarcoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H949706117\">",
"      Lung cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H949706124\">",
"      Esophageal cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H949706131\">",
"      Acute leukemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H949706138\">",
"      Contralateral breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H949706145\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/16447\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/16447|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?39/39/40563\" title=\"figure 1\">",
"      Schematic of the breast and regional lymph nodes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/16447|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?43/35/44604\" title=\"table 1\">",
"      Sarcoma after breast CA RT",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/40/20106?source=related_link\">",
"      Adjuvant endocrine therapy for hormone receptor-positive breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/42/31402?source=related_link\">",
"      Breast conserving therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/3/28729?source=related_link\">",
"      Breast sarcoma: Epidemiology, risk factors, clinical presentation, diagnosis, and staging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/21/34137?source=related_link\">",
"      Cardiotoxicity of radiation therapy for malignancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/63/44025?source=related_link\">",
"      Characteristics of hereditary breast and ovarian cancer syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/0/12298?source=related_link\">",
"      Cigarette smoking and other risk factors for lung cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/52/1866?source=related_link\">",
"      Clinical manifestations and diagnosis of lymphedema",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/46/17129?source=related_link\">",
"      Clinical manifestations and treatment of radiation-induced fibrosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/58/20393?source=related_link\">",
"      Clinical manifestations, pathologic features, and diagnosis of acute myeloid leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/34/38437?source=related_link\">",
"      Complications of peripheral nerve irradiation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/7/36986?source=related_link\">",
"      Cutaneous complications of conventional chemotherapy agents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/3/41017?source=related_link\">",
"      Postmastectomy chest wall irradiation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/55/42873?source=related_link\">",
"      Radiation techniques for locally advanced breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/33/24090?source=related_link\">",
"      Radiation-induced lung injury",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/7/11385?source=related_link\">",
"      Role of radiation therapy in breast conservation therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/28/38344?source=related_link\">",
"      Taxane-induced pulmonary toxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/46/39657?source=related_link\">",
"      Techniques of breast and chest wall irradiation for early stage breast cancer",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f29_41_30360="Pancreatic duct EUS";
var content_f29_41_30360=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F62822&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F62822&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Pancreatic duct seen on endoscopic ultrasound",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 335px; height: 613px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Top: Radial EUS image showing the pancreatic duct (PD) almost parallel with the common bile duct (CBD), and converging into the ampulla. Bottom: Simplification of top image.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Lyndon V. Hernandez, MD and Manoop S. Bhutani, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_41_30360=[""].join("\n");
var outline_f29_41_30360=null;
var title_f29_41_30361="Pathogenesis and etiology of primary hyperparathyroidism";
var content_f29_41_30361=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Pathogenesis and etiology of primary hyperparathyroidism",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/41/30361/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/41/30361/contributors\">",
"     Ghada El-Hajj Fuleihan, MD, MPH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/41/30361/contributors\">",
"     Andrew Arnold, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/41/30361/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/41/30361/contributors\">",
"     Clifford J Rosen, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/41/30361/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/41/30361/contributors\">",
"     Jean E Mulder, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?29/41/30361/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 28, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The routine measurement of serum calcium with the widespread use of multichannel biochemical screening initially led to a marked rise in the incidence of primary hyperparathyroidism. In the local population served by the Mayo Clinic, as an example, the annual incidence rose from 16 per 100,000 before 1974 (prescreening) to a peak of 112 per 100,000 several years later and then declined somewhat [",
"    <a class=\"abstract\" href=\"UTD.htm?29/41/30361/abstract/1\">",
"     1",
"    </a>",
"    ]. However, the rate has now fallen to 4 per 100,000, a rate lower than before screening was begun [",
"    <a class=\"abstract\" href=\"UTD.htm?29/41/30361/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The factors responsible for this change in the epidemiology of primary hyperparathyroidism are not understood. Possible contributing factors include a decreased exposure to ionizing radiation (see below) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/41/30361/abstract/1\">",
"     1",
"    </a>",
"    ], and improved vitamin D nutrition [",
"    <a class=\"abstract\" href=\"UTD.htm?29/41/30361/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Many years ago, clinical presentation was one of symptomatic renal or skeletal disease with moderate or severe hypercalcemia, but now most patients from western countries have few symptoms and mild hypercalcemia (",
"    <a class=\"graphic graphic_figure graphicRef62696 \" href=\"UTD.htm?42/31/43517\">",
"     figure 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/19/1338?source=see_link\">",
"     \"Clinical manifestations of primary hyperparathyroidism\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Primary hyperparathyroidism can occur at any age but the great majority of cases occur in subjects over the age of 45 years [",
"    <a class=\"abstract\" href=\"UTD.htm?29/41/30361/abstract/1\">",
"     1",
"    </a>",
"    ]. Women are affected twice as often as men, probably because the increase in bone resorption that follows menopause unmasks parathyroid gland hyperactivity.",
"   </p>",
"   <p>",
"    Experimental findings have advanced our understanding of the pathophysiology and causes of primary hyperparathyroidism. This topic will review these observations, beginning with a brief review of the basic aspects of parathyroid hormone and calcium homeostasis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PARATHYROID HORMONE AND CALCIUM HOMEOSTASIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Serum ionized calcium concentrations are normally maintained within the very narrow range that is required for the optimal activity of the many extracellular and intracellular processes regulated by calcium. The minute-to-minute regulation of the ionized calcium concentration is achieved through a tightly regulated calcium-parathyroid hormone (PTH) homeostatic system [",
"    <a class=\"abstract\" href=\"UTD.htm?29/41/30361/abstract/3\">",
"     3",
"    </a>",
"    ]. PTH is secreted almost instantaneously in response to very small reductions in serum ionized calcium, which are sensed by the calcium-sensing receptor (CaSR). The increase in PTH release raises the serum calcium concentration toward normal via three actions (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/56/36744?source=see_link\">",
"     \"Parathyroid hormone secretion and action\"",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Increased bone resorption, which occurs within minutes after PTH secretion increases.",
"     </li>",
"     <li>",
"      Increased intestinal calcium absorption mediated by increased production of calcitriol, the most active form of vitamin D, which occurs days after PTH secretion increases.",
"     </li>",
"     <li>",
"      Decreased urinary calcium excretion due to stimulation of calcium reabsorption in the distal tubule, which occurs within minutes after PTH secretion increases [",
"      <a class=\"abstract\" href=\"UTD.htm?29/41/30361/abstract/4,5\">",
"       4,5",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/36/2631?source=see_link\">",
"       \"Chapter 6F: Hormonal regulation of calcium and phosphate balance\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These changes result in normalization of serum ionized calcium concentrations, which then close the system's feedback loop.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Relationship between serum PTH and ionized calcium concentrations",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is a steep inverse sigmoidal relationship between the serum ionized calcium and PTH concentrations (",
"    <a class=\"graphic graphic_figure graphicRef50252 \" href=\"UTD.htm?33/8/33935\">",
"     figure 2",
"    </a>",
"    ). The response curve is defined by the following characteristics [",
"    <a class=\"abstract\" href=\"UTD.htm?29/41/30361/abstract/6\">",
"     6",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The set&ndash;point, which is the calcium concentration at which there is half-maximal inhibition of PTH secretion",
"     </li>",
"     <li>",
"      The slope of the curve at the set-point",
"     </li>",
"     <li>",
"      The maximal response of PTH to hypocalcemia",
"     </li>",
"     <li>",
"      The maximal suppression of PTH by hypercalcemia",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    An increase in the first three or a decrease in the last can result in hypersecretion of PTH.",
"   </p>",
"   <p>",
"    Primary hyperparathyroidism is characterized by abnormal regulation of PTH secretion by calcium. PTH secretion in this condition is not completely autonomous and can usually be partially inhibited by a further rise in serum calcium. If this did not occur, then patients with this disorder would have higher serum calcium concentrations than are usually found.",
"   </p>",
"   <p>",
"    The increase in PTH secretion in primary hyperparathyroidism is in part due to an elevation in set-point. The increase in the set-point, ranging between 15 to 30 percent above that of a normal parathyroid gland, is the major determinant of the severity of the hypercalcemia [",
"    <a class=\"abstract\" href=\"UTD.htm?29/41/30361/abstract/6\">",
"     6",
"    </a>",
"    ]. There is, in addition, a variable change in the slope of the calcium-PTH curve due to relative nonsuppressibility of PTH secretion [",
"    <a class=\"abstract\" href=\"UTD.htm?29/41/30361/abstract/7\">",
"     7",
"    </a>",
"    ]. The degrees of hypersecretion and nonsuppressibility are a function of tumor mass and range from none in patients with very small adenomas to considerable in patients with large ones. Both a functional change at the cellular level (a reduced number of calcium receptors on the parathyroid cell) and increased numbers of cells probably contribute to these changes in PTH secretion.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     The calcium-sensing receptor",
"    </span>",
"    &nbsp;&mdash;&nbsp;The receptor responsible for calcium-sensing by the parathyroid gland has been cloned; it is a seven transmembrane-domain, GTP-binding protein [",
"    <a class=\"abstract\" href=\"UTD.htm?29/41/30361/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. While germline inactivating mutations in this gene are commonly present in patients with familial hypocalciuric hypercalcemia (FHH) (see below), they do not appear to occur as acquired somatic mutations in sporadic parathyroid tumors [",
"    <a class=\"abstract\" href=\"UTD.htm?29/41/30361/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. There may be a small subset of patients with primary hyperparathyroidism and hypercalciuria, responsive to parathyroid surgery, which is due to inactivating germline mutation on the CaSR, thus expanding the phenotypic spectrum associated with CASR mutations [",
"    <a class=\"abstract\" href=\"UTD.htm?29/41/30361/abstract/12\">",
"     12",
"    </a>",
"    ]. There may be an association between the SRQ haplotype of the CaSR in patients with sporadic primary hyperparathyroidism [",
"    <a class=\"abstract\" href=\"UTD.htm?29/41/30361/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although there seem to be no somatic mutations of the gene, expression of the calcium-sensing protein is reduced in parathyroid adenomas and also in uremic hyperparathyroidism [",
"    <a class=\"abstract\" href=\"UTD.htm?29/41/30361/abstract/14-16\">",
"     14-16",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/50/18218?source=see_link\">",
"     \"Pathogenesis of renal osteodystrophy\"",
"    </a>",
"    .) In both instances, the reduction in expression of the calcium-sensing receptor on the surface of parathyroid cells may contribute to the increase in PTH secretion. However, PTH secretion from large adenomas may be more related to the increased cell mass since in one series, for example, there was little correlation between serum calcium concentrations and receptor expression [",
"    <a class=\"abstract\" href=\"UTD.htm?29/41/30361/abstract/17\">",
"     17",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/50/18218?source=see_link\">",
"     \"Pathogenesis of renal osteodystrophy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Inactivating heritable mutations in the calcium-sensing receptor gene cause familial hypocalciuric hypercalcemia, and are also found in a small percentage of patients with familial isolated hyperparathyroidism (see",
"    <a class=\"local\" href=\"#H21\">",
"     'Familial hyperparathyroidism'",
"    </a>",
"    below). These mutations render the receptor (expressed in the parathyroid glands, kidneys, and other tissues) relatively insensitive to calcium [",
"    <a class=\"abstract\" href=\"UTD.htm?29/41/30361/abstract/18\">",
"     18",
"    </a>",
"    ], causing a rightward shift in the calcium-PTH curve (see above) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/41/30361/abstract/19\">",
"     19",
"    </a>",
"    ] and increasing renal tubular reabsorption of calcium. It is important to distinguish this familial calcium-sensing disorder from typical primary hyperparathyroidism because parathyroid surgery is of no benefit. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/51/19258?source=see_link\">",
"     \"Disorders of the calcium-sensing receptor: Familial hypocalciuric hypercalcemia and autosomal dominant hypocalcemia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/26/5545?source=see_link\">",
"     \"Diagnosis and differential diagnosis of primary hyperparathyroidism\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     ETIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;A cause for primary hyperparathyroidism, such as irradiation or the rare genetic abnormalities in the MEN syndromes, can be identified in only a small number of patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Radiation exposure",
"    </span>",
"    &nbsp;&mdash;&nbsp;A history of irradiation to the head and neck, on average 20 to 40 years before the development of hyperparathyroidism, can be obtained in some patients [",
"    <a class=\"abstract\" href=\"UTD.htm?29/41/30361/abstract/20-23\">",
"     20-23",
"    </a>",
"    ]. As an example, in a cohort of cleanup workers who worked at the Chernobyl nuclear power plant in 1986, primary hyperparathyroidism subsequently developed in 15 of 61 workers (odds ratio compared with prevalence in nonexposed population 63.4, 95% CI 35.7-112.5) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/41/30361/abstract/23\">",
"     23",
"    </a>",
"    ]. The mean whole body radiation exposure ranged from 0.3 to 8.7 Gy.",
"   </p>",
"   <p>",
"    Hyperparathyroidism has also been reported in patients receiving radiation for benign conditions. The usual radiation dose given for benign conditions several decades ago was low; the mean dose in one study was 0.58 Gy [",
"    <a class=\"abstract\" href=\"UTD.htm?29/41/30361/abstract/24\">",
"     24",
"    </a>",
"    ]. Nevertheless, in this study of 2555 patients followed for up to 50 years, even doses as low as 0.5 Gy before age 16 years were associated with a small risk of primary hyperparathyroidism. The excess relative risk is dose-dependent, being about 5 to 10 at 1.0 Gy, whether the radiation came from external X-radiation [",
"    <a class=\"abstract\" href=\"UTD.htm?29/41/30361/abstract/24\">",
"     24",
"    </a>",
"    ] or from an atomic bomb [",
"    <a class=\"abstract\" href=\"UTD.htm?29/41/30361/abstract/25\">",
"     25",
"    </a>",
"    ]. However, the probability of primary hyperparathyroidism at this degree of exposure is still quite low, being less than 1 percent at 35 years and approaching 5 percent after 50 years of follow-up [",
"    <a class=\"abstract\" href=\"UTD.htm?29/41/30361/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One study compared the clinical presentation and course of hyperparathyroidism in exposed (49 patients) and nonexposed (389 patients) patients [",
"    <a class=\"abstract\" href=\"UTD.htm?29/41/30361/abstract/26\">",
"     26",
"    </a>",
"    ]. There were no clinically important differences with respect to presentation, pathology, or recurrences during six years of follow-up. However, the exposed patients had more concurrent thyroid tumors, which can make management more difficult [",
"    <a class=\"abstract\" href=\"UTD.htm?29/41/30361/abstract/27\">",
"     27",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/49/1818?source=see_link\">",
"     \"Radiation-induced thyroid cancer\"",
"    </a>",
"    .) Prior radiation exposure does not appear to increase the risk of having multigland parathyroid disease [",
"    <a class=\"abstract\" href=\"UTD.htm?29/41/30361/abstract/26,28,29\">",
"     26,28,29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Radioactive iodine therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are also case reports and case series that suggest an association between radioactive iodine (RAI) therapy (for the treatment of benign or malignant thyroid disease) and the subsequent development of primary hyperparathyroidism [",
"    <a class=\"abstract\" href=\"UTD.htm?29/41/30361/abstract/30\">",
"     30",
"    </a>",
"    ]. However, the incidence of primary hyperparathyroidism was not increased in a prospective study of 125 patients treated with RAI for thyrotoxicosis who were followed for an average of 21 years [",
"    <a class=\"abstract\" href=\"UTD.htm?29/41/30361/abstract/31\">",
"     31",
"    </a>",
"    ]. Additional studies are required before routine surveillance of serum calcium can be recommended in patients with a history of radioactive iodine therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3136394\">",
"    <span class=\"h2\">",
"     Calcium intake",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because PTH is secreted almost instantaneously in response to very small reductions in serum ionized calcium, it has been hypothesized that chronically low calcium intake may increase the risk of developing primary hyperparathyroidism, by causing chronic stimulation of the parathyroid gland. In one prospective cohort study, which followed over 58,000 female nurses for 22 years, primary hyperparathyroidism was diagnosed in 277 women [",
"    <a class=\"abstract\" href=\"UTD.htm?29/41/30361/abstract/32\">",
"     32",
"    </a>",
"    ]. The risk of developing primary hyperparathyroidism was inversely related to calcium intake (RR 0.56, 95% CI 0.37-0.86 for women in the group with the highest compared with lowest calcium intake). The decreased risk was significant after adjusting for age, vitamin D intake, BMI and race. Median total calcium intake (diet plus supplement) in the lowest to highest quintiles ranged from 522 to 1794 mg daily. Limitations of the study include potential inaccuracies in reporting calcium intake and in eliciting the diagnosis of primary hyperparathyroidism. Additional studies are warranted.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Genetic or chromosomal defects",
"    </span>",
"    &nbsp;&mdash;&nbsp;The cells in the abnormal parathyroid tissue are usually monoclonal.",
"   </p>",
"   <p>",
"    Abnormalities in key growth-controlling genes, protooncogenes or tumor suppressor genes, underlie the development of parathyroid tumors. The abnormalities include gain-of-function in genes such as cyclin",
"    <span class=\"nowrap\">",
"     D1/PRAD1",
"    </span>",
"    for sporadic tumors and RET for familial tumors, or loss-of-function mutations in genes such as MEN1 or HRPT2 for sporadic and familial tumors [",
"    <a class=\"abstract\" href=\"UTD.htm?29/41/30361/abstract/33-36\">",
"     33-36",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Cyclin D1/PRAD1 gene",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pericentric inversion on chromosome 11 results in a relocation of the PRAD1 (parathyroid adenoma 1) proto-oncogene so that it is juxtaposed to 5'-PTH gene-promoting sequences (the gene for PTH itself is on chromosome 11) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/41/30361/abstract/37-39\">",
"     37-39",
"    </a>",
"    ]. PRAD1 encodes cyclin D1 (bcl-1), a major regulator of the cell cycle. A putative tissue-specific enhancer from the 5'-PTH gene region results in overexpression of cyclin D1. Twenty to 40 percent of sporadic parathyroid adenomas overexpress cyclin D1 [",
"    <a class=\"abstract\" href=\"UTD.htm?29/41/30361/abstract/38-41\">",
"     38-41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Parathyroid cell proliferation in primary hyperparathyroidism has been hypothesized to be a consequence of a primary defect in PTH secretory control by calcium. However, transgenic mice in which cyclin D1 was overexpressed in the parathyroid glands have both excessive parathyroid cell proliferation and abnormal control of PTH secretion, suggesting that the proliferative defect is not solely a downstream consequence of the abnormal PTH-calcium relationship [",
"    <a class=\"abstract\" href=\"UTD.htm?29/41/30361/abstract/42\">",
"     42",
"    </a>",
"    ]. In this model, the excessive proliferation preceded the PTH secretory changes, indicating that the primary",
"    <span class=\"nowrap\">",
"     tumorigenic/proliferative",
"    </span>",
"    defects led to secondary dysregulation of the setpoint, rather than vice versa [",
"    <a class=\"abstract\" href=\"UTD.htm?29/41/30361/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     MEN1 gene",
"    </span>",
"    &nbsp;&mdash;&nbsp;MEN1 is a classic tumor suppressor gene that contributes to cell-selective advantage through bi-allelic inactivation [",
"    <a class=\"abstract\" href=\"UTD.htm?29/41/30361/abstract/44\">",
"     44",
"    </a>",
"    ]. The MEN1 gene was identified by positional cloning as the major source of predisposing germline mutations in familial MEN1. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/49/17174?source=see_link\">",
"     \"Multiple endocrine neoplasia type 1: Definition and genetics\"",
"    </a>",
"    .) It is also an important contributor to sporadic nonfamilial parathyroid adenomas.",
"   </p>",
"   <p>",
"    One report of sporadic parathyroid tumors found a somatic inactivating mutation in the MEN1 gene in 4 of 24 (16 percent) subjects with true sporadic tumors, and all of the tumors with this mutation had no expression of the wild-type allele [",
"    <a class=\"abstract\" href=\"UTD.htm?29/41/30361/abstract/45\">",
"     45",
"    </a>",
"    ]. In two other studies, the corresponding proportions were 12 to 13 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?29/41/30361/abstract/46,47\">",
"     46,47",
"    </a>",
"    ]. The mechanism by which the MEN1 gene product, a protein termed menin, functions normally and in tumorigenesis remains an active area of investigation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     HRPT2 gene",
"    </span>",
"    &nbsp;&mdash;&nbsp;Germ-line inactivating HRPT2 mutations have been described in a type of familial hyperparathyroidism, the hyperparathyroidism-jaw tumor syndrome, that is associated with an increased risk of parathyroid cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?29/41/30361/abstract/48\">",
"     48",
"    </a>",
"    ]. In addition, both somatic and germ-line mutations of this gene have been reported in patients with sporadic parathyroid carcinoma. The presence of germ-line mutations in some of these individuals suggests that they may have the hyperparathyroidism-jaw tumor syndrome or a phenotypic variant [",
"    <a class=\"abstract\" href=\"UTD.htm?29/41/30361/abstract/35,49\">",
"     35,49",
"    </a>",
"    ]. HRPT2 mutations are not generally a feature of typically presenting sporadic parathyroid adenomas [",
"    <a class=\"abstract\" href=\"UTD.htm?29/41/30361/abstract/50\">",
"     50",
"    </a>",
"    ], but can, of course, be present in adenomas associated with HPT-JT. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/23/13688?source=see_link\">",
"     \"Parathyroid carcinoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     RET gene",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tumor-specific mutations similar to those in MEN 2A or 2B (ie, gain-of-function RET mutations) are rarely, if ever, found in sporadic primary hyperparathyroidism. As an example, none of the known mutations occurred in 34 sporadic adenomas in one report [",
"    <a class=\"abstract\" href=\"UTD.htm?29/41/30361/abstract/51,52\">",
"     51,52",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/33/41495?source=see_link\">",
"     \"Classification and genetics of multiple endocrine neoplasia type 2\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Vitamin D receptor gene",
"    </span>",
"    &nbsp;&mdash;&nbsp;The vitamin D receptor (VDR) gene is a natural candidate for inactivation in parathyroid adenomas because of the well-established action of 1,25-dihydroxyvitamin D to inhibit proliferation of parathyroid cells in culture. Inactivation of the VDR gene does not seem to play a primary role in parathyroid gland tumorigenesis [",
"    <a class=\"abstract\" href=\"UTD.htm?29/41/30361/abstract/53\">",
"     53",
"    </a>",
"    ], but vitamin D deficiency may alter the phenotypic expression of parathyroid tumors [",
"    <a class=\"abstract\" href=\"UTD.htm?29/41/30361/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Wnt-b-catenin signaling pathway",
"    </span>",
"    &nbsp;&mdash;&nbsp;Aberrant Wnt-b-catenin signaling with accumulation of b-catenin within cells has been implicated in the development of several neoplasms including breast, prostate, colon, pancreas, stomach, and liver. In one report, 3 of 20 (15 percent) tumors from patients with hyperparathyroidism had identical homozygous somatic stabilizing mutations of b-catenin, whereas none were found in the 20 glands with secondary hyperplasias [",
"    <a class=\"abstract\" href=\"UTD.htm?29/41/30361/abstract/54\">",
"     54",
"    </a>",
"    ]. In a subsequent report, the same group identified a smaller proportion of adenomas with the same mutation, decreasing the overall prevalence to approximately 7 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?29/41/30361/abstract/55\">",
"     55",
"    </a>",
"    ]. These interesting findings need to be validated in future studies, and other investigators have sought but not yet found such mutations [",
"    <a class=\"abstract\" href=\"UTD.htm?29/41/30361/abstract/56-59\">",
"     56-59",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Ectopic PTH gene expression",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several cases of ectopic PTH production by non-parathyroid malignant neoplasms have been reported; tumor cell expression of the PTH gene and tumoral production of PTH was demonstrated in very few [",
"    <a class=\"abstract\" href=\"UTD.htm?29/41/30361/abstract/60,61\">",
"     60,61",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     PATHOLOGIC CONDITIONS IN PRIMARY HYPERPARATHYROIDISM",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following pathologic conditions have been found with hyperparathyroidism [",
"    <a class=\"abstract\" href=\"UTD.htm?29/41/30361/abstract/62\">",
"     62",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Adenoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Single adenomas account for up to 89 percent of cases of primary hyperparathyroidism and double adenomas are found in an additional 5 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?29/41/30361/abstract/63,64\">",
"     63,64",
"    </a>",
"    ]. Most adenomas consist of parathyroid chief cells. They are usually encapsulated and 50 percent are surrounded by normal parathyroid tissue. Some adenomas, however, are composed of oxyphil cells. These adenomas are usually larger than chief cell adenomas.",
"   </p>",
"   <p>",
"    PTH-secreting adenomas are occasionally located in the thymus gland. These tumors express a parathyroid-specific gene, GCMB, unlike normal human thymus, which expresses neither PTH nor GCMB [",
"    <a class=\"abstract\" href=\"UTD.htm?29/41/30361/abstract/65\">",
"     65",
"    </a>",
"    ]. This observation suggests that these tumors are derived from parathyroid cells that migrated during embryogenesis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Glandular hyperplasia",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a systematic review of 215 studies including 20,225 patients, multiple gland hyperplasia accounted for approximately 6 percent of cases of primary hyperparathyroidism [",
"    <a class=\"abstract\" href=\"UTD.htm?29/41/30361/abstract/64\">",
"     64",
"    </a>",
"    ]. In this case, all four glands are enlarged, with the lower glands typically being larger than the upper ones. The glands are usually composed of chief cells. Clear cell hyperplasia is very rare, and is the only form in which the upper glands are larger than the lower ones.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Carcinoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Parathyroid carcinomas account for about 1 to 2 percent of cases of hyperparathyroidism [",
"    <a class=\"abstract\" href=\"UTD.htm?29/41/30361/abstract/64,66\">",
"     64,66",
"    </a>",
"    ]. The diagnosis of carcinoma requires at least one of the following: local invasion of contiguous structures, lymph node or distant metastases. While not sufficient for diagnosis, characteristic histopathologic changes in parathyroid carcinoma include fibrous trabeculae, mitotic figures, and capsular or vascular invasion. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/23/13688?source=see_link\">",
"     \"Parathyroid carcinoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     CONDITIONS ASSOCIATED WITH PRIMARY HYPERPARATHYROIDISM",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Familial hyperparathyroidism",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hereditary forms of hyperparathyroidism are rare [",
"    <a class=\"abstract\" href=\"UTD.htm?29/41/30361/abstract/67\">",
"     67",
"    </a>",
"    ]. In contrast to sporadic hyperparathyroidism, the molecular basis of the various subtypes of hereditary hyperparathyroidism is well understood [",
"    <a class=\"abstract\" href=\"UTD.htm?29/41/30361/abstract/48,67\">",
"     48,67",
"    </a>",
"    ]. Probably the most common cause of this rare form of hyperparathyroidism is as part of the MEN type 1 or 2 syndromes. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/33/41495?source=see_link\">",
"     \"Classification and genetics of multiple endocrine neoplasia type 2\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/49/17174?source=see_link\">",
"     \"Multiple endocrine neoplasia type 1: Definition and genetics\"",
"    </a>",
"    .) It can also occur as familial primary hyperparathyroidism not associated with any other endocrine disorder, termed familial isolated hyperparathyroidism (FIHP), or in the familial hyperparathyroidism-jaw tumor syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?29/41/30361/abstract/67\">",
"     67",
"    </a>",
"    ], previously termed familial cystic parathyroid adenomatosis [",
"    <a class=\"abstract\" href=\"UTD.htm?29/41/30361/abstract/68\">",
"     68",
"    </a>",
"    ]. FHH and neonatal severe hyperparathyroidism are also part of the familial hyperparathyroidism syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?29/41/30361/abstract/67\">",
"     67",
"    </a>",
"    ], but because of the dual defect in calcium-sensing at the parathyroid gland and kidney, these syndromes are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/51/19258?source=see_link\">",
"     \"Disorders of the calcium-sensing receptor: Familial hypocalciuric hypercalcemia and autosomal dominant hypocalcemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Familial isolated hyperparathyroidism is rare and, in most instances, its genetic basis appears to be distinct from that in MEN type 1 or 2, FHH, or HPT-JT [",
"    <a class=\"abstract\" href=\"UTD.htm?29/41/30361/abstract/48,67,69,70\">",
"     48,67,69,70",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Familial hyperparathyroidism often presents with severe hypercalcemia; in one series of 16 patients, almost one-half had severe hypercalcemia (&gt;15",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [3.8",
"    <span class=\"nowrap\">",
"     mmol/L]),",
"    </span>",
"    one-third presented in parathyroid crisis, and 75 percent had multiple abnormal parathyroid glands [",
"    <a class=\"abstract\" href=\"UTD.htm?29/41/30361/abstract/71\">",
"     71",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a second series of 36 kindreds with previously diagnosed familial isolated hyperparathyroidism, clinical, biochemical, and mutational analyses were done to determine if other syndromic diagnoses were present [",
"    <a class=\"abstract\" href=\"UTD.htm?29/41/30361/abstract/70\">",
"     70",
"    </a>",
"    ]. None of the kindreds had MEN1 syndrome, while five had inactivating mutations of the calcium-sensing receptor gene and other features similar to familial hypocalciuric hypercalcemia; three had the hyperparathyroidism-jaw tumor syndrome. Thus, in this series, approximately 20 percent of kindreds with presumed familial isolated hyperparathyroidism had evidence of other syndromic diagnoses.",
"   </p>",
"   <p>",
"    Management of patients with familial hyperparathyroidism differs from that in sporadic hyperparathyroidism because of the variability in the presentations, including [",
"    <a class=\"abstract\" href=\"UTD.htm?29/41/30361/abstract/48,67\">",
"     48,67",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Penetrance",
"     </li>",
"     <li>",
"      Delay in onset of symptoms",
"     </li>",
"     <li>",
"      Severity of hypercalcemia",
"     </li>",
"     <li>",
"      Propensity to parathyroid cancer (hyperparathyroidism jaw-tumor syndrome)",
"     </li>",
"     <li>",
"      Feasibility and accuracy in assessment of carrier status",
"     </li>",
"     <li>",
"      High recurrence rate post-parathyroidectomy",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    DNA testing can play a role in the diagnosis or management of the familial hyperparathyroid syndromes, but the issues are complex and need to be considered on an individual basis [",
"    <a class=\"abstract\" href=\"UTD.htm?29/41/30361/abstract/48\">",
"     48",
"    </a>",
"    ]. RET mutation testing is mandatory in MEN2 for prevention of metastatic medullary thyroid carcinoma, and periodic surveillance that may include biochemical monitoring and imaging for associated tumors is advised in MEN1 and 2, as well as in hyperparathyroidism-jaw tumor syndrome. Subtotal parathyroidectomy, at times with autografting and cryopreservation, are recommended in MEN1 and 2. The role of HRPT2 mutation testing, biochemical surveillance, and surgical management related to hyperparathyroidism-jaw tumor syndrome is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/23/13688?source=see_link\">",
"     \"Parathyroid carcinoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Thiazide therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thiazide diuretics reduce urinary calcium excretion and therefore can cause mild hypercalcemia (up to 11.5",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [2.9",
"    <span class=\"nowrap\">",
"     mmol/L]).",
"    </span>",
"    (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/22/28007?source=see_link\">",
"     \"Etiology of hypercalcemia\"",
"    </a>",
"    .) In addition, thiazide therapy can unmask underlying primary hyperparathyroidism. Primary hyperparathyroidism is more likely when hypercalcemia persists after drug withdrawal or when the initial serum calcium value is above 12",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (3",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?29/41/30361/abstract/72\">",
"     72",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a population-based study of residents of Olmsted County, Minnesota, the annual age- and gender-adjusted incidence of thiazide-associated hypercalcemia was 7.7 per 100,000 (95% CI 5.9-9.5) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/41/30361/abstract/73\">",
"     73",
"    </a>",
"    ]. Hypercalcemia was identified a mean of six years after initiating thiazides. Hypercalcemia persisted in 21 of 33 patients who discontinued the thiazide, 18 of whom were diagnosed with primary hyperparathyroidism. Among all patients with thiazide-associated hypercalcemia, those subsequently diagnosed with primary hyperparathyroidism had higher average serum calcium (11.0 versus 10.7",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [2.75 versus 2.68",
"    <span class=\"nowrap\">",
"     mmol/L])",
"    </span>",
"    and PTH levels (59.8 versus 45.6",
"    <span class=\"nowrap\">",
"     pg/mL",
"    </span>",
"    [6.3 versus 4.8",
"    <span class=\"nowrap\">",
"     pmol/L]).",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Lithium therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/11/23736?source=see_link\">",
"     Lithium",
"    </a>",
"    increases serum total and ionized calcium and intact PTH levels within weeks, but these remain within the normal range in most subjects [",
"    <a class=\"abstract\" href=\"UTD.htm?29/41/30361/abstract/74-76\">",
"     74-76",
"    </a>",
"    ]. Nevertheless, even though hypercalcemia may not be present, lithium can induce a continued defect in calcium-PTH regulation: normocalcemic patients can have a slightly raised serum PTH concentration and an increase in mean parathyroid gland volume [",
"    <a class=\"abstract\" href=\"UTD.htm?29/41/30361/abstract/77\">",
"     77",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although estimates vary widely, approximately 10 to 20 percent of patients taking",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/11/23736?source=see_link\">",
"     lithium",
"    </a>",
"    develop hypercalcemia and hypocalciuria, and a smaller percentage have high serum PTH concentrations [",
"    <a class=\"abstract\" href=\"UTD.htm?29/41/30361/abstract/74,78\">",
"     74,78",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/22/28007?source=see_link\">",
"     \"Etiology of hypercalcemia\"",
"    </a>",
"    .) In a study of 142 patients on lithium for at least 15 years, the overall prevalence of hypercalcemia was 3.6 percent, approximately eight times that expected in the general Swedish population. In patients with surgically verified HPTH, the prevalence was 2.7 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?29/41/30361/abstract/79\">",
"     79",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/11/23736?source=see_link\">",
"     Lithium",
"    </a>",
"    also increases the serum magnesium and decreases urinary calcium and magnesium concentrations, findings reminiscent of familial benign hypocalciuric hypercalcemia, a syndrome caused by inactivation mutations in the CaSR [",
"    <a class=\"abstract\" href=\"UTD.htm?29/41/30361/abstract/74,80\">",
"     74,80",
"    </a>",
"    ]. Lithium decreases parathyroid gland sensitivity to calcium, shifting the set-point of the Ca-PTH curve to the right [",
"    <a class=\"abstract\" href=\"UTD.htm?29/41/30361/abstract/81-83\">",
"     81-83",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In one study of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/11/23736?source=see_link\">",
"     lithium",
"    </a>",
"    -treated patients, the value for the set-point of the serum ionized calcium concentrations was 1.26",
"    <span class=\"nowrap\">",
"     mmol/L,",
"    </span>",
"    as compared with 1.21",
"    <span class=\"nowrap\">",
"     mmol/L",
"    </span>",
"    in normal subjects [",
"    <a class=\"abstract\" href=\"UTD.htm?29/41/30361/abstract/82\">",
"     82",
"    </a>",
"    ]. Lithium is thought to exert an action downstream of the CaSR itself [",
"    <a class=\"abstract\" href=\"UTD.htm?29/41/30361/abstract/84,85\">",
"     84,85",
"    </a>",
"    ], although the precise mechanism by which it interferes with CaSR signaling is unknown [",
"    <a class=\"abstract\" href=\"UTD.htm?29/41/30361/abstract/81,82\">",
"     81,82",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/51/19258?source=see_link\">",
"     \"Disorders of the calcium-sensing receptor: Familial hypocalciuric hypercalcemia and autosomal dominant hypocalcemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Whereas altered calcium-sensing would be anticipated to result in four gland hyperplasia in patients with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/11/23736?source=see_link\">",
"     lithium",
"    </a>",
"    -induced hyperparathyroidism, equal or greater numbers of adenomas than hyperplasias have been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?29/41/30361/abstract/86-88\">",
"     86-88",
"    </a>",
"    ]. The median duration of lithium therapy in patients with adenomas was two years, whereas it was 12 years in those with four gland hyperplasia. It is possible that lithium unmasks adenomas in patients with pre-existing parathyroid lesions within a few years of starting therapy, or induces parathyroid hyperplasia with more chronic use [",
"    <a class=\"abstract\" href=\"UTD.htm?29/41/30361/abstract/86\">",
"     86",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    If the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/11/23736?source=see_link\">",
"     lithium",
"    </a>",
"    can be stopped without exacerbating the psychiatric condition, the hypercalcemia may resolve. Normalization of serum calcium is more likely to occur one to four weeks post-lithium withdrawal in patients with a relatively short duration of lithium use (less than a few years) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/41/30361/abstract/74\">",
"     74",
"    </a>",
"    ]. It is less likely in patients receiving lithium for more than 10 years [",
"    <a class=\"abstract\" href=\"UTD.htm?29/41/30361/abstract/86\">",
"     86",
"    </a>",
"    ]. In some patients, the serum calcium concentration may not fall for one to four months after lithium is discontinued [",
"    <a class=\"abstract\" href=\"UTD.htm?29/41/30361/abstract/79\">",
"     79",
"    </a>",
"    ]. Other probable predictors of calcium normalization include the underlying parathyroid gland pathology and mass, and the use of other drugs that may also affect calcium metabolism, such as thiazide diuretics.",
"   </p>",
"   <p>",
"    The effect of mild",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/11/23736?source=see_link\">",
"     lithium",
"    </a>",
"    -induced hyperparathyroidism on the skeleton is unclear. Two longitudinal studies of a total of 21 patients suggested significant bone mineral loss in the forearm after a short period (three to six months) of lithium therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?29/41/30361/abstract/89,90\">",
"     89,90",
"    </a>",
"    ]. However, these findings were not confirmed in a cross-sectional study of bone mineral density in the spine and the hip in 25 lithium-treated and 25 control patients [",
"    <a class=\"abstract\" href=\"UTD.htm?29/41/30361/abstract/91\">",
"     91",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In view of the uncertainty of the effect of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/11/23736?source=see_link\">",
"     lithium",
"    </a>",
"    on bone, we recommend periodic measurement of bone mineral density of the forearm in younger patients (&lt;45 years) and of the spine and hip in older patients who have persistent hypercalcemia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/55/11128?source=see_link\">",
"     \"Diagnosis and evaluation of osteoporosis in postmenopausal women\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4110665\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Primary hyperparathyroidism is characterized by abnormal regulation of PTH secretion by calcium. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Parathyroid hormone and calcium homeostasis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A cause for primary hyperparathyroidism, such as irradiation or the rare familial genetic abnormalities, can be identified in only a small number of patients. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Etiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Abnormalities in key growth-controlling genes, protooncogenes, or tumor suppressor genes underlie the development of parathyroid tumors, which may occur sporadically or in familial patterns. The underlying genetic abnormalities include gain-of-function changes in genes such as cyclin",
"      <span class=\"nowrap\">",
"       D1/PRAD1",
"      </span>",
"      for sporadic tumors and RET for familial tumors, or loss-of-function mutations in genes such as MEN1 or HRPT2 for sporadic and familial tumors. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Genetic or chromosomal defects'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Single adenomas account for about 80 to 85 percent of cases of primary hyperparathyroidism. Multiple gland hyperplasia accounts for approximately 10 to 15 percent, double adenomas for an additional 2 to 5 percent, and parathyroid carcinoma for about 1 percent of cases of primary hyperparathyroidism. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Pathologic conditions in primary hyperparathyroidism'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/41/30361/abstract/1\">",
"      Wermers RA, Khosla S, Atkinson EJ, et al. Incidence of primary hyperparathyroidism in Rochester, Minnesota, 1993-2001: an update on the changing epidemiology of the disease. J Bone Miner Res 2006; 21:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/41/30361/abstract/2\">",
"      Rao DS, Honasoge M, Divine GW, et al. Effect of vitamin D nutrition on parathyroid adenoma weight: pathogenetic and clinical implications. J Clin Endocrinol Metab 2000; 85:1054.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/41/30361/abstract/3\">",
"      Brown EM. Extracellular Ca2+ sensing, regulation of parathyroid cell function, and role of Ca2+ and other ions as extracellular (first) messengers. Physiol Rev 1991; 71:371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/41/30361/abstract/4\">",
"      Friedman PA, Gesek FA. Calcium transport in renal epithelial cells. Am J Physiol 1993; 264:F181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/41/30361/abstract/5\">",
"      Gesek FA, Friedman PA. On the mechanism of parathyroid hormone stimulation of calcium uptake by mouse distal convoluted tubule cells. J Clin Invest 1992; 90:749.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/41/30361/abstract/6\">",
"      Brown EM. Four-parameter model of the sigmoidal relationship between parathyroid hormone release and extracellular calcium concentration in normal and abnormal parathyroid tissue. J Clin Endocrinol Metab 1983; 56:572.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/41/30361/abstract/7\">",
"      Brossard JH, Whittom S, Lepage R, D'Amour P. Carboxyl-terminal fragments of parathyroid hormone are not secreted preferentially in primary hyperparathyroidism as they are in other hypercalcemic conditions. J Clin Endocrinol Metab 1993; 77:413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/41/30361/abstract/8\">",
"      Brown EM, Gamba G, Riccardi D, et al. Cloning and characterization of an extracellular Ca(2+)-sensing receptor from bovine parathyroid. Nature 1993; 366:575.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/41/30361/abstract/9\">",
"      Brown EM, Pollak M, Seidman CE, et al. Calcium-ion-sensing cell-surface receptors. N Engl J Med 1995; 333:234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/41/30361/abstract/10\">",
"      Hosokawa Y, Pollak MR, Brown EM, Arnold A. Mutational analysis of the extracellular Ca(2+)-sensing receptor gene in human parathyroid tumors. J Clin Endocrinol Metab 1995; 80:3107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/41/30361/abstract/11\">",
"      Cetani F, Pinchera A, Pardi E, et al. No evidence for mutations in the calcium-sensing receptor gene in sporadic parathyroid adenomas. J Bone Miner Res 1999; 14:878.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/41/30361/abstract/12\">",
"      Carling T, Szabo E, Bai M, et al. Familial hypercalcemia and hypercalciuria caused by a novel mutation in the cytoplasmic tail of the calcium receptor. J Clin Endocrinol Metab 2000; 85:2042.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/41/30361/abstract/13\">",
"      Scillitani A, Guarnieri V, Battista C, et al. Primary hyperparathyroidism and the presence of kidney stones are associated with different haplotypes of the calcium-sensing receptor. J Clin Endocrinol Metab 2007; 92:277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/41/30361/abstract/14\">",
"      Kifor O, Moore FD Jr, Wang P, et al. Reduced immunostaining for the extracellular Ca2+-sensing receptor in primary and uremic secondary hyperparathyroidism. J Clin Endocrinol Metab 1996; 81:1598.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/41/30361/abstract/15\">",
"      Gogusev J, Duchambon P, Hory B, et al. Depressed expression of calcium receptor in parathyroid gland tissue of patients with hyperparathyroidism. Kidney Int 1997; 51:328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/41/30361/abstract/16\">",
"      Cetani F, Picone A, Cerrai P, et al. Parathyroid expression of calcium-sensing receptor protein and in vivo parathyroid hormone-Ca(2+) set-point in patients with primary hyperparathyroidism. J Clin Endocrinol Metab 2000; 85:4789.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/41/30361/abstract/17\">",
"      Farnebo F, Enberg U, Grimelius L, et al. Tumor-specific decreased expression of calcium sensing receptor messenger ribonucleic acid in sporadic primary hyperparathyroidism. J Clin Endocrinol Metab 1997; 82:3481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/41/30361/abstract/18\">",
"      Pollak MR, Brown EM, Chou YH, et al. Mutations in the human Ca(2+)-sensing receptor gene cause familial hypocalciuric hypercalcemia and neonatal severe hyperparathyroidism. Cell 1993; 75:1297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/41/30361/abstract/19\">",
"      Khosla, S, Ebeling, PR, Firek, AF, et al. Calcium infusion suggests a \"set-point\" abnormality of parathyroid function in familial benign hypercalcemia and more complex disturbances in primary hyperparathyroidism. J Clin Endocrinol Metab 1993; 76:715.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/41/30361/abstract/20\">",
"      Beard, CM, Heath, H III, O'Fallon, WM, et al. Therapeutic radiation and hyperparathyroidism: a case-control study in Rochester, Minn. Arch Intern Med 1989; 149:1887.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/41/30361/abstract/21\">",
"      Tisell LE, Hansson G, Lindberg S, Ragnhult I. Hyperparathyroidism in persons treated with X-rays for tuberculous cervical adenitis. Cancer 1977; 40:846.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/41/30361/abstract/22\">",
"      McMullen T, Bodie G, Gill A, et al. Hyperparathyroidism after irradiation for childhood malignancy. Int J Radiat Oncol Biol Phys 2009; 73:1164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/41/30361/abstract/23\">",
"      Boehm BO, Rosinger S, Belyi D, Dietrich JW. The parathyroid as a target for radiation damage. N Engl J Med 2011; 365:676.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/41/30361/abstract/24\">",
"      Schneider AB, Gierlowski TC, Shore-Freedman E, et al. Dose-response relationships for radiation-induced hyperparathyroidism. J Clin Endocrinol Metab 1995; 80:254.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/41/30361/abstract/25\">",
"      Fujiwara S, Sposto R, Ezaki H, et al. Hyperparathyroidism among atomic bomb survivors in Hiroshima. Radiat Res 1992; 130:372.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/41/30361/abstract/26\">",
"      Tezelman S, Rodriguez JM, Shen W, et al. Primary hyperparathyroidism in patients who have received radiation therapy and in patients who have not received radiation therapy. J Am Coll Surg 1995; 180:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/41/30361/abstract/27\">",
"      Wilson SD, Doffek KM, Wang TS, et al. Primary hyperparathyroidism with a history of head and neck irradiation: the consequences of associated thyroid tumors. Surgery 2011; 150:869.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/41/30361/abstract/28\">",
"      Woll M, Sippel RS, Chen H. Does previous head and neck irradiation increase the chance of multigland disease in patients with hyperparathyroidism? Ann Surg Oncol 2011; 18:2240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/41/30361/abstract/29\">",
"      Ippolito G, Palazzo FF, Sebag F, Henry JF. Long-term follow-up after parathyroidectomy for radiation-induced hyperparathyroidism. Surgery 2007; 142:819.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/41/30361/abstract/30\">",
"      Cola&ccedil;o SM, Si M, Reiff E, Clark OH. Hyperparathyroidism after radioactive iodine therapy. Am J Surg 2007; 194:323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/41/30361/abstract/31\">",
"      Fj&auml;lling M, Dackenberg A, Hedman I, Tisell LE. An evaluation of the risk of developing hyperparathyroidism after 131I treatment for thyrotoxicosis. Acta Chir Scand 1983; 149:681.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/41/30361/abstract/32\">",
"      Paik JM, Curhan GC, Taylor EN. Calcium intake and risk of primary hyperparathyroidism in women: prospective cohort study. BMJ 2012; 345:e6390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/41/30361/abstract/33\">",
"      Hendy GN. Molecular mechanisms of primary hyperparathyroidism. Rev Endocr Metab Disord 2000; 1:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/41/30361/abstract/34\">",
"      Arnold A, Shattuck TM, Mallya SM, et al. Molecular pathogenesis of primary hyperparathyroidism. J Bone Miner Res 2002; 17 Suppl 2:N30.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/41/30361/abstract/35\">",
"      Shattuck TM, V&auml;lim&auml;ki S, Obara T, et al. Somatic and germ-line mutations of the HRPT2 gene in sporadic parathyroid carcinoma. N Engl J Med 2003; 349:1722.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/41/30361/abstract/36\">",
"      Westin G, Bj&ouml;rklund P, Akerstr&ouml;m G. Molecular genetics of parathyroid disease. World J Surg 2009; 33:2224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/41/30361/abstract/37\">",
"      Arnold A, Kim HG, Gaz RD, et al. Molecular cloning and chromosomal mapping of DNA rearranged with the parathyroid hormone gene in a parathyroid adenoma. J Clin Invest 1989; 83:2034.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/41/30361/abstract/38\">",
"      Hsi ED, Zukerberg LR, Yang WI, Arnold A. Cyclin D1/PRAD1 expression in parathyroid adenomas: an immunohistochemical study. J Clin Endocrinol Metab 1996; 81:1736.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/41/30361/abstract/39\">",
"      Rosenberg CL, Kim HG, Shows TB, et al. Rearrangement and overexpression of D11S287E, a candidate oncogene on chromosome 11q13 in benign parathyroid tumors. Oncogene 1991; 6:449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/41/30361/abstract/40\">",
"      Hemmer S, Wasenius VM, Haglund C, et al. Deletion of 11q23 and cyclin D1 overexpression are frequent aberrations in parathyroid adenomas. Am J Pathol 2001; 158:1355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/41/30361/abstract/41\">",
"      Vasef MA, Brynes RK, Sturm M, et al. Expression of cyclin D1 in parathyroid carcinomas, adenomas, and hyperplasias: a paraffin immunohistochemical study. Mod Pathol 1999; 12:412.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/41/30361/abstract/42\">",
"      Imanishi Y, Hosokawa Y, Yoshimoto K, et al. Primary hyperparathyroidism caused by parathyroid-targeted overexpression of cyclin D1 in transgenic mice. J Clin Invest 2001; 107:1093.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/41/30361/abstract/43\">",
"      Mallya SM, Gallagher JJ, Wild YK, et al. Abnormal parathyroid cell proliferation precedes biochemical abnormalities in a mouse model of primary hyperparathyroidism. Mol Endocrinol 2005; 19:2603.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/41/30361/abstract/44\">",
"      Agarwal SK, Kester MB, Debelenko LV, et al. Germline mutations of the MEN1 gene in familial multiple endocrine neoplasia type 1 and related states. Hum Mol Genet 1997; 6:1169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/41/30361/abstract/45\">",
"      Heppner C, Kester MB, Agarwal SK, et al. Somatic mutation of the MEN1 gene in parathyroid tumours. Nat Genet 1997; 16:375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/41/30361/abstract/46\">",
"      Carling T, Correa P, Hessman O, et al. Parathyroid MEN1 gene mutations in relation to clinical characteristics of nonfamilial primary hyperparathyroidism. J Clin Endocrinol Metab 1998; 83:2960.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/41/30361/abstract/47\">",
"      Farnebo F, Teh BT, Kyt&ouml;l&auml; S, et al. Alterations of the MEN1 gene in sporadic parathyroid tumors. J Clin Endocrinol Metab 1998; 83:2627.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/41/30361/abstract/48\">",
"      Falchetti A, Marini F, Giusti F, et al. DNA-based test: when and why to apply it to primary hyperparathyroidism clinical phenotypes. J Intern Med 2009; 266:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/41/30361/abstract/49\">",
"      Cetani F, Pardi E, Borsari S, et al. Genetic analyses of the HRPT2 gene in primary hyperparathyroidism: germline and somatic mutations in familial and sporadic parathyroid tumors. J Clin Endocrinol Metab 2004; 89:5583.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/41/30361/abstract/50\">",
"      Krebs LJ, Shattuck TM, Arnold A. HRPT2 mutational analysis of typical sporadic parathyroid adenomas. J Clin Endocrinol Metab 2005; 90:5015.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/41/30361/abstract/51\">",
"      Pausova Z, Soliman E, Amizuka N, et al. Role of the RET proto-oncogene in sporadic hyperparathyroidism and in hyperparathyroidism of multiple endocrine neoplasia type 2. J Clin Endocrinol Metab 1996; 81:2711.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/41/30361/abstract/52\">",
"      Padberg BC, Schr&ouml;der S, Jochum W, et al. Absence of RET proto-oncogene point mutations in sporadic hyperplastic and neoplastic lesions of the parathyroid gland. Am J Pathol 1995; 147:1600.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/41/30361/abstract/53\">",
"      Samander EH, Arnold A. Mutational analysis of the vitamin D receptor does not support its candidacy as a tumor suppressor gene in parathyroid adenomas. J Clin Endocrinol Metab 2006; 91:5019.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/41/30361/abstract/54\">",
"      Bj&ouml;rklund P, Akerstr&ouml;m G, Westin G. Accumulation of nonphosphorylated beta-catenin and c-myc in primary and uremic secondary hyperparathyroid tumors. J Clin Endocrinol Metab 2007; 92:338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/41/30361/abstract/55\">",
"      Bj&ouml;rklund P, Lindberg D, Akerstr&ouml;m G, Westin G. Stabilizing mutation of CTNNB1/beta-catenin and protein accumulation analyzed in a large series of parathyroid tumors of Swedish patients. Mol Cancer 2008; 7:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/41/30361/abstract/56\">",
"      Ikeda S, Ishizaki Y, Shimizu Y, et al. Immunohistochemistry of cyclin D1 and beta-catenin, and mutational analysis of exon 3 of beta-catenin gene in parathyroid adenomas. Int J Oncol 2002; 20:463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/41/30361/abstract/57\">",
"      Costa-Guda J, Arnold A. Absence of stabilizing mutations of beta-catenin encoded by CTNNB1 exon 3 in a large series of sporadic parathyroid adenomas. J Clin Endocrinol Metab 2007; 92:1564.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/41/30361/abstract/58\">",
"      Cetani F, Pardi E, Banti C, et al. Beta-catenin activation is not involved in sporadic parathyroid carcinomas and adenomas. Endocr Relat Cancer 2010; 17:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/41/30361/abstract/59\">",
"      Haglund F, Andreasson A, Nilsson IL, et al. Lack of S37A CTNNB1/&beta;-catenin mutations in a Swedish cohort of 98 parathyroid adenomas. Clin Endocrinol (Oxf) 2010; 73:552.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/41/30361/abstract/60\">",
"      Nussbaum SR, Gaz RD, Arnold A. Hypercalcemia and ectopic secretion of parathyroid hormone by an ovarian carcinoma with rearrangement of the gene for parathyroid hormone. N Engl J Med 1990; 323:1324.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/41/30361/abstract/61\">",
"      VanHouten JN, Yu N, Rimm D, et al. Hypercalcemia of malignancy due to ectopic transactivation of the parathyroid hormone gene. J Clin Endocrinol Metab 2006; 91:580.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/41/30361/abstract/62\">",
"      Salti GI, Fedorak I, Yashiro T, et al. Continuing evolution in the operative management of primary hyperparathyroidism. Arch Surg 1992; 127:831.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/41/30361/abstract/63\">",
"      Bartsch D, Nies C, Hasse C, et al. Clinical and surgical aspects of double adenoma in patients with primary hyperparathyroidism. Br J Surg 1995; 82:926.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/41/30361/abstract/64\">",
"      Ruda JM, Hollenbeak CS, Stack BC Jr. A systematic review of the diagnosis and treatment of primary hyperparathyroidism from 1995 to 2003. Otolaryngol Head Neck Surg 2005; 132:359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/41/30361/abstract/65\">",
"      Maret A, Bourdeau I, Ding C, et al. Expression of GCMB by intrathymic parathyroid hormone-secreting adenomas indicates their parathyroid cell origin. J Clin Endocrinol Metab 2004; 89:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/41/30361/abstract/66\">",
"      Wynne AG, van Heerden J, Carney JA, Fitzpatrick LA. Parathyroid carcinoma: clinical and pathologic features in 43 patients. Medicine (Baltimore) 1992; 71:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/41/30361/abstract/67\">",
"      Marx SJ, Simonds WF, Agarwal SK, et al. Hyperparathyroidism in hereditary syndromes: special expressions and special managements. J Bone Miner Res 2002; 17 Suppl 2:N37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/41/30361/abstract/68\">",
"      Mallette LE, Malini S, Rappaport MP, Kirkland JL. Familial cystic parathyroid adenomatosis. Ann Intern Med 1987; 107:54.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/41/30361/abstract/69\">",
"      Simonds WF, Robbins CM, Agarwal SK, et al. Familial isolated hyperparathyroidism is rarely caused by germline mutation in HRPT2, the gene for the hyperparathyroidism-jaw tumor syndrome. J Clin Endocrinol Metab 2004; 89:96.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/41/30361/abstract/70\">",
"      Simonds WF, James-Newton LA, Agarwal SK, et al. Familial isolated hyperparathyroidism: clinical and genetic characteristics of 36 kindreds. Medicine (Baltimore) 2002; 81:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/41/30361/abstract/71\">",
"      Huang SM, Duh QY, Shaver J, et al. Familial hyperparathyroidism without multiple endocrine neoplasia. World J Surg 1997; 21:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/41/30361/abstract/72\">",
"      Christensson T, Hellstr&ouml;m K, Wengle B. Hypercalcemia and primary hyperparathyroidism. Prevalence in patients receiving thiazides as detected in a health screen. Arch Intern Med 1977; 137:1138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/41/30361/abstract/73\">",
"      Wermers RA, Kearns AE, Jenkins GD, Melton LJ 3rd. Incidence and clinical spectrum of thiazide-associated hypercalcemia. Am J Med 2007; 120:911.e9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/41/30361/abstract/74\">",
"      Mallette LE, Eichhorn E. Effects of lithium carbonate on human calcium metabolism. Arch Intern Med 1986; 146:770.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/41/30361/abstract/75\">",
"      Mak TW, Shek CC, Chow CC, et al. Effects of lithium therapy on bone mineral metabolism: a two-year prospective longitudinal study. J Clin Endocrinol Metab 1998; 83:3857.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/41/30361/abstract/76\">",
"      McKnight RF, Adida M, Budge K, et al. Lithium toxicity profile: a systematic review and meta-analysis. Lancet 2012; 379:721.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/41/30361/abstract/77\">",
"      Mallette LE, Khouri K, Zengotita H, et al. Lithium treatment increases intact and midregion parathyroid hormone and parathyroid volume. J Clin Endocrinol Metab 1989; 68:654.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/41/30361/abstract/78\">",
"      Lehmann SW, Lee J. Lithium-associated hypercalcemia and hyperparathyroidism in the elderly: What do we know? J Affect Disord 2013; 146:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/41/30361/abstract/79\">",
"      Bendz H, Sj&ouml;din I, Toss G, Berglund K. Hyperparathyroidism and long-term lithium therapy--a cross-sectional study and the effect of lithium withdrawal. J Intern Med 1996; 240:357.",
"     </a>",
"    </li>",
"    <li>",
"     El-Hajj Fuleihan G, Brown EM, Heath H III. The Familial Benign Hypocalciuric Hypercalcemic Syndromes. In: Principles of Bone Biology, Bilezikian JP, Raisz LG, Rodan GA (Eds), Academic Press, San Diego 1996.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/41/30361/abstract/81\">",
"      Brown EM. Lithium induces abnormal calcium-regulated PTH release in dispersed bovine parathyroid cells. J Clin Endocrinol Metab 1981; 52:1046.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/41/30361/abstract/82\">",
"      Haden ST, Stoll AL, McCormick S, et al. Alterations in parathyroid dynamics in lithium-treated subjects. J Clin Endocrinol Metab 1997; 82:2844.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/41/30361/abstract/83\">",
"      McHenry CR, Lee K. Lithium therapy and disorders of the parathyroid glands. Endocr Pract 1996; 2:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/41/30361/abstract/84\">",
"      Racke F, McHenry CR, Wentworth D. Lithium-induced alterations in parathyroid cell function: insight into the pathogenesis of lithium-associated hyperparathyroidism. Am J Surg 1994; 168:462.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/41/30361/abstract/85\">",
"      McHenry CR, Stenger DB, Racke F. Investigation of calcium-induced hydrolysis of phosphoinositides in normal and lithium-treated parathyroid cells. Am J Surg 1995; 170:484.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/41/30361/abstract/86\">",
"      Nordenstr&ouml;m J, Strig&aring;rd K, Perbeck L, et al. Hyperparathyroidism associated with treatment of manic-depressive disorders by lithium. Eur J Surg 1992; 158:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/41/30361/abstract/87\">",
"      J&auml;rhult J, Ander S, Asking B, et al. Long-term results of surgery for lithium-associated hyperparathyroidism. Br J Surg 2010; 97:1680.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/41/30361/abstract/88\">",
"      Awad SS, Miskulin J, Thompson N. Parathyroid adenomas versus four-gland hyperplasia as the cause of primary hyperparathyroidism in patients with prolonged lithium therapy. World J Surg 2003; 27:486.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/41/30361/abstract/89\">",
"      Plenge P, Rafaelsen OJ. Lithium effects on calcium, magnesium and phosphate in man: effects on balance, bone mineral content, faecal and urinary excretion. Acta Psychiatr Scand 1982; 66:361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/41/30361/abstract/90\">",
"      Christiansen C, Baastrup PC, Transb&oslash;l I. Development of 'primary' hyperparathyroidism during lithium therapy: longitudinal study. Neuropsychobiology 1980; 6:280.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/41/30361/abstract/91\">",
"      Nordenstr&ouml;m J, Elvius M, B&aring;gedahl-Strindlund M, et al. Biochemical hyperparathyroidism and bone mineral status in patients treated long-term with lithium. Metabolism 1994; 43:1563.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2038 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-200.215.4.194-6EBEB1F6CE-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_41_30361=[""].join("\n");
var outline_f29_41_30361=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H4110665\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PARATHYROID HORMONE AND CALCIUM HOMEOSTASIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Relationship between serum PTH and ionized calcium concentrations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      The calcium-sensing receptor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      ETIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Radiation exposure",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Radioactive iodine therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3136394\">",
"      Calcium intake",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Genetic or chromosomal defects",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Cyclin D1/PRAD1 gene",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - MEN1 gene",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - HRPT2 gene",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - RET gene",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Vitamin D receptor gene",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Wnt-b-catenin signaling pathway",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Ectopic PTH gene expression",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      PATHOLOGIC CONDITIONS IN PRIMARY HYPERPARATHYROIDISM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Adenoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Glandular hyperplasia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      CONDITIONS ASSOCIATED WITH PRIMARY HYPERPARATHYROIDISM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Familial hyperparathyroidism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Thiazide therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Lithium therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4110665\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ENDO/2038\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/2038|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?42/31/43517\" title=\"figure 1\">",
"      Presentation of hyperparathyroidism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?33/8/33935\" title=\"figure 2\">",
"      PTH and calcium",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/36/2631?source=related_link\">",
"      Chapter 6F: Hormonal regulation of calcium and phosphate balance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/33/41495?source=related_link\">",
"      Classification and genetics of multiple endocrine neoplasia type 2",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/19/1338?source=related_link\">",
"      Clinical manifestations of primary hyperparathyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/26/5545?source=related_link\">",
"      Diagnosis and differential diagnosis of primary hyperparathyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/55/11128?source=related_link\">",
"      Diagnosis and evaluation of osteoporosis in postmenopausal women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/51/19258?source=related_link\">",
"      Disorders of the calcium-sensing receptor: Familial hypocalciuric hypercalcemia and autosomal dominant hypocalcemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/22/28007?source=related_link\">",
"      Etiology of hypercalcemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/49/17174?source=related_link\">",
"      Multiple endocrine neoplasia type 1: Definition and genetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/23/13688?source=related_link\">",
"      Parathyroid carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/56/36744?source=related_link\">",
"      Parathyroid hormone secretion and action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/50/18218?source=related_link\">",
"      Pathogenesis of renal osteodystrophy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/49/1818?source=related_link\">",
"      Radiation-induced thyroid cancer",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f29_41_30362="Induction therapy for acute myeloid leukemia in younger adults";
var content_f29_41_30362=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"7\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Induction therapy for acute myeloid leukemia in younger adults",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/41/30362/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/41/30362/contributors\">",
"     Richard A Larson, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/41/30362/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/41/30362/contributors\">",
"     Bob Lowenberg, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/41/30362/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/41/30362/contributors\">",
"     Rebecca F Connor, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?29/41/30362/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 24, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once the diagnosis of acute myeloid leukemia (AML) is established, induction chemotherapy is given with the goal of rapidly restoring normal bone marrow function. Among patients with acute myeloid leukemia (AML), treatment regimens and outcomes may differ between younger and older adults. Although there is no clear dividing line between younger and older adults when dealing with AML, in most studies, \"older adults\" has been defined as over age 55 to 60 years.",
"   </p>",
"   <p>",
"    The initial treatment of younger adults with de novo AML will be reviewed here. The following exceptions, which require modification of standard treatment regimens, are discussed separately:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Treatment of older adults with AML (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/29/29146?source=see_link\">",
"       \"Treatment of acute myeloid leukemia in older adults\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Treatment of therapy-related AML (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/35/39480?source=see_link\">",
"       \"Therapy-related myeloid neoplasms: Acute myeloid leukemia and myelodysplastic syndrome\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Treatment of acute promyelocytic leukemia (FAB M3) (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/11/28858?source=see_link\">",
"       \"Initial treatment of acute promyelocytic leukemia in adults\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?0/12/200?source=see_link\">",
"       \"Clinical manifestations, pathologic features, and diagnosis of acute promyelocytic leukemia in adults\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Treatment of relapsed or resistant AML (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/51/29498?source=see_link\">",
"       \"Treatment of relapsed or refractory acute myeloid leukemia\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Induction therapy aims to reduce the total body leukemia cell population from approximately 10",
"    <sup>",
"     12",
"    </sup>",
"    to below the cytologically detectable level of approximately 10",
"    <sup>",
"     9",
"    </sup>",
"    cells. It is generally assumed, however, that a substantial burden of leukemia cells persists undetected (ie, presence of \"minimal residual disease\"), leading to relapse within a few weeks or months if no further therapy is administered. The role of this postinduction or \"remission consolidation\" therapy is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/50/12073?source=see_link&amp;anchor=H2#H2\">",
"     \"Remission criteria in acute myeloid leukemia and monitoring for residual disease\", section on 'Definition of complete remission (CR)'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/55/17274?source=see_link\">",
"     \"Post-remission therapy for acute myeloid leukemia in younger adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PRETREATMENT EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because of the rigorous nature of the chemotherapy required for the successful treatment of AML, particular attention should be paid in the history and physical examination to the presence of co-morbid conditions in the patient that could complicate overall management [",
"    <a class=\"abstract\" href=\"UTD.htm?29/41/30362/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     History",
"    </span>",
"    &nbsp;&mdash;&nbsp;While all elements of the patient's history are pertinent to the problem at hand, some are particularly relevant to complications that might arise during treatment. These include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A prior history of a hematologic disorder (eg, myelodysplastic syndrome, myeloproliferative disorder, Fanconi anemia, or familial platelet disorder) or a malignancy treated with chemotherapy",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      radiation therapy. Such patients with \"secondary\" or therapy-related AML have a relatively worse prognosis, which is also influenced by a higher incidence of unfavorable cytogenetics. (See",
"      <a class=\"local\" href=\"#H6905621\">",
"       'Therapy-related AML'",
"      </a>",
"      below and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/42/39594?source=see_link&amp;anchor=H13#H13\">",
"       \"Cytogenetics in acute myeloid leukemia\", section on 'Therapy-related myeloid neoplasms (t-MDS/t-AML)'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/55/36730?source=see_link&amp;anchor=H6#H6\">",
"       \"Prognosis of acute myeloid leukemia\", section on 'Antecedent hematologic disorders'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A history of congestive failure or other cardiac disease would mandate careful monitoring of the large amounts of intravenous fluids used during induction remission and may influence the decision to use cardiotoxic drugs (eg, anthracyclines).",
"     </li>",
"     <li>",
"      Prior transfusions or multiple previous pregnancies may presage difficulties with adequate transfusion support or herald the occurrence of transfusion reactions after red cell or platelet administration, due to the presence of alloantibodies to antigens present in normal blood donors but absent in the patient. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/3/37945?source=see_link&amp;anchor=H16695439#H16695439\">",
"       \"Refractoriness to platelet transfusion therapy\", section on 'Etiology'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Careful appraisal for possible drug allergies (eg, penicillin and other antibiotics) is critical, since virtually every patient will require antibiotic therapy.",
"     </li>",
"     <li>",
"      Renal insufficiency, which might affect schedule and dose of therapy with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/53/20314?source=see_link\">",
"       cytarabine",
"      </a>",
"      as well as management of tumor lysis syndrome.",
"     </li>",
"     <li>",
"      Hepatic disease, which might affect schedule and dose of therapy with anthracyclines.",
"     </li>",
"     <li>",
"      A history of prior herpes simplex infections, HIV, or tuberculosis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to a history and physical examination, it is our practice to perform the following pretreatment studies in patients with AML (",
"    <a class=\"graphic graphic_table graphicRef56955 \" href=\"UTD.htm?0/0/3\">",
"     table 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Laboratory studies include a complete blood count with differential, chemistries with liver and renal function and electrolytes, glucose, prothrombin time (PT), activated partial thromboplastin time (aPTT), fibrinogen, lactate dehydrogenase (LDH), calcium, phosphorus, uric acid, albumin and total protein, and serology for herpes simplex virus (HSV), cytomegalovirus (CMV), hepatitis B, hepatitis C, and HIV infection. Elevated serum lysozyme levels may be associated with renal dysfunction, particularly in monocytic leukemias. Human leukocyte antigen (HLA) typing should be performed for patients who are candidates for hematopoietic cell transplantation. HLA A,B typing should be done in all patients to facilitate procurement of compatible platelets in the event of platelet transfusion refractoriness.",
"     </li>",
"     <li>",
"      Unilateral bone marrow aspiration with trephine biopsy is recommended for all patients. This sample should be sent for pathologic review, immunophenotyping, cytochemistry, and metaphase cytogenetics. Mutation analysis for c-KIT, FLT3-ITD, CEBPA, and NPM1 mutations should be performed, if available. Since samples for cytogenetics occasionally fail to produce adequate numbers of metaphase cells, fluorescence in-situ hybridization (FISH) for the more common AML cytogenetic anomalies can be performed, including monosomies or deletions involving chromosomes 5 and 7, trisomy 8, 11q23 rearrangements, inv(16) or t(16;16), and t(8;21). In all instances in which acute promyelocytic leukemia is suspected, FISH for t(15;17) should be obtained. Evaluation of 30 metaphase cells, however, provides more information than FISH analyses at diagnosis. A core needle biopsy is particularly useful if the marrow cannot be aspirated. Bilateral biopsies are generally not required for AML, although they may be informative if bone marrow necrosis is present. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/55/36730?source=see_link&amp;anchor=H9#H9\">",
"       \"Prognosis of acute myeloid leukemia\", section on 'Gene mutations'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Placement of a central venous access catheter with two or three independent ports. Implantable devices (such as Mediports or Infusaposts) should be avoided during induction chemotherapy because of the higher risks of bleeding or infection and associated impediments to rapid removal in event of infection. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?43/32/44553?source=see_link\">",
"       \"Overview of central venous access\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Dental evaluation for possible infection foci [",
"      <a class=\"abstract\" href=\"UTD.htm?29/41/30362/abstract/2\">",
"       2",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A chest x-ray, an electrocardiogram, and a study of cardiac function (eg, ejection fraction measured by echocardiogram or MUGA) should be performed at baseline, especially for patients with a cardiac history, prior anthracycline exposure, or cardiovascular symptoms.",
"     </li>",
"     <li>",
"      Men and women with childbearing potential should receive counseling about the potential effect of treatment on their fertility and options for fertility-preserving measures. Women should have a serum pregnancy test. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/7/38010?source=see_link\">",
"       \"Fertility preservation in patients undergoing gonadotoxic treatment or gonadal resection\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Lymphocytotoxic (anti-HLA) antibody screen for multiparous women and multi-transfused patients.",
"     </li>",
"     <li>",
"      Patients with neurologic signs or symptoms should undergo imaging studies to evaluate for meningeal disease, myeloid sarcoma (chloroma), or central nervous system bleeding. Lumbar puncture is indicated in symptomatic patients to examine the cerebrospinal fluid (CSF) for leukemic involvement. This procedure is not routinely performed in asymptomatic patients because of the risk of bleeding and the theoretical possibility of introducing malignant cells into a sanctuary site. If lumbar puncture is performed, CSF should be sent for both cytology (examination of stained cytospin slides) and flow cytometry. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/0/25607?source=see_link&amp;anchor=H7#H7\">",
"       \"Involvement of the central nervous system with acute myeloid leukemia\", section on 'Evaluation'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The speed with which intensive remission induction chemotherapy should begin varies with the individual patient's condition and treatment options. In general, it is far more important to stabilize a patient's condition and correct or control co-morbidities such as infection, bleeding, hyperuricemia, renal dysfunction, anemia, and thrombocytopenia, than it is to immediately start chemotherapy. The clinical consequences of the speed with which induction chemotherapy is started may be age dependent [",
"    <a class=\"abstract\" href=\"UTD.htm?29/41/30362/abstract/3\">",
"     3",
"    </a>",
"    ]. Oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/16/16648?source=see_link\">",
"     hydroxyurea",
"    </a>",
"    can be used for cytoreduction of an elevated peripheral blast cell count while these problems are addressed. This interval of several days also allows for complete genetic screening where the results will have an impact on the choice of treatment. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/53/14168?source=see_link\">",
"     \"Overview of the complications of acute myeloid leukemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     CHEMOTHERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Combination chemotherapy is the primary treatment modality for patients with AML. Options for induction chemotherapy include standard or high dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/53/20314?source=see_link\">",
"     cytarabine",
"    </a>",
"    in combination with an anthracycline. Most remissions require only a single course. Approximately one-quarter to one-third of patients will require a second induction cycle to obtain a complete remission. A \"double induction\" regimen where induction chemotherapy is quickly repeated for a second cycle is most frequently employed in Europe. The following sections review these different treatment options.",
"   </p>",
"   <p>",
"    For younger adults with newly diagnosed AML, we recommend remission induction treatment with a combination of an anthracycline, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/15/43254?source=see_link\">",
"     daunorubicin",
"    </a>",
"    , for three days and \"standard\" dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/53/20314?source=see_link\">",
"     cytarabine",
"    </a>",
"    for seven days (",
"    <a class=\"graphic graphic_table graphicRef78251 \" href=\"UTD.htm?11/58/12204\">",
"     table 2",
"    </a>",
"    ), rather than an anthracycline plus high dose cytarabine (HDAC). HDAC is associated with increased toxicity and does not appear to improve clinical outcomes when compared with standard dose cytarabine administered in combination with an anthracycline. Treatment-related mortality, the rate of early relapse, and overall survival are not clearly improved. This is described in more detail below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Standard dose cytarabine plus an anthracycline (7+3)",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15233610\">",
"    <span class=\"h3\">",
"     Choice of anthracycline",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most commonly used induction regimens for AML are the so-called \"7+3\" regimens, which combine a seven-day continuous intravenous infusion of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/53/20314?source=see_link\">",
"     cytarabine",
"    </a>",
"    (100 or 200",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    per day) with a short infusion or bolus of an anthracycline given on days one through three. The most commonly used anthracycline in this regimen is",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/15/43254?source=see_link\">",
"     daunorubicin",
"    </a>",
"    , but other anthracyclines (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/43/40630?source=see_link\">",
"     idarubicin",
"    </a>",
"    ) or synthetic anthracycline analogues (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/31/37368?source=see_link\">",
"     mitoxantrone",
"    </a>",
"    ) have been used.",
"   </p>",
"   <p>",
"    Protocols that have substituted other anthracyclines have not improved response rates (",
"    <a class=\"graphic graphic_table graphicRef78251 \" href=\"UTD.htm?11/58/12204\">",
"     table 2",
"    </a>",
"    ). At present, there is no conclusive evidence to recommend one \"7+3\" regimen over another. Depending on dose, schedule, and patient selection criteria, they have similar response rates and share common toxicities, such as severe degrees of myelosuppression with moderate mucositis, and diarrhea [",
"    <a class=\"abstract\" href=\"UTD.htm?29/41/30362/abstract/4-6\">",
"     4-6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The most common remission induction regimen used for patients with AML is standard dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/53/20314?source=see_link\">",
"     cytarabine",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/15/43254?source=see_link\">",
"     daunorubicin",
"    </a>",
"    . Cytarabine plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/43/40630?source=see_link\">",
"     idarubicin",
"    </a>",
"    , a lipophilic analogue of daunorubicin, has shown nearly equivalent complete remission (CR) rates, survival, and cardiotoxicity when compared with cytarabine plus daunorubicin in prospective randomized trials [",
"    <a class=\"abstract\" href=\"UTD.htm?29/41/30362/abstract/7\">",
"     7",
"    </a>",
"    ]. As an example:",
"   </p>",
"   <p>",
"    A randomized trial compared roughly equitoxic doses of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/15/43254?source=see_link\">",
"     daunorubicin",
"    </a>",
"    (50",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    daily for five days) with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/43/40630?source=see_link\">",
"     idarubicin",
"    </a>",
"    (12",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    daily for three days), each administered with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/53/20314?source=see_link\">",
"     cytarabine",
"    </a>",
"    (100",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    by continuous infusion daily for seven days), as induction therapy in 1064 patients with previously untreated AML [",
"    <a class=\"abstract\" href=\"UTD.htm?29/41/30362/abstract/8\">",
"     8",
"    </a>",
"    ]. The two treatments resulted in identical rates of CR (78 percent each), overall survival at five years (48 percent each), and relapse-free survival at five years (41 percent each). When compared with daunorubicin, idarubicin was associated with significantly higher rates of sepsis (9 versus 5 percent), and death within 60 days (5 versus 2 percent).",
"   </p>",
"   <p>",
"    Based upon these observations, we prefer",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/15/43254?source=see_link\">",
"     daunorubicin",
"    </a>",
"    to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/43/40630?source=see_link\">",
"     idarubicin",
"    </a>",
"    when combined induction therapy is given with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/53/20314?source=see_link\">",
"     cytarabine",
"    </a>",
"    . The administration of cytarabine plus daunorubicin is described in more detail in the following section.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15233617\">",
"    <span class=\"h3\">",
"     Dosing of daunorubicin",
"    </span>",
"    &nbsp;&mdash;&nbsp;As described above, we prefer the combination of &ldquo;standard dose&rdquo;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/53/20314?source=see_link\">",
"     cytarabine",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/15/43254?source=see_link\">",
"     daunorubicin",
"    </a>",
"    for remission induction in AML. In this regimen, cytarabine is given by continuous intravenous (IV) infusion for seven days plus daunorubicin by intravenous push or short infusion daily for the first three days. Standard dosing for patients less than 60 years old include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/53/20314?source=see_link\">",
"       Cytarabine",
"      </a>",
"      100",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      for 7 days plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/15/43254?source=see_link\">",
"       daunorubicin",
"      </a>",
"      90",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      for 3 days",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/53/20314?source=see_link\">",
"       Cytarabine",
"      </a>",
"      200",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      for 7 days plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/15/43254?source=see_link\">",
"       daunorubicin",
"      </a>",
"      60",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      for 3 days",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Depending upon age and patient selection, 70 to 80 percent of younger adults achieve a complete remission (CR) with these regimens [",
"    <a class=\"abstract\" href=\"UTD.htm?29/41/30362/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. Most remissions come after a single course. In the past,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/15/43254?source=see_link\">",
"     daunorubicin",
"    </a>",
"    had been commonly employed at a dose of 45",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"     ;",
"    </span>",
"    however, randomized studies suggest that higher doses of daunorubicin, up to 90",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    per day, are more effective and no more toxic than 45",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"     .",
"    </span>",
"    As an example:",
"   </p>",
"   <p>",
"    A phase III trial of 657 adults (age 17 to 60 years) with untreated AML randomly assigned induction therapy with seven days of continuous IV infusion",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/53/20314?source=see_link\">",
"     cytarabine",
"    </a>",
"    (100",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    per day) plus three once-daily doses of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/15/43254?source=see_link\">",
"     daunorubicin",
"    </a>",
"    at either 45 or 90",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?29/41/30362/abstract/9\">",
"     9",
"    </a>",
"    ]. Patients who attained a CR were offered consolidation therapy based upon risk stratification with allogeneic hematopoietic cell transplantation or high-dose cytarabine, with or without",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/3/1078?source=see_link\">",
"     gemtuzumab ozogamicin",
"    </a>",
"    . When compared with patients assigned to the 45",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    daunorubicin dose, patients assigned to the 90",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    dose had the following significant outcomes:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A higher CR rate (71 versus 57 percent)",
"     </li>",
"     <li>",
"      A longer median overall survival (24 versus 16 months)",
"     </li>",
"     <li>",
"      Similar rates of severe (grade",
"      <span class=\"nowrap\">",
"       3/4/5)",
"      </span>",
"      adverse events. Specifically, there were similar rates of cardiac and hematopoietic toxicity between the two groups and the higher dose of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/15/43254?source=see_link\">",
"       daunorubicin",
"      </a>",
"      did not appear to impair the ability to proceed with consolidation therapy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The CR rate for the 45",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    arm in this study was lower than that reported in several other clinical trials using 60",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/15/43254?source=see_link\">",
"     daunorubicin",
"    </a>",
"    in younger adults. A similar randomized trial in older adults performed by another cooperative group also found higher CR rates with 90",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    daunorubicin compared with 45",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    (52 versus 35 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/41/30362/abstract/6\">",
"     6",
"    </a>",
"    ]. A similar randomized trial using",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/53/20314?source=see_link\">",
"     cytarabine",
"    </a>",
"    200",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    in younger adults also reported higher CR rates (83 versus 72 percent) and overall survival at five years (47 versus 35 percent) with 90",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    compared with 45",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?29/41/30362/abstract/10\">",
"     10",
"    </a>",
"    ]. There have been no randomized trials comparing 60",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    with 90",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    of daunorubicin. As such, we consider induction regimens employing either 60",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    or 90",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    of daunorubicin to be appropriate for younger adults with AML.",
"   </p>",
"   <p>",
"    The combination of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/53/20314?source=see_link\">",
"     cytarabine",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/15/43254?source=see_link\">",
"     daunorubicin",
"    </a>",
"    results in severe pancytopenia in all patients and therefore requires transfusion support and antibiotics as needed. The median number of days with an absolute neutrophil count less than 500 and a platelet count less than 50,000 are approximately 16 and 15, respectively. Common non-hematologic side effects seen in the majority of patients include stomatitis (mostly mild), alopecia, nausea and vomiting (25 percent severe), and diarrhea (mostly mild to moderate). Daunorubicin can be associated with an infusion reaction and cardiac arrhythmias; a flu-like syndrome and rash due to cytarabine may be seen during induction. These are discussed in more detail separately. (See",
"    <a class=\"local\" href=\"#H14\">",
"     'Supportive care'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/57/43930?source=see_link&amp;anchor=H42#H42\">",
"     \"Infusion reactions to systemic chemotherapy\", section on 'Anthracyclines and related agents'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/57/43930?source=see_link&amp;anchor=H58#H58\">",
"     \"Infusion reactions to systemic chemotherapy\", section on 'Cytarabine'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5115635\">",
"    <span class=\"h3\">",
"     Adding a third agent",
"    </span>",
"    &nbsp;&mdash;&nbsp;As described above, remission induction treatment commonly consists of the combination of an anthracycline for three days and \"standard\" dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/53/20314?source=see_link\">",
"     cytarabine",
"    </a>",
"    for seven days, the so-called \"7+3\" regimens (",
"    <a class=\"graphic graphic_table graphicRef78251 \" href=\"UTD.htm?11/58/12204\">",
"     table 2",
"    </a>",
"    ). Most studies of adding a third or fourth drug have not improved response rates. Specifically, attempts to improve response with several potentially non-cross-resistant drugs have not been successful (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9545?source=see_link\">",
"     fludarabine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/57/30617?source=see_link\">",
"     etoposide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/2/32807?source=see_link\">",
"     topotecan",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/54/35685?source=see_link\">",
"     thioguanine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/31/37368?source=see_link\">",
"     mitoxantrone",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/41/30362/abstract/11-20\">",
"     11-20",
"    </a>",
"    ]. Ongoing trials continue to investigate a potential benefit from the addition of other agents (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/22/19815?source=see_link\">",
"     cladribine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/3/1078?source=see_link\">",
"     gemtuzumab ozogamicin",
"    </a>",
"    , FLT3 inhibitors). Studies of a third agent in older adults with AML are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/29/29146?source=see_link&amp;anchor=H732965#H732965\">",
"     \"Treatment of acute myeloid leukemia in older adults\", section on 'Gemtuzumab ozogamicin (GO)'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As an example, provisional data suggest a benefit from the addition of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/22/19815?source=see_link\">",
"     cladribine",
"    </a>",
"    to standard induction therapy. Two randomized studies from the Polish Adult Leukemia Group suggest that the addition of cladribine results in higher rates of complete remission and improved survival [",
"    <a class=\"abstract\" href=\"UTD.htm?29/41/30362/abstract/21,22\">",
"     21,22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the larger of these trials, 652 younger adults (&lt;60 years) with previously untreated AML were randomly assigned to receive induction therapy with one of three regimens [",
"    <a class=\"abstract\" href=\"UTD.htm?29/41/30362/abstract/21\">",
"     21",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      DA &mdash;",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/15/43254?source=see_link\">",
"       Daunorubicin",
"      </a>",
"      60",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      once daily on days 1 through 3 plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/53/20314?source=see_link\">",
"       cytarabine",
"      </a>",
"      200",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      as a continuous infusion on days 1 though 7",
"     </li>",
"     <li>",
"      DAC &mdash; DA plus intravenous",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/22/19815?source=see_link\">",
"       cladribine",
"      </a>",
"      5",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      administered on days 1 through 5",
"     </li>",
"     <li>",
"      DAF &mdash; DA plus intravenous",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9545?source=see_link\">",
"       fludarabine",
"      </a>",
"      25",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      on days 1 through 5",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients who attained a complete remission (CR) went on to consolidation therapy with chemotherapy or hematopoietic cell transplantation, depending upon the cytogenetic risk and availability of a donor. Toxicities were similar to those seen in other studies of &ldquo;7+3&rdquo; regimens and similar among the three treatment arms. CR was attained in 56, 68, and 59 percent of patients assigned to DA, DAC, and DAF, respectively. Corresponding rates of overall survival at three years were 33, 45, and 35 percent.",
"   </p>",
"   <p>",
"    These results suggest that the addition of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/22/19815?source=see_link\">",
"     cladribine",
"    </a>",
"    improves survival in patients receiving induction with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/15/43254?source=see_link\">",
"     daunorubicin",
"    </a>",
"    60",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/53/20314?source=see_link\">",
"     cytarabine",
"    </a>",
"    200",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"     .",
"    </span>",
"    It is not known how this compares with daunorubicin 90",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    plus cytarabine 100",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    or whether cladribine would improve outcomes with this regimen. We await further independent confirmation of a benefit prior to the standard incorporation of this agent into induction therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     High dose cytarabine",
"    </span>",
"    &nbsp;&mdash;&nbsp;High dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/53/20314?source=see_link\">",
"     cytarabine",
"    </a>",
"    (HDAC) refers to cytarabine doses of 5 to 36",
"    <span class=\"nowrap\">",
"     grams/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    administered in one of multiple published doses and schedules, most commonly 1000 to 3000",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    intravenously over one to three hours every 12 hours for 8 to 12 doses. This compares to standard dose cytarabine, which refers to a cytarabine dose of 100 to 200",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    per day given as a seven-day continuous infusion. Prospective randomized cooperative group trials have evaluated the use of HDAC in combination with an anthracycline for induction therapy in newly diagnosed AML (",
"    <a class=\"graphic graphic_table graphicRef78251 \" href=\"UTD.htm?11/58/12204\">",
"     table 2",
"    </a>",
"    ). HDAC is associated with increased toxicity and does not appear to improve clinical outcomes when compared with standard dose cytarabine administered in combination with an anthracycline [",
"    <a class=\"abstract\" href=\"UTD.htm?29/41/30362/abstract/23-26\">",
"     23-26",
"    </a>",
"    ]. In a subset analysis of one large phase III trial, patients &lt;45 years showed a survival advantage for HDAC over conventional cytarabine when both were combined with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/15/43254?source=see_link\">",
"     daunorubicin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?29/41/30362/abstract/27\">",
"     27",
"    </a>",
"    ]. Until further validated, we do",
"    <strong>",
"     not",
"    </strong>",
"    use HDAC routinely for remission induction; however, HDAC alone could be considered in patients who are not candidates for anthracyclines during induction. (See",
"    <a class=\"local\" href=\"#H6905368\">",
"     'Patients with cardiac disease'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The following trial illustrates the similar response rates and increased toxicity seen when HDAC is used in this setting:",
"   </p>",
"   <p>",
"    In a trial of double induction chemotherapy, 860 younger adults (&le;60 years) with AML were randomly assigned to treatment with intermediate-doses of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/53/20314?source=see_link\">",
"     cytarabine",
"    </a>",
"    (200",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    for cycle 1 and 1000",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    twice daily for cycle 2) or HDAC (1000",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    twice daily for cycle 1 and 2000",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    twice daily for cycle 2) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/41/30362/abstract/28\">",
"     28",
"    </a>",
"    ]. For each group,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/43/40630?source=see_link\">",
"     idarubicin",
"    </a>",
"    was administered with cycle 1 and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/5/37973?source=see_link\">",
"     amsacrine",
"    </a>",
"    was administered with cycle 2. Patients who achieved a complete remission (CR) were treated with non-cytarabine containing consolidation therapy. When compared with intermediate-dose cytarabine, HDAC resulted in:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Similar rates of CR (82 versus 80 percent), CR after cycle 1 (66 versus 60 percent), and 30-day mortality (10 percent each).",
"     </li>",
"     <li>",
"      Similar rates of event-free survival (35 versus 34 percent) and overall survival (42 versus 40 percent) at five years.",
"     </li>",
"     <li>",
"      Higher rates of severe (grade",
"      <span class=\"nowrap\">",
"       3/4)",
"      </span>",
"      toxicity after cycle 1 (61 versus 51 percent) and of delayed neutrophil and platelet recovery in cycle 2. This excess toxicity was notable for skin reactions, gastrointestinal toxicity, and ocular toxicity.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For younger adults with newly diagnosed AML, we recommend remission induction treatment with a combination of an anthracycline plus \"standard\" dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/53/20314?source=see_link\">",
"     cytarabine",
"    </a>",
"    (",
"    <a class=\"graphic graphic_table graphicRef78251 \" href=\"UTD.htm?11/58/12204\">",
"     table 2",
"    </a>",
"    ) rather than an anthracycline plus HDAC. HDAC is associated with increased toxicity and does not appear to improve clinical outcomes when compared with standard dose cytarabine administered in combination with an anthracycline. Treatment-related mortality, the rate of early relapse, and overall survival are not clearly improved.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Double induction chemotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Double induction chemotherapy refers to the readministration of induction chemotherapy at a set interval after the first cycle of induction chemotherapy regardless of the initial response to treatment. This approach has been used by some centers in Europe. The relative benefits provided from double induction chemotherapy compared with a single course of intensive post-remission chemotherapy or prolonged maintenance therapy are not clear [",
"    <a class=\"abstract\" href=\"UTD.htm?29/41/30362/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We do not administer double induction chemotherapy but routinely apply a second cycle of induction chemotherapy, if needed. We evaluate response to the initial induction treatment with a bone marrow aspiration and biopsy seven days after completion of the first cycle of induction chemotherapy. The second course of induction is started with no further delay if cytologically evident persisting disease (greater than 5 to 10 percent of the marrow volume) is found. (See",
"    <a class=\"local\" href=\"#H25\">",
"     'Evaluation of response'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     MONITORING DURING TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chemotherapy for AML is highly toxic, primarily to the hematopoietic system and most patients will have a prolonged hospital stay and will require blood product support. The following are offered as guidelines for monitoring during induction chemotherapy:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Daily laboratory testing should be performed and generally includes a complete blood count and chemistries with renal function, glucose, and electrolytes. Calcium, phosphorus, and uric acid levels should be monitored until normal. Liver function tests should be assessed at least weekly. PT, PTT, and fibrinogen should be measured in patients with abnormal bleeding; PT should be assessed weekly.",
"     </li>",
"     <li>",
"      Patients receiving high dose",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/53/20314?source=see_link\">",
"       cytarabine",
"      </a>",
"      need a daily neurologic examination during and for several days after administration to evaluate cerebellar function. Commonly used tests include finger-to-nose testing and monitoring of the patient's signature, speech, and gait over time.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     SUPPORTIVE CARE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Improvements in supportive care, especially the use of anti-emetics, transfusions and antibiotics, have enhanced the outlook for both young and older patients with leukemia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12878257\">",
"    <span class=\"h2\">",
"     Anti-emetic prophylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ability of patients to tolerate chemotherapy has improved considerably as the result of highly effective anti-emetic medications. Even beyond improving patient comfort, anti-emetic therapy enables patients to maintain their oral hydration and nutritional status and avoid the risks of gastrointestinal bleeding or even a Mallory-Weiss tear from forceful vomiting. For young adults receiving",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/53/20314?source=see_link\">",
"     cytarabine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/15/43254?source=see_link\">",
"     daunorubicin",
"    </a>",
"    or high-dose cytarabine for AML, we prefer to premedicate with 16 mg of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/2/21544?source=see_link\">",
"     ondansetron",
"    </a>",
"    as monotherapy administered without steroids [",
"    <a class=\"abstract\" href=\"UTD.htm?29/41/30362/abstract/30,31\">",
"     30,31",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/18/39210?source=see_link&amp;anchor=H1044202#H1044202\">",
"     \"Prevention and treatment of chemotherapy-induced nausea and vomiting\", section on 'Induction therapy for acute leukemia'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Cytopenias",
"    </span>",
"    &nbsp;&mdash;&nbsp;All patients treated with traditional induction chemotherapy will develop anemia and thrombocytopenia requiring intervention. Red cells and platelets should be replaced as necessary. Myeloid growth factors (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/13/23767?source=see_link\">",
"     filgrastim",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/13/23767?source=see_link\">",
"     granulocyte colony-stimulating factor",
"    </a>",
"    ) are not routinely used during remission induction chemotherapy for AML [",
"    <a class=\"abstract\" href=\"UTD.htm?29/41/30362/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Transfusions",
"    </span>",
"    &nbsp;&mdash;&nbsp;In general, we transfuse packed red blood cells to all symptomatic patients with anemia or any asymptomatic patient with a hemoglobin &le;7 to 8",
"    <span class=\"nowrap\">",
"     g/dL.",
"    </span>",
"    We aim to maintain the hemoglobin between 8 and 10",
"    <span class=\"nowrap\">",
"     g/dL,",
"    </span>",
"    depending on the patient&rsquo;s age, symptoms, and comorbid conditions. We transfuse platelets prophylactically for patients with platelet counts",
"    <span class=\"nowrap\">",
"     &lt;10,000/microL",
"    </span>",
"    or to any patient with signs of overt bleeding, such as oral purpura. Transfusion of multiple platelet units beyond a single plateletpheresis unit is not beneficial for non-bleeding patients [",
"    <a class=\"abstract\" href=\"UTD.htm?29/41/30362/abstract/33\">",
"     33",
"    </a>",
"    ]. Blood products should be leukocyte depleted and irradiated to minimize the risk of immunologic mediated events. Cytomegalovirus (CMV) negative patients who are candidates for hematopoietic cell transplantation should receive CMV negative blood products. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/52/5961?source=see_link\">",
"     \"Indications for red cell transfusion in the adult\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/5/24665?source=see_link\">",
"     \"Leukoreduction to prevent complications of blood transfusion\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/6/20586?source=see_link&amp;anchor=H558395349#H558395349\">",
"     \"Clinical and laboratory aspects of platelet transfusion therapy\", section on 'Leukemia and chemotherapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Growth factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Growth factors such as granulocyte-macrophage colony-stimulating factor (GM-CSF) or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/13/23767?source=see_link\">",
"     granulocyte colony-stimulating factor",
"    </a>",
"    (G-CSF) are not used routinely in patients undergoing induction chemotherapy for AML and the long-term safety of these agents in leukemia patients remains to be determined. Malignant myeloblasts do express receptors for these growth factors. Their use in this setting has been studied both in an attempt to decrease the duration of neutropenia and to potentially sensitize or \"prime\" leukemia cells for chemotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?29/41/30362/abstract/32,34\">",
"     32,34",
"    </a>",
"    ]. An alternative hypothesis is that growth factors may disrupt the adhesion of leukemia blasts to the bone marrow niche thereby making them more susceptible to chemotherapy circulating in the blood.",
"   </p>",
"   <p>",
"    Virtually all trials showed a modest reduction in the duration of severe neutropenia following the use of these growth factors, but there has been no effect on the nadir, and the impact on the incidence of severe infection, antibiotic usage, and the duration of hospitalization has been variable [",
"    <a class=\"abstract\" href=\"UTD.htm?29/41/30362/abstract/32,35\">",
"     32,35",
"    </a>",
"    ]. There were no other significant effects on treatment outcome. Differences in dose and schedule, specific growth factor and chemotherapy agents used, and the particular disease (ie, AML or ALL) and age group studied prevent firm conclusions.",
"   </p>",
"   <p>",
"    A prospective, multicenter trial evaluated the use of G-CSF, given immediately before and during chemotherapy but not after chemotherapy, in 640 patients &le;60 years of age with newly-diagnosed AML [",
"    <a class=\"abstract\" href=\"UTD.htm?29/41/30362/abstract/36\">",
"     36",
"    </a>",
"    ]. Patients underwent double induction therapy with a combination of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/53/20314?source=see_link\">",
"     cytarabine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/43/40630?source=see_link\">",
"     idarubicin",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/5/37973?source=see_link\">",
"     amsacrine",
"    </a>",
"    . They were randomly assigned to receive or not receive G-CSF during induction. Patients assigned to receive G-CSF had the following outcomes when compared with those not assigned to G-CSF:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Similar rates of complete remission (79 and 83 percent, respectively) and four-year overall survival (40 versus 35 percent, respectively).",
"     </li>",
"     <li>",
"      Significantly higher rates of four-year disease-free survival after the first CR (42 versus 33 percent) with a decreased rate of relapse.",
"     </li>",
"     <li>",
"      In a subgroup analysis, G-CSF priming did not improve outcome in those with an unfavorable karyotype. However, among patients with standard-risk AML there was improved overall survival and disease-free survival.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Subsequent multicenter randomized trials of G-CSF priming have had mixed results. As an example, a multicenter randomized trial of 259 patients with newly diagnosed AML also demonstrated a decreased relapse rate among patients with standard risk disease treated with the growth factor GM-CSF [",
"    <a class=\"abstract\" href=\"UTD.htm?29/41/30362/abstract/34,37\">",
"     34,37",
"    </a>",
"    ]. In contrast, a larger randomized trial of 917 adults with newly diagnosed AML failed to confirm a benefit from G-CSF priming in patients who received standard dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/53/20314?source=see_link\">",
"     cytarabine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?29/41/30362/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For the time being, the use of myeloid growth factors during remission induction chemotherapy for AML is not routinely recommended [",
"    <a class=\"abstract\" href=\"UTD.htm?29/41/30362/abstract/32\">",
"     32",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/9/33945?source=see_link&amp;anchor=H523774212#H523774212\">",
"     \"Use of granulocyte colony stimulating factors in patients with chemotherapy-induced neutropenia\", section on 'Primary prophylaxis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Infections",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prolonged period of neutropenia associated with chemotherapy in patients with AML is frequently associated with neutropenic fevers and a high risk of infection with bacteria or fungi and viral reactivation. In order to minimize the risk of infection, patients are typically placed on \"neutropenic precautions\" with or without the addition of prophylactic antibiotics, antifungals, or antivirals. In addition, patients should be screened for possible infectious foci (eg, dental status).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Precautions",
"    </span>",
"    &nbsp;&mdash;&nbsp;The majority of infections acquired during induction therapy are due to endogenous flora. Even so, precautions are taken to limit exposure to exogenous pathogens. As such, patients are routinely placed on \"neutropenic precautions,\" the components of which vary by institution. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/59/3001?source=see_link&amp;anchor=H875811313#H875811313\">",
"     \"Prophylaxis of infection during chemotherapy-induced neutropenia in high-risk adults\", section on 'Infection control precautions'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Most commonly, these precautions include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      A high-efficiency particulate air (HEPA)-filtered room",
"     </li>",
"     <li>",
"      Diet free of raw berries or vegetables grown in dirt",
"     </li>",
"     <li>",
"      No sick visitors",
"     </li>",
"     <li>",
"      No smoking",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    While routinely part of \"standard precautions,\" hand washing by all visitors and caregivers cannot be over-emphasized and should be strictly enforced. Most of the other precautions have not been tested in prospective, randomized trials but have been used because they are relatively simple to institute and are logical ways to limit exposure to potential pathogens.",
"   </p>",
"   <p>",
"    The benefit of a neutropenic diet was examined in a prospective, randomized trial of 153 patients with newly diagnosed AML undergoing induction therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?29/41/30362/abstract/39\">",
"     39",
"    </a>",
"    ]. Patients were randomly assigned to diets either containing raw fruits or vegetables (raw diet) or not (cooked diet). Patients randomly assigned to the cooked diet had similar rates of major infection when compared with those who received the raw diet (35 versus 29 percent, respectively). There was no difference in overall survival. We advise our patients to limit their intake of raw fruits and vegetables to those that can be easily peeled (eg, bananas, oranges).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Prophylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Infectious Disease Society of America (IDSA) recommends that herpes simplex virus (HSV)-seropositive patients with leukemia receive",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/7/31856?source=see_link\">",
"     acyclovir",
"    </a>",
"    antiviral prophylaxis [",
"    <a class=\"abstract\" href=\"UTD.htm?29/41/30362/abstract/40\">",
"     40",
"    </a>",
"    ]. The use of prophylactic antibiotics and antifungals varies by institution. Some institutions administer prophylaxis with fluoroquinolones",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    antifungals (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"     fluconazole",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/15/20730?source=see_link\">",
"     itraconazole",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/60/33737?source=see_link\">",
"     posaconazole",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"     voriconazole",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    ) during the period of neutropenia [",
"    <a class=\"abstract\" href=\"UTD.htm?29/41/30362/abstract/41\">",
"     41",
"    </a>",
"    ]. The effectiveness of these interventions varies among institutions depending upon the local flora and results of surveillance cultures. The possibility of benefit is balanced by the concern for selecting for drug-resistant organisms. Pneumocystis pneumonia and CMV infections, which commonly require prophylaxis in patients with ALL or following hematopoietic cell transplantation, are rarely observed in AML patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/59/3001?source=see_link\">",
"     \"Prophylaxis of infection during chemotherapy-induced neutropenia in high-risk adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who develop neutropenic fever require prompt evaluation and immediate administration of parenteral antibiotics tailored to the prominent organisms and resistance patterns of the institution. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/52/40778?source=see_link\">",
"     \"Treatment of neutropenic fever syndromes in adults with hematologic malignancies and hematopoietic cell transplant recipients (high-risk patients)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Tumor lysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is a risk of tumor lysis syndrome in patients treated for AML. The risk is highest among patients with hyperleukocytosis and marked elevations in the serum lactate dehydrogenase but can be observed in any subtype. This syndrome is best prevented via appropriate treatment with intravenous hydration to ensure adequate urine flow (&gt;100",
"    <span class=\"nowrap\">",
"     mL/hour),",
"    </span>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/54/34661?source=see_link\">",
"     rasburicase",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/40/25223?source=see_link\">",
"     allopurinol",
"    </a>",
"    , and correction of any electrolyte disturbances and elements of reversible renal failure (",
"    <a class=\"graphic graphic_table graphicRef57607 \" href=\"UTD.htm?22/10/22701\">",
"     table 3",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/20/3402?source=see_link&amp;anchor=H21712037#H21712037\">",
"     \"Tumor lysis syndrome: Prevention and treatment\", section on 'Clinical impact of TLS'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Menorrhagia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Premenopausal women are at risk for severe and prolonged menorrhagia during induction therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/26/37285?source=see_link\">",
"     \"Heavy or irregular uterine bleeding during chemotherapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Other complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other complications that may develop during AML treatment, such as electrolyte abnormalities, hyperleukocytosis, disseminated intravascular coagulation, necrotizing enterocolitis, and involvement of the eyes, joints, and central nervous system, are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/53/14168?source=see_link\">",
"     \"Overview of the complications of acute myeloid leukemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     EVALUATION OF RESPONSE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The initial response to treatment is typically evaluated seven days after the final doses of induction chemotherapy with a unilateral bone marrow aspirate and biopsy as this generally corresponds with the maximum chemotherapy effect. A core biopsy is required to assess marrow cellularity:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      If hypoplasia with a cellularity less than 5 percent is documented, most patients will recover two to three weeks later with normal hematopoiesis. A repeat aspiration and biopsy is performed once adequate values for absolute neutrophil count",
"      <span class=\"nowrap\">",
"       (&gt;1000/microL)",
"      </span>",
"      and platelet count",
"      <span class=\"nowrap\">",
"       (&gt;100,000/microL)",
"      </span>",
"      are obtained and the patient is independent from red cell transfusions. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/50/12073?source=see_link\">",
"       \"Remission criteria in acute myeloid leukemia and monitoring for residual disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      If the bone marrow cellularity is above 5 percent at this time and indeterminate for residual AML, a repeat bone marrow is recommended in 7 to 14 days.",
"     </li>",
"     <li>",
"      If residual leukemic blasts (greater than 5 to 10 percent of the marrow volume) are found on the bone marrow aspirate or biopsy, a second cycle of induction is recommended if the patient can tolerate immediate retreatment. If the initial induction therapy had been",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/53/20314?source=see_link\">",
"       cytarabine",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/15/43254?source=see_link\">",
"       daunorubicin",
"      </a>",
"      , these same drugs are usually employed for five and two or three days, respectively. One meta-analysis of sequential cooperative group protocols conducted between 1983 and 1993 suggested that patients who attain a complete remission (CR) after this second cycle of induction have a similar prognosis to those who attain a CR with initial induction [",
"      <a class=\"abstract\" href=\"UTD.htm?29/41/30362/abstract/42\">",
"       42",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The central nervous system (CNS) can be a sanctuary site for occult disease. Once a complete remission is documented by bone marrow aspiration and biopsy, a lumbar puncture to evaluate for CNS involvement is recommended particularly for patients with a high white blood cell count",
"    <span class=\"nowrap\">",
"     (&gt;100,000/microL)",
"    </span>",
"    at the time of diagnosis. This should also be considered for patients with a monoblastic phenotype, inv(16), or CD56 positivity. A review of the treatment of this complication can be found elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/0/25607?source=see_link\">",
"     \"Involvement of the central nervous system with acute myeloid leukemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     POST-REMISSION TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Attainment of a complete remission is the first step in the treatment of AML. However, relapse can be expected in the following weeks to months if no further therapy is given. Post-induction or \"remission consolidation\" therapy is an essential component of the treatment of AML. This is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/55/17274?source=see_link\">",
"     \"Post-remission therapy for acute myeloid leukemia in younger adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     SPECIAL SCENARIOS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;AML is occasionally diagnosed during pregnancy. If detected during the first trimester, immediate termination of pregnancy followed by treatment of the leukemia is advisable, as combination chemotherapy given during this time is associated with an unacceptably high incidence of fetal abnormalities",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    fetal loss [",
"    <a class=\"abstract\" href=\"UTD.htm?29/41/30362/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The management of patients diagnosed later in pregnancy, such as late in the second trimester or during the third trimester, poses a difficult therapeutic dilemma. In the latter group of patients, if the leukemia is relatively indolent, it is sometimes possible to manage patients conservatively with leukapheresis",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    transfusion, with induction of labor and delivery of a viable fetus as soon as possible. However, it is often difficult, if not impossible, to predict whether the AML will take an indolent course for some weeks. The hazard of a delay of adequate AML treatment until delivery should be carefully considered as it may imply a significant risk to the mother.",
"   </p>",
"   <p>",
"    There have been many reports of patients treated with chemotherapy later in their pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?29/41/30362/abstract/43-47\">",
"     43-47",
"    </a>",
"    ]. The majority of these women have not aborted. There have been no reports of leukemia occurring in the children, nor an increased incidence of fetal abnormalities in infants who have been exposed to full-dose antileukemia chemotherapy during the later stages of gestation. A literature review of 160 pregnant patients treated with anthracyclines for a variety of malignancies, reported the delivery of normal infants in 73 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?29/41/30362/abstract/43\">",
"     43",
"    </a>",
"    ]. Common unfavorable fetal outcomes included fetal death (9 percent), prematurity (6 percent), and malformations (3 percent).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6905368\">",
"    <span class=\"h2\">",
"     Patients with cardiac disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with a history of congestive failure or other cardiac disease mandate careful monitoring of the large amounts of intravenous fluids used during induction remission and may influence the decision to use cardiotoxic drugs (eg, anthracyclines). A study of cardiac function (eg, ejection fraction measured by echocardiogram or MUGA) should be performed at baseline, especially for patients with a cardiac history, prior anthracycline exposure, or cardiovascular symptoms.",
"   </p>",
"   <p>",
"    Although anthracycline-based therapy is recommended for remission induction in patients with AML, patients with underlying cardiac disease may not be able to tolerate the use of an anthracycline since this agent is toxic to cardiac cells.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"     Doxorubicin",
"    </a>",
"    or other anthracyclines should not be routinely administered to patients with a baseline ejection fraction below 40 percent. Patients with an ejection fraction greater than 40 percent may require monitoring, and guidelines for this are available. Contrary to common belief,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/31/37368?source=see_link\">",
"     mitoxantrone",
"    </a>",
"    is not a safe alternative in patients with cardiac disease. The use of anthracyclines in patients with cardiac disease is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/46/41706?source=see_link&amp;anchor=H15#H15\">",
"     \"Cardiotoxicity of anthracycline-like chemotherapy agents\", section on 'Approaches for reducing the risk'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/46/41706?source=see_link&amp;anchor=H25#H25\">",
"     \"Cardiotoxicity of anthracycline-like chemotherapy agents\", section on 'Pretreatment assessment and subsequent monitoring'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    When an anthracycline is not an option, single agent high dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/53/20314?source=see_link\">",
"     cytarabine",
"    </a>",
"    (HiDAC) may be administered for induction therapy. Alternatives include cytarabine by continuous infusion together with oral 6-",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/54/35685?source=see_link\">",
"     thioguanine",
"    </a>",
"    at 100",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day",
"    </span>",
"    for seven days; HiDAC plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/57/30617?source=see_link\">",
"     etoposide",
"    </a>",
"    ; or the combination of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9545?source=see_link\">",
"     fludarabine",
"    </a>",
"    , cytarabine, plus G-CSF (FLAG).",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/3/1078?source=see_link\">",
"     Gemtuzumab ozogamicin",
"    </a>",
"    was useful in this situation but this agent is no longer commercially available. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'High dose cytarabine'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/51/29498?source=see_link&amp;anchor=H8#H8\">",
"     \"Treatment of relapsed or refractory acute myeloid leukemia\", section on 'Chemotherapy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/29/29146?source=see_link&amp;anchor=H732965#H732965\">",
"     \"Treatment of acute myeloid leukemia in older adults\", section on 'Gemtuzumab ozogamicin (GO)'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6905614\">",
"    <span class=\"h2\">",
"     Extramedullary disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Up to 10 percent of patients with AML will have extramedullary (eg, leukemia cutis, myeloid sarcoma) involvement at some point during the disease course. The approach to the evaluation and treatment of patients with extramedullary AML with or without evidence of AML on bone marrow biopsy is similar to that for patients with overt AML [",
"    <a class=\"abstract\" href=\"UTD.htm?29/41/30362/abstract/48\">",
"     48",
"    </a>",
"    ]. However, the following modifications may be indicated:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Imaging can determine the extent of extramedullary involvement, aid in radiation treatment planning, and assess treatment response. Computed tomography (CT) can determine the extent of disease outside of the central nervous system (CNS) [",
"      <a class=\"abstract\" href=\"UTD.htm?29/41/30362/abstract/49-51\">",
"       49-51",
"      </a>",
"      ]. Combined positron emission tomography",
"      <span class=\"nowrap\">",
"       (PET)/CT",
"      </span>",
"      may be preferred over CT for radiation therapy planning. Magnetic resonance imaging (MRI) with gadolinium can assess CNS involvement. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/0/25607?source=see_link&amp;anchor=H12#H12\">",
"       \"Involvement of the central nervous system with acute myeloid leukemia\", section on 'Imaging'",
"      </a>",
"      .) &nbsp;",
"     </li>",
"     <li>",
"      Patients with suspected extramedullary involvement in a location amenable to biopsy should undergo a biopsy of the involved tissue. Tissue should be examined with cytology, immunohistochemistry, flow cytometry, cytogenetics, and genetic testing, when possible. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/58/20393?source=see_link&amp;anchor=H12#H12\">",
"       \"Clinical manifestations, pathologic features, and diagnosis of acute myeloid leukemia\", section on 'Pathologic features'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Treatment of central nervous system involvement consists of the administration of intrathecal chemotherapy, with the addition of cranial radiation in patients who do not respond fully to chemotherapy, or in whom cranial nerve involvement is present. This is discussed in more detail separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/0/25607?source=see_link&amp;anchor=H14#H14\">",
"       \"Involvement of the central nervous system with acute myeloid leukemia\", section on 'Treatment'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Radiation therapy may be incorporated into the treatment approach, either before induction chemotherapy for patients with compression of vital structures or as consolidation after induction chemotherapy for patients with persistent extramedullary involvement after chemotherapy. Myeloblasts are very radiation sensitive, and doses greater than 2000 to 3000 cGy are rarely needed. There are limited data regarding the use of radiation therapy for consolidation in patients with extramedullary disease in the absence of bone marrow involvement.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Without systemic remission induction chemotherapy, patients presenting with extramedullary AML will almost always progress to systemic disease, usually within three to six months [",
"    <a class=\"abstract\" href=\"UTD.htm?29/41/30362/abstract/52\">",
"     52",
"    </a>",
"    ]. In comparison, treatment with AML-type induction chemotherapy with or without radiation therapy results in survival rates that are similar to those seen in patients with AML without extramedullary disease [",
"    <a class=\"abstract\" href=\"UTD.htm?29/41/30362/abstract/53,54\">",
"     53,54",
"    </a>",
"    ]. Given the rarity of this condition, there is a paucity of data regarding the role of radiation therapy in this setting.",
"   </p>",
"   <p>",
"    Radiation therapy can result in local control in the vast majority of patients with extramedullary involvement. A retrospective single institution case series of 38 patients with extramedullary AML presented data on the 22 patients who received radiation therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?29/41/30362/abstract/49\">",
"     49",
"    </a>",
"    ]. Radiation therapy was administered for disease that persisted after induction chemotherapy or for extramedullary involvement at the time of relapse. The median dose was 20 Gy but ranged from 6 Gy to 36 Gy. At a median follow-up of 11 months from completion of radiation, local progression was seen in only one patient (who had received 6 Gy of radiation therapy for gingival swelling). Long term toxicity included clinically significant hearing loss and neurocognitive dysfunction, occurring in one patient each after whole brain radiation therapy.",
"   </p>",
"   <p>",
"    We administer local radiation to the entire cranium and cervical cord for patients with cranial neuropathy due to meningeal involvement along the base of the brain. A radiation dose of 24 Gy administered in 12 fractions appears to provide good local control with acceptable toxicity while still allowing for the later use of radiation as part of a conditioning regimen for hematopoietic cell transplantation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6905621\">",
"    <span class=\"h2\">",
"     Therapy-related AML",
"    </span>",
"    &nbsp;&mdash;&nbsp;Therapy-related myeloid neoplasms now account for approximately 10 to 20 percent of all cases of AML. This is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/35/39480?source=see_link\">",
"     \"Therapy-related myeloid neoplasms: Acute myeloid leukemia and myelodysplastic syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15233308\">",
"    <span class=\"h2\">",
"     Philadelphia chromosome positive AML",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Philadelphia chromosome, t(9;22)(q34;q11.2), or its gene product, BCR-ABL1, is found in a small percentage of patients with AML (2 percent) and a higher percentage of patients with mixed-phenotype acute leukemia (38 percent) and has been associated with a worse clinical outcome [",
"    <a class=\"abstract\" href=\"UTD.htm?29/41/30362/abstract/55\">",
"     55",
"    </a>",
"    ]. Many of these patients have features suggesting chronic myeloid leukemia presenting in myeloid blast crisis after a short preclinical phase. While tyrosine kinase inhibitors (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/39/22136?source=see_link\">",
"     dasatinib",
"    </a>",
"    ) have been widely studied in the treatment of Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL), there is a paucity of data regarding the use of these agents in Philadelphia chromosome positive AML (Ph+ AML). Case reports have had mixed results reporting some patients with responses to TKIs and others without [",
"    <a class=\"abstract\" href=\"UTD.htm?29/41/30362/abstract/56-62\">",
"     56-62",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The addition of a TKI to standard induction therapy has improved survival rates among patients with Ph+ ALL. This indirect evidence suggests that a TKI would be of benefit to patients with Ph+ mixed-phenotype acute leukemia. When the Philadelphia chromosome is present in a patient with mixed-phenotype acute leukemia, we suggest the use of induction therapy that contains a TKI, such as that used for patients with Ph+ ALL. These patients are candidates for early allogeneic stem cell transplantation as soon as their leukemia enters remission. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/28/44489?source=see_link&amp;anchor=H58829265#H58829265\">",
"     \"Induction therapy for Philadelphia chromosome positive acute lymphoblastic leukemia in adults\", section on 'TKI plus chemotherapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9675567\">",
"    <span class=\"h2\">",
"     Mixed-phenotype acute leukemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mixed-phenotype acute leukemia is a rare entity accounting for less than 5 percent of acute leukemias [",
"    <a class=\"abstract\" href=\"UTD.htm?29/41/30362/abstract/63\">",
"     63",
"    </a>",
"    ]. There is no standard therapy for patients with this condition and practice varies widely. Some patients are treated with AML-type induction therapy, some with ALL-type induction therapy, and some with hybrid treatment regimens [",
"    <a class=\"abstract\" href=\"UTD.htm?29/41/30362/abstract/64\">",
"     64",
"    </a>",
"    ]. These leukemias may derive from a primitive hematopoietic stem cell with variable degrees of lineage differentiation. An early allogeneic hematopoietic cell transplant should be considered for these patients.",
"   </p>",
"   <p>",
"    Data regarding the use of these regimens in this setting come from retrospective analyses of children and adults with mixed-phenotype acute leukemia. As an example, a retrospective analysis of 32 children with mixed-phenotype acute leukemia reported higher complete remission (CR) rates after ALL-type induction than after AML-type induction (83 versus 52 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/41/30362/abstract/65\">",
"     65",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Another international retrospective analysis of 100 children and adults with mixed-phenotype acute leukemia as defined by the 2008 WHO classification reported a median survival of 18 months and a five-year survival rate of 37 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?29/41/30362/abstract/66\">",
"     66",
"    </a>",
"    ]. Treatment was selected by the managing physician and information regarding the treatment choice by age group was not presented. The following characteristics were associated with a significantly shorter median survival:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Age &gt;15 years (11 versus 139 months)",
"     </li>",
"     <li>",
"      Philadelphia chromosome (Ph) positive leukemias (8 versus 139 months for Ph negative disease), but few of these patients received tyrosine kinase inhibitor therapy for",
"      <span class=\"nowrap\">",
"       BCR/ABL.",
"      </span>",
"     </li>",
"     <li>",
"      AML-type induction (11 versus 139 months for ALL-type induction):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      With ALL-type induction, 23 of 27 patients (85 percent) attained a CR; three developed early relapse. The median survival was 139 months.",
"     </li>",
"     <li>",
"      With AML-type induction, 14 or 34 patients (41 percent) attained a CR; 15 did not respond; there were three treatment-related deaths. The median survival was 11 months.",
"     </li>",
"     <li>",
"      With",
"      <span class=\"nowrap\">",
"       AML/ALL",
"      </span>",
"      hybrid induction, three of five patients attained a CR; there were two treatment-related deaths.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These studies suggest that a CR can be attained with any of these approaches. The mortality rate associated with hybrid regimens in this and other studies is higher than with the other regimens with no obvious survival benefit. A choice among the ALL-type and AML-type regimens is largely made based upon the age of the patient. We suggest an ALL-type regimen for patients younger than age 15 and an AML-type regimen for patients over 15 years. If a response is not seen after initial therapy, a trial of the alternate therapy may be attempted.",
"   </p>",
"   <p>",
"    The addition of a TKI to standard induction therapy has improved survival rates among patients with Ph+ ALL. This indirect evidence suggests that a TKI would be of benefit to patients with Ph+ mixed-phenotype acute leukemia. When the Philadelphia chromosome is present in a patient with mixed-phenotype acute leukemia, we suggest the use of induction therapy that contains a TKI, such as that used for patients with Ph+ ALL. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/28/44489?source=see_link&amp;anchor=H58829265#H58829265\">",
"     \"Induction therapy for Philadelphia chromosome positive acute lymphoblastic leukemia in adults\", section on 'TKI plus chemotherapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7012811\">",
"    <span class=\"h2\">",
"     AML with gene mutations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Abnormalities in certain genes (mutations in c-KIT, FLT3-ITD, CEBPA, and NPM1) confer prognostic significance in adult patients with AML and are considered in the risk stratification for post-remission therapy. Whether induction therapy should differ depending upon the presence of gene mutations is unknown, but under active investigation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/55/36730?source=see_link&amp;anchor=H9#H9\">",
"     \"Prognosis of acute myeloid leukemia\", section on 'Gene mutations'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/55/17274?source=see_link&amp;anchor=H2#H2\">",
"     \"Post-remission therapy for acute myeloid leukemia in younger adults\", section on 'Risk stratification'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h1\">",
"     CLINICAL TRIALS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Often there is no better therapy to offer a patient than enrollment onto a well-designed, scientifically valid, peer-reviewed clinical trial. Additional information and instructions for referring a patient to an appropriate research center can be obtained from the United States National Institutes of Health (",
"    <a class=\"external\" href=\"file://www.clinicaltrials.gov/\">",
"     www.clinicaltrials.gov",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?14/4/14402?source=see_link\">",
"       \"Patient information: Acute myeloid leukemia (AML) (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?37/13/38098?source=see_link\">",
"       \"Patient information: Leukemia in adults (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?33/30/34275?source=see_link\">",
"       \"Patient information: Acute myeloid leukemia (AML) treatment in adults (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The treatment of acute myeloid leukemia (AML) begins with an initial course of intensive combination chemotherapy referred to as \"remission induction therapy\" with a goal of obtaining a complete remission.",
"     </li>",
"     <li>",
"      For younger adults with newly diagnosed AML, we recommend remission induction treatment with a combination of an anthracycline, such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/15/43254?source=see_link\">",
"       daunorubicin",
"      </a>",
"      , for three days and \"standard\" dose",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/53/20314?source=see_link\">",
"       cytarabine",
"      </a>",
"      for seven days, rather than an anthracycline plus high dose cytarabine (",
"      <a class=\"graphic graphic_table graphicRef78251 \" href=\"UTD.htm?11/58/12204\">",
"       table 2",
"      </a>",
"      ) (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). Depending upon age and patient selection, 60 to 80 percent of younger adults achieve a complete remission with this regimen. Equi-cytotoxic doses of other anthracycline-like drugs (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/43/40630?source=see_link\">",
"       idarubicin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?36/31/37368?source=see_link\">",
"       mitoxantrone",
"      </a>",
"      ) are probably equally effective. While some randomized trials suggest a benefit from adding a third drug (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/22/19815?source=see_link\">",
"       cladribine",
"      </a>",
"      ), these results need further confirmation. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Standard dose cytarabine plus an anthracycline (7+3)'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      General treatment principles apply to most disease presentations and patient populations. However, involvement of certain scenarios, such as mixed-phenotype acute leukemia, Philadelphia chromosome positive AML, therapy-related AML, extramedullary involvement, or AML that occurs during pregnancy, has unique therapeutic implications. (See",
"      <a class=\"local\" href=\"#H27\">",
"       'Special scenarios'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Induction chemotherapy is highly toxic, primarily to the hematopoietic system, and requires careful monitoring to evaluate for cytopenias, infections, bleeding, tumor lysis syndrome, electrolyte imbalances, and other complications. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Monitoring during treatment'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H14\">",
"       'Supportive care'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/53/14168?source=see_link\">",
"       \"Overview of the complications of acute myeloid leukemia\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The initial response to treatment is evaluated 7 to 10 days after completion of induction chemotherapy with a unilateral bone marrow aspirate and biopsy. A lumbar puncture should be performed at the time of documented complete remission for a subset of patients. (See",
"      <a class=\"local\" href=\"#H25\">",
"       'Evaluation of response'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Attainment of a complete remission is only the first step in the treatment of AML. However, relapse can be expected in the following weeks to months if no further therapy were given. Postinduction or \"remission consolidation\" therapy is an essential component of the treatment of AML. This is presented separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/55/17274?source=see_link\">",
"       \"Post-remission therapy for acute myeloid leukemia in younger adults\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/41/30362/abstract/1\">",
"      D&ouml;hner H, Estey EH, Amadori S, et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood 2010; 115:453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/41/30362/abstract/2\">",
"      Williford SK, Salisbury PL 3rd, Peacock JE Jr, et al. The safety of dental extractions in patients with hematologic malignancies. J Clin Oncol 1989; 7:798.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/41/30362/abstract/3\">",
"      Sekeres MA, Elson P, Kalaycio ME, et al. Time from diagnosis to treatment initiation predicts survival in younger, but not older, acute myeloid leukemia patients. Blood 2009; 113:28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/41/30362/abstract/4\">",
"      Atallah E, Cortes J, O'Brien S, et al. Establishment of baseline toxicity expectations with standard frontline chemotherapy in acute myelogenous leukemia. Blood 2007; 110:3547.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/41/30362/abstract/5\">",
"      Mandelli F, Vignetti M, Suciu S, et al. Daunorubicin versus mitoxantrone versus idarubicin as induction and consolidation chemotherapy for adults with acute myeloid leukemia: the EORTC and GIMEMA Groups Study AML-10. J Clin Oncol 2009; 27:5397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/41/30362/abstract/6\">",
"      L&ouml;wenberg B, Ossenkoppele GJ, van Putten W, et al. High-dose daunorubicin in older patients with acute myeloid leukemia. N Engl J Med 2009; 361:1235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/41/30362/abstract/7\">",
"      Rowe JM, Neuberg D, Friedenberg W, et al. A phase 3 study of three induction regimens and of priming with GM-CSF in older adults with acute myeloid leukemia: a trial by the Eastern Cooperative Oncology Group. Blood 2004; 103:479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/41/30362/abstract/8\">",
"      Ohtake S, Miyawaki S, Fujita H, et al. Randomized study of induction therapy comparing standard-dose idarubicin with high-dose daunorubicin in adult patients with previously untreated acute myeloid leukemia: the JALSG AML201 Study. Blood 2011; 117:2358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/41/30362/abstract/9\">",
"      Fernandez HF, Sun Z, Yao X, et al. Anthracycline dose intensification in acute myeloid leukemia. N Engl J Med 2009; 361:1249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/41/30362/abstract/10\">",
"      Lee JH, Joo YD, Kim H, et al. A randomized trial comparing standard versus high-dose daunorubicin induction in patients with acute myeloid leukemia. Blood 2011; 118:3832.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/41/30362/abstract/11\">",
"      Arlin Z, Case DC Jr, Moore J, et al. Randomized multicenter trial of cytosine arabinoside with mitoxantrone or daunorubicin in previously untreated adult patients with acute nonlymphocytic leukemia (ANLL). Lederle Cooperative Group. Leukemia 1990; 4:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/41/30362/abstract/12\">",
"      MacCallum PK, Davis CL, Rohatiner AZ, et al. Mitoxantrone and cytosine arabinoside as treatment for acute myelogenous leukemia (AML) at first recurrence. Leukemia 1993; 7:1496.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/41/30362/abstract/13\">",
"      B&uuml;chner T, Hiddemann W, W&ouml;rmann B, et al. Double induction strategy for acute myeloid leukemia: the effect of high-dose cytarabine with mitoxantrone instead of standard-dose cytarabine with daunorubicin and 6-thioguanine: a randomized trial by the German AML Cooperative Group. Blood 1999; 93:4116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/41/30362/abstract/14\">",
"      Ho AD, Lipp T, Ehninger G, et al. Combination of mitoxantrone and etoposide in refractory acute myelogenous leukemia--an active and well-tolerated regimen. J Clin Oncol 1988; 6:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/41/30362/abstract/15\">",
"      Feldman EJ, Alberts DS, Arlin Z, et al. Phase I clinical and pharmacokinetic evaluation of high-dose mitoxantrone in combination with cytarabine in patients with acute leukemia. J Clin Oncol 1993; 11:2002.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/41/30362/abstract/16\">",
"      Estey EH, Thall PF, Cortes JE, et al. Comparison of idarubicin + ara-C-, fludarabine + ara-C-, and topotecan + ara-C-based regimens in treatment of newly diagnosed acute myeloid leukemia, refractory anemia with excess blasts in transformation, or refractory anemia with excess blasts. Blood 2001; 98:3575.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/41/30362/abstract/17\">",
"      Russo D, Malagola M, de Vivo A, et al. Multicentre phase III trial on fludarabine, cytarabine (Ara-C), and idarubicin versus idarubicin, Ara-C and etoposide for induction treatment of younger, newly diagnosed acute myeloid leukaemia patients. Br J Haematol 2005; 131:172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/41/30362/abstract/18\">",
"      Bishop JF, Lowenthal RM, Joshua D, et al. Etoposide in acute nonlymphocytic leukemia. Australian Leukemia Study Group. Blood 1990; 75:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/41/30362/abstract/19\">",
"      Hann IM, Stevens RF, Goldstone AH, et al. Randomized comparison of DAT versus ADE as induction chemotherapy in children and younger adults with acute myeloid leukemia. Results of the Medical Research Council's 10th AML trial (MRC AML10). Adult and Childhood Leukaemia Working Parties of the Medical Research Council. Blood 1997; 89:2311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/41/30362/abstract/20\">",
"      B&uuml;chner T, Schlenk RF, Schaich M, et al. Acute Myeloid Leukemia (AML): different treatment strategies versus a common standard arm--combined prospective analysis by the German AML Intergroup. J Clin Oncol 2012; 30:3604.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/41/30362/abstract/21\">",
"      Holowiecki J, Grosicki S, Giebel S, et al. Cladribine, but not fludarabine, added to daunorubicin and cytarabine during induction prolongs survival of patients with acute myeloid leukemia: a multicenter, randomized phase III study. J Clin Oncol 2012; 30:2441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/41/30362/abstract/22\">",
"      Holowiecki J, Grosicki S, Robak T, et al. Addition of cladribine to daunorubicin and cytarabine increases complete remission rate after a single course of induction treatment in acute myeloid leukemia. Multicenter, phase III study. Leukemia 2004; 18:989.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/41/30362/abstract/23\">",
"      Bishop JF, Matthews JP, Young GA, et al. A randomized study of high-dose cytarabine in induction in acute myeloid leukemia. Blood 1996; 87:1710.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/41/30362/abstract/24\">",
"      Weick JK, Kopecky KJ, Appelbaum FR, et al. A randomized investigation of high-dose versus standard-dose cytosine arabinoside with daunorubicin in patients with previously untreated acute myeloid leukemia: a Southwest Oncology Group study. Blood 1996; 88:2841.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/41/30362/abstract/25\">",
"      Phillips GL, Reece DE, Shepherd JD, et al. High-dose cytarabine and daunorubicin induction and postremission chemotherapy for the treatment of acute myelogenous leukemia in adults. Blood 1991; 77:1429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/41/30362/abstract/26\">",
"      Schiller G, Gajewski J, Nimer S, et al. A randomized study of intermediate versus conventional-dose cytarabine as intensive induction for acute myelogenous leukaemia. Br J Haematol 1992; 81:170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/41/30362/abstract/27\">",
"      Willemze R, Suciu S, Mandelli F, et al. High dose (HD-AraC) vs standard dose cytosine arabinoside (SD-AraC) during induction and IL-2 vs observation after consolidation/autologous stem cell transplantation in patients with acute myelogenous leukemia (AML): Final report of the AML-12 trial of EORTC and GIMEMA Leukemia Groups on the value of high dose AraC. Blood (ASH Annual Meeting Abstracts) 2011; 118:abstract 257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/41/30362/abstract/28\">",
"      L&ouml;wenberg B, Pabst T, Vellenga E, et al. Cytarabine dose for acute myeloid leukemia. N Engl J Med 2011; 364:1027.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/41/30362/abstract/29\">",
"      Castaigne S, Chevret S, Archimbaud E, et al. Randomized comparison of double induction and timed-sequential induction to a \"3 + 7\" induction in adults with AML: long-term analysis of the Acute Leukemia French Association (ALFA) 9000 study. Blood 2004; 104:2467.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.nccn.org/professionals/physician_gls/pdf/antiemesis.pdf (Accessed on February 07, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/41/30362/abstract/31\">",
"      Basch E, Prestrud AA, Hesketh PJ, et al. Antiemetics: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 2011; 29:4189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/41/30362/abstract/32\">",
"      Smith TJ, Khatcheressian J, Lyman GH, et al. 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol 2006; 24:3187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/41/30362/abstract/33\">",
"      Slichter SJ, Kaufman RM, Assmann SF, et al. Dose of prophylactic platelet transfusions and prevention of hemorrhage. N Engl J Med 2010; 362:600.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/41/30362/abstract/34\">",
"      Thomas X, Raffoux E, Renneville A, et al. Which AML subsets benefit from leukemic cell priming during chemotherapy? Long-term analysis of the ALFA-9802 GM-CSF study. Cancer 2010; 116:1725.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/41/30362/abstract/35\">",
"      Wheatley K, Goldstone AH, Littlewood T, et al. Randomized placebo-controlled trial of granulocyte colony stimulating factor (G-CSF) as supportive care after induction chemotherapy in adult patients with acute myeloid leukaemia: a study of the United Kingdom Medical Research Council Adult Leukaemia Working Party. Br J Haematol 2009; 146:54.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/41/30362/abstract/36\">",
"      L&ouml;wenberg B, van Putten W, Theobald M, et al. Effect of priming with granulocyte colony-stimulating factor on the outcome of chemotherapy for acute myeloid leukemia. N Engl J Med 2003; 349:743.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/41/30362/abstract/37\">",
"      Thomas X, Raffoux E, Botton Sd, et al. Effect of priming with granulocyte-macrophage colony-stimulating factor in younger adults with newly diagnosed acute myeloid leukemia: a trial by the Acute Leukemia French Association (ALFA) Group. Leukemia 2007; 21:453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/41/30362/abstract/38\">",
"      Pabst T, Vellenga E, van Putten W, et al. Favorable effect of priming with granulocyte colony-stimulating factor in remission induction of acute myeloid leukemia restricted to dose escalation of cytarabine. Blood 2012; 119:5367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/41/30362/abstract/39\">",
"      Gardner A, Mattiuzzi G, Faderl S, et al. Randomized comparison of cooked and noncooked diets in patients undergoing remission induction therapy for acute myeloid leukemia. J Clin Oncol 2008; 26:5684.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/41/30362/abstract/40\">",
"      Freifeld AG, Bow EJ, Sepkowitz KA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america. Clin Infect Dis 2011; 52:e56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/41/30362/abstract/41\">",
"      Segal BH, Freifeld AG, Baden LR, et al. Prevention and treatment of cancer-related infections. J Natl Compr Canc Netw 2008; 6:122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/41/30362/abstract/42\">",
"      Rowe JM, Kim HT, Cassileth PA, et al. Adult patients with acute myeloid leukemia who achieve complete remission after 1 or 2 cycles of induction have a similar prognosis: a report on 1980 patients registered to 6 studies conducted by the Eastern Cooperative Oncology Group. Cancer 2010; 116:5012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/41/30362/abstract/43\">",
"      Germann N, Goffinet F, Goldwasser F. Anthracyclines during pregnancy: embryo-fetal outcome in 160 patients. Ann Oncol 2004; 15:146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/41/30362/abstract/44\">",
"      Chelghoum Y, Vey N, Raffoux E, et al. Acute leukemia during pregnancy: a report on 37 patients and a review of the literature. Cancer 2005; 104:110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/41/30362/abstract/45\">",
"      Pizzuto J, Aviles A, Noriega L, et al. Treatment of acute leukemia during pregnancy: presentation of nine cases. Cancer Treat Rep 1980; 64:679.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/41/30362/abstract/46\">",
"      Reynoso EE, Shepherd FA, Messner HA, et al. Acute leukemia during pregnancy: the Toronto Leukemia Study Group experience with long-term follow-up of children exposed in utero to chemotherapeutic agents. J Clin Oncol 1987; 5:1098.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/41/30362/abstract/47\">",
"      Cardonick E, Iacobucci A. Use of chemotherapy during human pregnancy. Lancet Oncol 2004; 5:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/41/30362/abstract/48\">",
"      Bakst RL, Tallman MS, Douer D, Yahalom J. How I treat extramedullary acute myeloid leukemia. Blood 2011; 118:3785.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/41/30362/abstract/49\">",
"      Bakst R, Wolden S, Yahalom J. Radiation therapy for chloroma (granulocytic sarcoma). Int J Radiat Oncol Biol Phys 2012; 82:1816.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/41/30362/abstract/50\">",
"      Fritz J, Vogel W, Bares R, Horger M. Radiologic spectrum of extramedullary relapse of myelogenous leukemia in adults. AJR Am J Roentgenol 2007; 189:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/41/30362/abstract/51\">",
"      Lee EY, Anthony MP, Leung AY, et al. Utility of FDG PET/CT in the assessment of myeloid sarcoma. AJR Am J Roentgenol 2012; 198:1175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/41/30362/abstract/52\">",
"      Yamauchi K, Yasuda M. Comparison in treatments of nonleukemic granulocytic sarcoma: report of two cases and a review of 72 cases in the literature. Cancer 2002; 94:1739.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/41/30362/abstract/53\">",
"      Lan TY, Lin DT, Tien HF, et al. Prognostic factors of treatment outcomes in patients with granulocytic sarcoma. Acta Haematol 2009; 122:238.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/41/30362/abstract/54\">",
"      Tsimberidou AM, Kantarjian HM, Estey E, et al. Outcome in patients with nonleukemic granulocytic sarcoma treated with chemotherapy with or without radiotherapy. Leukemia 2003; 17:1100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/41/30362/abstract/55\">",
"      Atfy M, Al Azizi NM, Elnaggar AM. Incidence of Philadelphia-chromosome in acute myelogenous leukemia and biphenotypic acute leukemia patients: And its role in their outcome. Leuk Res 2011; 35:1339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/41/30362/abstract/56\">",
"      Kondo T, Tasaka T, Sano F, et al. Philadelphia chromosome-positive acute myeloid leukemia (Ph + AML) treated with imatinib mesylate (IM): a report with IM plasma concentration and bcr-abl transcripts. Leuk Res 2009; 33:e137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/41/30362/abstract/57\">",
"      Ritchie DS, McBean M, Westerman DA, et al. Complete molecular response of e6a2 BCR-ABL-positive acute myeloid leukemia to imatinib then dasatinib. Blood 2008; 111:2896.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/41/30362/abstract/58\">",
"      Cho BS, Kim HJ, Lee S, et al. Successful interim therapy with imatinib prior to allogeneic stem cell transplantation in Philadelphia chromosome-positive acute myeloid leukemia. Eur J Haematol 2007; 79:170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/41/30362/abstract/59\">",
"      Isoda A, Nakahashi H, Hoshino T, et al. Insufficient outcomes with imatinib mesylate: case report of Ph-positive acute myeloid leukemia evolving from myelodysplastic syndrome. Am J Hematol 2007; 82:501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/41/30362/abstract/60\">",
"      Ueda K, Horiike S, Zen K, et al. Complete cytogenetic and molecular response to treatment with imatinib mesylate for philadelphia chromosome positive acute myeloid leukemia with multilineage dysplasia. Leuk Lymphoma 2006; 47:1967.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/41/30362/abstract/61\">",
"      Pompetti F, Spadano A, Sau A, et al. Long-term remission in BCR/ABL-positive AML-M6 patient treated with Imatinib Mesylate. Leuk Res 2007; 31:563.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/41/30362/abstract/62\">",
"      Jentsch-Ullrich K, Pelz AF, Braun H, et al. Complete molecular remission in a patient with Philadelphia-chromosome positive acute myeloid leukemia after conventional therapy and imatinib. Haematologica 2004; 89:ECR15.",
"     </a>",
"    </li>",
"    <li>",
"     Swerdlow SH, Campo E, Harris NL, et al. World Health Organization classification of tumours of haematopoietic and lymphoid tissues, IARC Press, Lyon 2008.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/41/30362/abstract/64\">",
"      Weinberg OK, Arber DA. Mixed-phenotype acute leukemia: historical overview and a new definition. Leukemia 2010; 24:1844.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/41/30362/abstract/65\">",
"      Mejstrikova E, Volejnikova J, Fronkova E, et al. Prognosis of children with mixed phenotype acute leukemia treated on the basis of consistent immunophenotypic criteria. Haematologica 2010; 95:928.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/41/30362/abstract/66\">",
"      Matutes E, Pickl WF, Van't Veer M, et al. Mixed-phenotype acute leukemia: clinical and laboratory features and outcome in 100 patients defined according to the WHO 2008 classification. Blood 2011; 117:3163.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4525 Version 18.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-210.101.131.231-4F3FA9F29D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_41_30362=[""].join("\n");
var outline_f29_41_30362=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H32\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PRETREATMENT EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      History",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Studies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      CHEMOTHERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Standard dose cytarabine plus an anthracycline (7+3)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15233610\">",
"      - Choice of anthracycline",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15233617\">",
"      - Dosing of daunorubicin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5115635\">",
"      - Adding a third agent",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      High dose cytarabine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Double induction chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      MONITORING DURING TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      SUPPORTIVE CARE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12878257\">",
"      Anti-emetic prophylaxis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Cytopenias",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Transfusions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Growth factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Infections",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Precautions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Prophylaxis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Tumor lysis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Menorrhagia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Other complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      EVALUATION OF RESPONSE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      POST-REMISSION TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      SPECIAL SCENARIOS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Pregnancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6905368\">",
"      Patients with cardiac disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6905614\">",
"      Extramedullary disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6905621\">",
"      Therapy-related AML",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15233308\">",
"      Philadelphia chromosome positive AML",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9675567\">",
"      Mixed-phenotype acute leukemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7012811\">",
"      AML with gene mutations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      CLINICAL TRIALS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/4525\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/4525|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?0/0/3\" title=\"table 1\">",
"      Pretreatment eval AML",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?11/58/12204\" title=\"table 2\">",
"      AML induction regimens",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?22/10/22701\" title=\"table 3\">",
"      TLS risk stratification",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/46/41706?source=related_link\">",
"      Cardiotoxicity of anthracycline-like chemotherapy agents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/6/20586?source=related_link\">",
"      Clinical and laboratory aspects of platelet transfusion therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/58/20393?source=related_link\">",
"      Clinical manifestations, pathologic features, and diagnosis of acute myeloid leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/12/200?source=related_link\">",
"      Clinical manifestations, pathologic features, and diagnosis of acute promyelocytic leukemia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/42/39594?source=related_link\">",
"      Cytogenetics in acute myeloid leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/7/38010?source=related_link\">",
"      Fertility preservation in patients undergoing gonadotoxic treatment or gonadal resection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/26/37285?source=related_link\">",
"      Heavy or irregular uterine bleeding during chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/52/5961?source=related_link\">",
"      Indications for red cell transfusion in the adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/28/44489?source=related_link\">",
"      Induction therapy for Philadelphia chromosome positive acute lymphoblastic leukemia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/57/43930?source=related_link\">",
"      Infusion reactions to systemic chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/11/28858?source=related_link\">",
"      Initial treatment of acute promyelocytic leukemia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/0/25607?source=related_link\">",
"      Involvement of the central nervous system with acute myeloid leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/5/24665?source=related_link\">",
"      Leukoreduction to prevent complications of blood transfusion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/32/44553?source=related_link\">",
"      Overview of central venous access",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/53/14168?source=related_link\">",
"      Overview of the complications of acute myeloid leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?14/4/14402?source=related_link\">",
"      Patient information: Acute myeloid leukemia (AML) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?33/30/34275?source=related_link\">",
"      Patient information: Acute myeloid leukemia (AML) treatment in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?37/13/38098?source=related_link\">",
"      Patient information: Leukemia in adults (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/55/17274?source=related_link\">",
"      Post-remission therapy for acute myeloid leukemia in younger adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/18/39210?source=related_link\">",
"      Prevention and treatment of chemotherapy-induced nausea and vomiting",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/55/36730?source=related_link\">",
"      Prognosis of acute myeloid leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/59/3001?source=related_link\">",
"      Prophylaxis of infection during chemotherapy-induced neutropenia in high-risk adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/3/37945?source=related_link\">",
"      Refractoriness to platelet transfusion therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/50/12073?source=related_link\">",
"      Remission criteria in acute myeloid leukemia and monitoring for residual disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/35/39480?source=related_link\">",
"      Therapy-related myeloid neoplasms: Acute myeloid leukemia and myelodysplastic syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/29/29146?source=related_link\">",
"      Treatment of acute myeloid leukemia in older adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/52/40778?source=related_link\">",
"      Treatment of neutropenic fever syndromes in adults with hematologic malignancies and hematopoietic cell transplant recipients (high-risk patients)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/51/29498?source=related_link\">",
"      Treatment of relapsed or refractory acute myeloid leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/20/3402?source=related_link\">",
"      Tumor lysis syndrome: Prevention and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/9/33945?source=related_link\">",
"      Use of granulocyte colony stimulating factors in patients with chemotherapy-induced neutropenia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f29_41_30363="Empiric therapy SPT";
var content_f29_41_30363=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F57622&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F57622&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Empiric antibiotic therapy for septic pelvic thrombophlebitis",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Options for empiric gram-negative and anaerobic coverage include:",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1_start\">",
"       Monotherapy with a beta-lactam/beta-lactamase inhibitor, such as one of the following:",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Ampicillin-sulbactam (3 g every six hours)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Piperacillin/tazobactam (4.5 g every eight hours)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Ticarcillin-clavulanate (3.1 g every four hours)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       A third generation cephalosporin such as ceftriaxone (1 g IV every 24 hours)",
"       <strong>",
"        PLUS",
"       </strong>",
"       metronidazole (500 mg IV every eight hours)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       For patients with beta-lactam intolerance, alternative empiric regimens include:",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       A fluoroquinolone (eg, ciprofloxacin 400 mg IV every 12 hours or levofloxacin 500 mg IV daily)",
"       <strong>",
"        PLUS",
"       </strong>",
"       metronidazole (500 mg IV every eight hours)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1_start\">",
"       Monotherapy with a carbapenem, such as one of the following:",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Imipenem (500 mg every six hours)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Meropenem (1 g every 8 hours)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Ertapenem (1 g daily)",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_41_30363=[""].join("\n");
var outline_f29_41_30363=null;
var title_f29_41_30364="Anti-emetic agents for postoperative nausea and vomiting";
var content_f29_41_30364=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F65891&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F65891&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Anti-emetic agents for postoperative nausea and vomiting*",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Drug",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"4\">",
"        Relative risk (95% CI)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        Nausea",
"       </td>",
"       <td class=\"subtitle2\">",
"        Vomiting",
"       </td>",
"       <td class=\"subtitle2\">",
"        Nausea and vomiting",
"       </td>",
"       <td class=\"subtitle2\">",
"        Rescue antiemetic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Droperidol",
"       </td>",
"       <td>",
"        0.65 (0.60-0.71)",
"       </td>",
"       <td>",
"        0.65 (0.61-0.70)",
"       </td>",
"       <td>",
"        0.62 (0.58-0.67)",
"       </td>",
"       <td>",
"        0.53 (0.47-0.60)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Dexamethasone",
"       </td>",
"       <td>",
"        0.57 (0.48-0.69)",
"       </td>",
"       <td>",
"        0.51 (0.46-0.57)",
"       </td>",
"       <td>",
"        0.49 (0.44-0.54)",
"       </td>",
"       <td>",
"        0.50 (0.42-0.59)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cyclizine",
"       </td>",
"       <td>",
"        0.65 (0.47-0.90)",
"       </td>",
"       <td>",
"        0.57 (0.43-0.75)",
"       </td>",
"       <td>",
"        0.68 (0.58-0.80)",
"       </td>",
"       <td>",
"        0.27 (0.14-0.62)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Metoclopramide",
"       </td>",
"       <td>",
"        0.82 (0.76-0.88)",
"       </td>",
"       <td>",
"        0.75 (0.70-0.81)",
"       </td>",
"       <td>",
"        0.76 (0.70-0.82)",
"       </td>",
"       <td>",
"        0.78 (0.69-0.88)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ondansetron",
"       </td>",
"       <td>",
"        0.68 (0.63-0.74)",
"       </td>",
"       <td>",
"        0.55 (0.50-0.59)",
"       </td>",
"       <td>",
"        0.56 (0.50-0.63)",
"       </td>",
"       <td>",
"        0.55 (0.49-0.61)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Dolasetron",
"       </td>",
"       <td>",
"        0.82 (0.76-0.90)",
"       </td>",
"       <td>",
"        0.63 (0.51-0.76)",
"       </td>",
"       <td>",
"        0.72 (0.62-0.83)",
"       </td>",
"       <td>",
"        0.67 (0.57-0.79)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Tropisetron",
"       </td>",
"       <td>",
"        0.77 (0.71-0.84)",
"       </td>",
"       <td>",
"        0.59 (0.50-0.69)",
"       </td>",
"       <td>",
"        0.70 (0.61-0.81)",
"       </td>",
"       <td>",
"        0.62 (0.53-0.72)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Granisetron",
"       </td>",
"       <td>",
"        0.53 (0.45-0.63)",
"       </td>",
"       <td>",
"        0.40 (0.35-0.46)",
"       </td>",
"       <td>",
"        0.39 (0.31-0.48)",
"       </td>",
"       <td>",
"        0.29 (0.22-0.39)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Romasetron",
"       </td>",
"       <td>",
"        0.62 (0.40-0.96)",
"       </td>",
"       <td>",
"        0.42 (0.28-0.63)",
"       </td>",
"       <td>",
"        0.51 (0.39-0.68)",
"       </td>",
"       <td>",
"        0.38 (0.15-0.99)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Placebo versus drug.",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Carlisle J, Stevenson CA. Drugs for preventing postoperative nausea and vomiting. Cochrane Database Syst Rev 2006; 3:CD004125.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_41_30364=[""].join("\n");
var outline_f29_41_30364=null;
var title_f29_41_30365="Toddler to early school age";
var content_f29_41_30365=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F60734&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=8\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F60734&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=8\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Dietary recommendations for toddlers to early-school-age children",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Food groups and number of daily servings",
"       </td>",
"       <td class=\"subtitle1\">",
"        Age 12 to 23 months",
"       </td>",
"       <td class=\"subtitle1\">",
"        Age 2 to 3 years",
"       </td>",
"       <td class=\"subtitle1\">",
"        Age 4 to 8 years",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Milk and milk products*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" rowspan=\"2\">",
"        <em>",
"         Low-fat or fat-free milk or milk products",
"        </em>",
"       </td>",
"       <td>",
"        2 cups/day (whole milk or milk products)",
"       </td>",
"       <td>",
"        2 to 2.5 cups/day",
"       </td>",
"       <td>",
"        2.5 to 3 cups/day",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\" colspan=\"4\">",
"        <p>",
"         1 cup equivalent =",
"        </p>",
"        <p>",
"         1 cup of milk or yogurt, 1&frac12; ounces of natural cheese, 2 ounces of processed cheese, 1/3 cup of shredded cheese",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Meat and other protein foods",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" rowspan=\"2\">",
"        <em>",
"         Includes beef, chicken, pork, poultry, fish, eggs, peanut butter, and legumes",
"        </em>",
"       </td>",
"       <td>",
"        1&frac12; ounces/day",
"       </td>",
"       <td>",
"        2 ounces/day",
"       </td>",
"       <td>",
"        3 to 4 ounces/day",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\" colspan=\"4\">",
"        <p>",
"         1 ounce equivalent =",
"        </p>",
"        <p>",
"         1 ounce of beef, poultry, or fish, &frac14; cup cooked beans, 1 egg, 1 tablespoon peanut butter",
"         <sup>",
"          &bull;",
"         </sup>",
"         , &frac12; ounce of nuts",
"         <sup>",
"          &bull;",
"         </sup>",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Breads, cereals and starches",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" rowspan=\"2\">",
"        <em>",
"         Includes whole-grain breads, infant and cooked cereals, rice, pasta, ready-to-eat cereals. Half of all starches should be whole grains.",
"        </em>",
"       </td>",
"       <td>",
"        2 ounces/day",
"       </td>",
"       <td>",
"        3 ounces/day",
"       </td>",
"       <td>",
"        4 to 5 ounces/day",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\" colspan=\"4\">",
"        <p>",
"         1 ounce equivalent =",
"        </p>",
"        <p>",
"         1 slice whole-grain bread, &frac12; cup cooked cereal, rice or pasta, 1 cup dry cereal",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Fruits",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" rowspan=\"2\">",
"        <em>",
"         Includes one source of vitamin C daily (citrus fruits and juices, strawberries) and one source of vitamin A every other day (dark green and yellow fruits, melons)",
"        </em>",
"       </td>",
"       <td>",
"        1 cup/day",
"       </td>",
"       <td>",
"        1 cup/day",
"       </td>",
"       <td>",
"        1 to 1&frac12; cups/day",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\" colspan=\"4\">",
"        <p>",
"         1 cup equivalent =",
"        </p>",
"        <p>",
"         1 cup of fruit or 100 percent fruit juice",
"         <sup>",
"          &Delta;",
"         </sup>",
"         , &frac12; cup of dried fruit",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Vegetables",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" rowspan=\"2\">",
"        <em>",
"         Includes one source of vitamin C daily (broccoli and tomatoes) and one source of vitamin A every other day (spinach, sweet potatoes, corn, squash)",
"        </em>",
"       </td>",
"       <td>",
"        &frac34; cup/day",
"       </td>",
"       <td>",
"        1 cup/day",
"       </td>",
"       <td>",
"        1&frac12; cups/day",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\" colspan=\"4\">",
"        <p>",
"         1 cup equivalent =",
"        </p>",
"        <p>",
"         1 cup of raw or cooked vegetables or vegetable juice, 2 cups of raw leafy greens",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Fats and oils",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" rowspan=\"2\">",
"        <em>",
"         Includes margarine, butter, oils",
"        </em>",
"       </td>",
"       <td>",
"        Do not limit*",
"       </td>",
"       <td>",
"        3 teaspoons/day",
"       </td>",
"       <td>",
"        4 teaspoons/day",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\" colspan=\"4\">",
"        <p>",
"         1 teaspoon equivalent =",
"        </p>",
"        <p>",
"         1 teaspoon oil, margarine, butter or mayonnaise, 1 tablespoon salad dressing, sour cream or light mayonnaise",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Miscellaneous",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" rowspan=\"2\">",
"        <em>",
"         Desserts, sweets, soft drinks, candy, jams and jelly",
"        </em>",
"       </td>",
"       <td colspan=\"4\">",
"        Limit to small amount, use sparingly",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Limit intake",
"       </td>",
"       <td>",
"        165 to 170 discretionary calories",
"       </td>",
"       <td>",
"        170 to 195 discretionary calories",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    NOTE: For more details, go to",
"    <a href=\"file://www.myplate.gov\" target=\"_blank\">",
"     www.myplate.gov",
"    </a>",
"    .",
"    <div class=\"footnotes\">",
"     * Low fat products are not recommended for children under the age of 2.",
"     <br>",
"      <span class=\"bullet\">",
"       &bull;",
"      </span>",
"      May be a choking hazard for children under the age of 3.",
"      <br>",
"       &Delta; Children should be encouraged to consume whole fruits. Recommended to limit fruit juice to 4 to 6 ounces for children 1 to 6 years of age. Recommended to limit fruit juice to 8 to 12 ounces for children 7 to 18 years of age.",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Adapted with permission from: Texas Children's Hospital Pediatric Nutrition Reference Guide 2010, 9th Ed. Bunting KD, Mills J, Phillips S, et al (eds). Copyright &copy; 2010 Texas Children's Hospital. All rights reserved.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_41_30365=[""].join("\n");
var outline_f29_41_30365=null;
var title_f29_41_30366="Response to exercise";
var content_f29_41_30366=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F62094&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F62094&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Normal response to exercise",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 275px; height: 418px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Changes in oxygen uptake (VO2), carbon dioxide production (VCO2) and respiratory gas exchange ratio (R) after incremental treadmill exercise in a normal subject. Maximal oxygen uptake (VO2 max) and onset of the anaerobic threshold are identified; the latter occurs as oxygen uptake reaches a plateau. Carbon dioxide is derived from both oxidative metabolism (metabolic CO2) and, once the anaerobic threshold is reached, from the buffering of lactate by bicarbonate (nonmetabolic CO2).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Physiologic Principles and Clinical Applications, Weber, Janicki (Eds), 1986, Saunders, Philadelphia, pp. 151-167.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_41_30366=[""].join("\n");
var outline_f29_41_30366=null;
var title_f29_41_30367="Enterocele and rectocele";
var content_f29_41_30367=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F57126&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F57126&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Sagittal section of pelvis, showing relative position of rectocele and enterocele",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 440px; height: 328px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Te Linde's Operative Gynecology, 6th Edition, Matingly RF and Thompson JD, editors. J.B. Lippincott Co., Philadelphia, 1985. Copyright &copy; 1985 Lippincott Williams &amp;Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_41_30367=[""].join("\n");
var outline_f29_41_30367=null;
